Clinical and genetic epidemiology of malignant hyperthermia by Ali, Essameldeen Mohamed Aboelsaod
 
 





Essameldeen Mohamed Aboelsaod Ali 
Submitted in accordance with the requirements for the degree of Doctor of Philosophy 
The University of Leeds 
Faculty of Medicine and Health 
Leeds Institute of Medical Research at St. James’s 
September 2019  
 i 
I. Declaration 
I hereby declare that the work submitted is my own and that appropriate credit has 
been given where reference has been made to the work of others. 
This copy has been supplied on the understanding that it is a copyright material and 
that no quotation from the thesis may be published without proper acknowledgement. 
The right that Essameldeen Ali has to be identified as the author of this work has been 
asserted by him in accordance with the Copyright, Designs and Patents Act 1988. 




“Praise to Allah, who has guided us to this; and we would never have been guided if 
Allah had not guided us.”, Surah 7, Al-A’raf: The Heights, Verse 43 
I would like to acknowledge the Newton-Mosharafa funding programme of the British 
Council for funding my doctorate. Also, I would like to thank the Cultural Affairs and 
Mission Sector, Ministry of Higher Education of the Egyptian Government that offered 
financial and logistic support for me and my family throughout the last four years. I 
would like to acknowledge the Egyptian Cultural Bureau in London and all its 
employees for offering support whenever I needed it. 
I would like to thank my supervisors Phil and Pawan for their continued support 
throughout my PhD. I would like to express my appreciation for both of them directing 
me through a completely new research experience and always making me feel as their 
priority. 
I am grateful to Marie-Anne for her guidance, advice and constructing comments 
throughout my PhD. Many thanks to Catherine, Dorota and all other members of the 
MH unit for willingly providing help and showing support whenever I needed it. Thanks 
to Rachel for going through all the ups and downs together over the last long and tiring 
four years! 
I would like to thank my parents who made the person who I’m, providing unconditional 
support and endless love throughout my life. Last but not least, I would like to express 
my gratitude to Rehab, as while I have been focusing on my PhD for the last four 




Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic disorder that 
occurs in susceptible patients in exposure to triggering volatile anaesthetics and/or 
succinylcholine. With the advances in the anaesthetic practice in recent years, we 
have to re-think about our understanding of the clinical epidemiology of MH. The 
development in the anaesthetic agents and techniques would influence the clinical 
presentation of MH and alter the outcomes of the disease. On the other hand, the 
emergency nature of the anaesthetic MH reaction undermines the quality of clinical 
information available for retrospective studies about the condition. 
Genetically, the introduction of next-generation sequencing (NGS) methods enabled 
screening of the whole ryanodine receptor 1 gene (RYR1). As more than 300 variants 
have been detected in the RYR1, and of these, 48 variants have been functionally 
characterised as causative for MH, we have to evaluate the effects of these mutations 
on the clinical presentation of MH. A genotype-phenotype correlation should enable 
us to better understand the variable penetrance of MH. Additionally, we will be able to 
evaluate the relationship between MH and other RYR1-related muscle diseases; 
namely, congenital myopathies. The overlap between different subtypes of congenital 
myopathies and the potential risk of MH in these different subtypes originating from 
this overlap is an ongoing scientific perplexity. 
Finally, we will try to gather information about the extent of the MH problem in Egypt, 
a country with a population approaching 100 million and many inadequacies in the 
operating health systems. 
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1 General Introduction 
1.1 Malignant hyperthermia 
1.1.1 Overview 
Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered in susceptible 
patients by the commonly used volatile anaesthetics and/or depolarising muscle 
relaxant, succinylcholine. It affects skeletal muscles leading to disturbance of calcium 
(Ca+2) homeostasis, which lead to myofilament interaction and increased muscular 
activity with a resulting state of hypermetabolism (DENBOROUGH, 1979, Fill et al., 
1990, Gillard et al., 1991). MH was first described in 1960 in a patient with a family 
history of anaesthesia related deaths who developed a hyperthermic reaction to 
general anaesthetics (Denborough and Lovell, 1960). The pathophysiology of the 
disorder, figure 1-1, consists of massive Ca+2 release through a defective ryanodine 
receptor type 1 (RyR1) that is expressed in skeletal muscles (McCarthy, 2004). 
Additionally, it is thought that a basal Ca+2 leak through the RyR1 contributes to the 
pathogenesis of MH (Yang et al., 2007, Eltit et al., 2012). The condition was described 
in different ethnic groups (Rosenberg et al., 2015) and several scientific groups have 
been founded with the mutual interest to investigate its clinical presentation and 
elaborate its genetic background (https://www.emhg.org, https://my.mhaus.org 
https://pie.med.utoronto.ca/MH/index.htm, http://malignanthyperthermia.org.au). 
Several reports from other parts of the world about MH have been published from 
different countries (Centre for Arab Genomic Studies, 2016, Iqbal et al., 2017, 
Sumitani et al., 2011). MH only presents in susceptible patients at exposure to 
triggering volatile anaesthetics and/or succinylcholine. As it is estimated that only ~2% 
of the general population is exposed to these triggering agents each year, the 
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occurrence of MH reactions is considered very rare. Furthermore, not every 
susceptible patient presents with an MH reaction on each anaesthetic exposure 
(Robinson et al., 2006). Therefore, the reported prevalence of MH of 1 in 2,000 to 1 in 
10,000 (Monnier et al., 2002, Miller, 2003) is considered an underestimation of the 
true prevalence of MH susceptibility. 
 
  
Figure 1-1: Schematic illustration of the excitation-contraction coupling mechanism of skeletal 
muscles. Several proteins are involved in the Ca+2 release mechanism from the sarcoplasmic reticulum 
and may play a role in the pathogenesis of MH. Stac3à SH3 and cysteine rich domain 3, Cav1.1à voltage 
gated Ca+2 channel or dihydropyridine receptor, and RyR1à ryanodine receptor type 1. 
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1.1.2 Clinical presentation of an MH reaction 
The clinical phenotype of MH is variable ranging from a mild reaction that passes 
unnoticed to a severe fulminant form that could be life-threatening and may lead to 
death. Due to the simple monitoring techniques that anaesthetists used to depend 
upon when MH first described in the early 1960s, it was given the term malignant 
hyperpyrexia (Hopkins, 2000). The malignant component of the name refers to the 
high fatality rate associated with the disorder and the hyperpyrexia part, was used to 
describe the state of progressive increase in body temperature that used to end into 
death. With the advances in monitoring facilities, it became apparent that the 
hyperthermic feature of the disorder is a late sign (Ellis et al., 1990). The classic form 
of MH is now better described as a state of hypermetabolism (Hopkins, 2000) that 
usually starts with increased CO2 production and tachycardia. The severe fulminant 
reaction consists of features of metabolic stimulation in the form of hypercapnia, 
tachycardia, acidosis, and hyperthermia; in addition to manifestations of increased 
muscular activity such as muscular rigidity, elevated serum creatine kinase (CK) 
levels, and hyperkalaemia (Ellis et al., 1990). 
Initially, patients who were reported to have developed MH reactions according to the 
muscular features of the reaction were grouped into rigid and nonrigid reactions (Britt 
and Kalow, 1970). Hackle and colleague (Hackl et al., 1990) used a statistical logistic 
regression model to predict MH susceptibility, and the best model they were able to 
generate was able to classify 78% of cases. Furthermore, a clinical grading scale was 
generated using a Delphi method by Larach and colleagues (Larach et al., 1994) 
based on the opinion of a panel of eleven experts in MH. They generated a point-
based scoring system of different clinical indicators of MH to calculate a raw score. 
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This score is used to quantitively estimate the likelihood of a suspected anaesthetic 
reaction to be a true MH reaction. This score did not take into consideration the 
temporal relations of clinical details of the reaction and was markedly affected by 
missing data. 
Based on the clinical details of 402 patients who developed an anaesthetic reaction 
and were referred to the Leeds MH Investigation Unit for diagnosis of MH 
susceptibility, Ellis and colleagues (Ellis et al., 1990) classified the clinical features of 
the reactions into eight different categories following the recognition of masseter 
muscle spasm (MMS) as a clinical problem. The categories described included: a) 
severe fulminant life-threatening form with both hypermetabolism and increased 
muscular activity, b) moderate features of metabolic and muscular derangements that 
never appeared to be life-threatening, c) mild metabolic disturbance, d) masseter 
spasm with features of rhabdomyolysis such as elevated serum CK or myoglobinuria, 
e) masseter spasm with metabolic derangement, f) masseter spasm only, g) 
perioperative death or cardiac arrest that cannot be explained otherwise, and h) 
postoperative presentation of fever or rhabdomyolysis. 
1.1.3 Management of an MH reaction 
The patient who was reported to have the first described case of MH reaction managed 
to survive the reaction; mainly because the anaesthetist was alerted by the patient’s 
family history of anaesthesia related deaths. As the anaesthetist started to notice 
abnormal signs on the patients, all the volatile anaesthetics were switched off; and the 
patient allowed to emerge from anaesthesia with some symptomatic treatment 
(Denborough and Lovell, 1960). This incident highlights the importance of the early 
recognition of signs of MH for proper management, and obviously, it is very crucial to 
 5 
remove all triggering agents once an MH reaction is suspected. The European 
Malignant Hyperthermia Group (EMHG), is a group established in the early 1980s by 
likeminded anaesthesiologists and scientists interested in MH, has published 
guidelines for recognition and management of MH crisis (Glahn et al., 2010). This 
guidance includes a list of clinical signs of MH reactions classified into early and late 
signs. Also, it lists possible differential diagnoses such as light anaesthesia, infection 
and septicaemia, pheochromocytoma, thyroid crisis, and equipment failure. 
The basic principles of proper management of an MH crisis are still the same since 
the first described case of MH: early recognition and stopping all triggering agents. 
Immediate steps of treatment according to the EMHG guidelines include stopping of 
all triggering agents and switching to non-triggering anaesthesia, e.g. total intravenous 
anaesthesia (TIVA), declaring an emergency, hyperventilation with 100% O2, and 
close monitoring of temperature, blood pressure, oxygen saturation and end-tidal CO2 
(etCO2). Other steps described for the treatment of an MH crisis include treatment of 
other symptoms of the reaction. Hyperthermia should be treated vigorously with 
surface cooling, IV administration of chilled saline, and intravesical and intragastric 
irrigation with iced saline until temperature reaches <38.5℃. Both components of 
acidosis should be treated with hyperventilation for respiratory acidosis and sodium 
bicarbonate (NaHCO3) for metabolic acidosis with a pH <7.2. Other measures include 
treatment of hyperkalaemia and arrhythmias and maintaining adequate urinary output 
to protect against acute renal failure due to severe rhabdomyolysis. 
The specific treatment of an MH reaction is dantrolene sodium. Its mechanism of 
action includes inhibition of Ca+2 release from the sarcoplasmic reticulum (Zucchi and 
RoncaTestoni, 1997) and inhibition of extracellular Ca+2 entry and increase in the 
affinity of the RyR1 to magnesium (Mg+2) (Cherednichenko et al., 2008, Choi et al., 
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2017). Mg+2, in turn, competes with Ca+2 at channel activation sites and at the same 
time binds to the inhibitory sites (Steele and Duke, 2007). It was found to treat porcine 
stress syndrome, a similar condition of MH in pigs that will be discussed later, it was 
suggested to be used for the treatment of MH in humans (Harrison, 1975). The 
mortality rate of MH has since dramatically dropped to less than 10% (Strazis and Fox, 
1993). It is used at a dose of 2 mg/kg intravenous (IV) and repeated until stabilisation 
of the cardiac and respiratory symptoms, with some patients requiring the maximum 
dose of 10 mg/kg to be exceeded. 
1.1.4 Diagnosis of MH susceptibility 
Different literature described earlier, attempted to classify the clinical details of the 
anaesthetic reaction to predict the likelihood of the clinical diagnosis of MH. However, 
predicting MH susceptibility in patients before they develop an anaesthetic reaction 
could be lifesaving through offering trigger-free anaesthesia, e.g. TIVA, to susceptible 
patients. Based on several indicators, the EMHG have listed the most common 
reasons for an individual to be referred for investigation of MH susceptibility (Hopkins 
et al., 2015). These reasons include a family history of MH or unexplained deaths in 
the perioperative period. Clinical reasons include exertional rhabdomyolysis, 
idiopathic high serum CK levels, exertional heat stroke, and myopathy with detection 
of a rare uncharacterised potentially pathogenic ryanodine receptor type 1 gene 
(RYR1) variant. Based on the anaesthetic history, reasons listed included an adverse 
reaction to general anaesthesia where a triggering agent has been used. This adverse 
reaction should involve a combination of signs of hypermetabolism such as an 
inappropriate increase of etCO2, tachycardia and temperature increase and muscle 
involvement such as muscular rigidity and rhabdomyolysis. Initial signs of the reaction 
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should be evident during anaesthesia or within 60 minutes of discontinuation of 
anaesthesia. 
1.1.5 The in vitro contracture test 
According to these criteria for referral of patients for diagnosis of MH susceptibility, 
patients referred are tested using the gold standard in vitro contracture test (IVCT). A 
standardised protocol was first agreed upon in April 1983 based on the expert opinion 
of physicians from eight European countries who were involved in screening patients 
for MH susceptibility (Ellis, 1984). Its main principle is the abnormal contractures of 
muscle specimens of MH susceptible patients when exposed to RyR1 agonists ex 
vivo. Incremental concentrations of halothane and caffeine are applied to a freshly 
biopsied muscle specimen from the quadriceps muscle, either its vastus medialis or 
lateralis, while hung in a bath filled with Krebs-Ringer solution. The contracture of the 
electrically stimulated muscle is measured in grams, and a positive test is considered 
diagnostic with a threshold increase of a ≥0.2 grams at 2% halothane and 2 mmol 
caffeine concentration measured from the basal contracture line. 
The European protocol includes performing three tests: static halothane, dynamic 
halothane and static caffeine test; each on a sperate muscle specimen. The resulting 
diagnoses of these three tests are: MH susceptible to both halothane and caffeine 
(MHShc) when the muscle contracture exceeds the threshold of ≥0.2 gram for both 
halothane and caffeine tests, MH susceptible to either of them when the muscle reacts 
to halothane only (MHSh), or to caffeine only (MHSc), or MH not susceptible (MHN) 
when the three muscle specimens do not react in either of the three tests. Historically, 
the term equivocal or MHE was used to describe the diagnosis when the muscle 
specimen reacts only to either of the two agonists. Clinically, for the safety of the 
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patients and to increase the sensitivity of the IVCT, patients are treated as at risk of 
MH in case any of the diagnoses MHShc, MHSh, MHSc, or MHE are confirmed. 
A variation of this protocol is performed according to the standards of the North 
American Malignant Hyperthermia Group, the caffeine halothane contracture test 
(CHCT) (Larach, 1989). The differences between both protocols include the use of a 
single concentration of halothane of 3% in the CHCT instead of three concentrations 
of 0.5%, 1% and 2% in the IVCT; no dynamic halothane test according to the North 
American MH group protocol; and caffeine concentrations used for CHCT are 0.5 
mmol, 1 mmol, 2 mmol, 4 mmol and 32 mmol, while for IVCT an added concentration 
of 1.5 mmol is used. Additionally, the CHCT offers an optional additional test that 
includes the application of incremental concentrations of caffeine to a muscle 
specimen that has been exposed to 1% halothane concentration for 10 minutes. The 
diagnostic sensitivity of the IVCT is estimated to be 99% while it is estimated to have 
a specificity of 93.6% (Ording et al., 1997). The relatively low specificity because of a 
larger number of false-positive results is owed to the conservative approach towards 
considering equivocal cases as at risk of MH for the sake of patients’ clinical safety. 
On the other hand, the North American MH Group protocol, the CHCT, was found to 
have a sensitivity of 97% and a specificity of 78% (Allen et al., 1998). 
1.1.6 The Leeds MH Investigation Unit 
St James’s University Hospital, Leeds Teaching Hospitals NHS foundation trust hosts 
the national centre for MH investigation in the UK; the Leeds MH Investigation Unit. 
The unit was founded in the early 1970s and is a member of the European Malignant 
Hyperthermia Group. More than 7000 patients have had their MH susceptibility status 
confirmed using IVCT. In addition to MH, the unit provides expertise in other inherited 
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muscle disorders. The unit provides MH screening through the muscle biopsy list 
where muscle specimens are transferred to the on-site unit lab to be tested with IVCT. 
The unit also provides genetic screening, anaesthetic advice for patients who tested 
susceptible to MH and their family members, and a 24-hour hotline service for 
anaesthetists and medical staff for queries about MH. The unit also is one of the major 
research units for MH and related musculoskeletal disorders. 
The patient who had the clinical reaction is labelled as the proband for his/her family. 
Later on, when this patient’s susceptibility status is confirmed with IVCT, the patient is 
labelled as the index case for his/her family, being the first member of the family to be 
diagnosed. Situations when the proband and the index case for the family is not the 
same individual include patients who are too young to be tested, therefore, a first-of-
kin would be tested first, usually one of the parents; patients who suffer from a severe 
systematic condition being unfit for the procedure; and patients who died due to a fatal 
reaction. 
1.1.7 The Leeds MH Investigation Unit database and archive 
Files for the more than 7000 patients who have been tested for MH susceptibility at 
the unit using IVCT are stored in the unit archive. These files contain muscle biopsy 
reports, IVCT traces, neuropathologists examination reports of muscle biopsy, and 
basal serum CK level at the time of the biopsy. For MH probands who developed a 
suspected anaesthetic reaction, clinical details of the reaction, which are obtained 
from referral letters, anaesthetic charts or the unit clinical details survey form, are 
stored in patients’ files. The unit also has its clinical database that is generated using 
a FileMaker Pro© program to keep a digital form of this information about tested 
patients. This information is stored in two different databases with different login 
 10 
credentials for each to maintain patients’ confidentiality. Copies of genetic testing 
reports for patients tested at the unit are kept in patients’ files, and the results are 
uploaded on a separate genetic table on the unit database. 
1.1.8 Other muscular disorders related to MH 
Other muscular disorders are described to be associated with MH. Of these disorders, 
exertional heat illness (EHI), which involves dysregulation of the thermal homeostasis 
resulting from an interaction between physiological and environmental factors 
(Muldoon et al., 2007, Capacchione and Muldoon, 2009). The clinical picture of EHI 
includes heat exhaustion which is considered a mild form of EHI that may progress, if 
untreated, into exertional heat stroke (Glazer, 2005). Heat exhaustion usually presents 
with dizziness, weakness and discomfort. Other manifestations of EHI may involve 
heat syncope, which develops due to marked dilatation of blood vessels to dissipate 
heat leading to hypotension and fainting attacks, and exertional heat cramps. Other 
muscle-related disorders associated with MH include exertional rhabdomyolysis that 
could be a manifestation of other muscular diseases, including EHI. It usually presents 
because of muscle breakdown leading to the release of creatine kinase and myoglobin 
in the bloodstream, which may subsequently affect renal function. Another disorder 
associated with MH and will be discussed in more details in this study is central core 
disease and its broader family of congenital myopathies. 
1.1.9 Porcine stress syndrome 
Porcine stress syndrome is a muscular disorder presented in special breeds of pigs 
and triggered by different factors such as stress, transport, and high ambient 
temperature. It is described as the inability of the affected pigs to handle environmental 
stresses described early (Marple et al., 1968). Biochemical changes that occur in the 
 11 
muscle of affected pigs include increased rate of glycolysis and depletion of muscle 
glycogen (Briskey et al., 1966), increased lactate production in muscles (Dildey et al., 
1970) and degradation of muscle proteins. It was found to be triggered by exposure to 
halothane. It presents with a rise of core body temperature of the affected animal, 
muscular rigidity and death. The quality of meat produced from these affected animals 
is less favourable as the meat is described to be pale, soft and exudative.  
1.2 Calcium homeostasis in skeletal muscles and the regulating genes 
1.2.1 The excitation-contraction coupling mechanism and the role of Ca+2 
The excitation-contraction coupling is the process through which the action potential 
generated along the muscle fibre membranes leads to the intracellular release of Ca+2 
from the sarcoplasmic reticulum (SR) which activates the actin and myosin filaments 
to interact to produce the mechanical shortening of muscle fibres and muscle 
contraction. This process involves the interaction between several proteins involved 
in the cellular Ca+2 homeostasis. As shown in figure 1-1, the dihydropyridine receptor 
(DHPR) which is located across the cell membrane in the transverse tubules (T-
tubules) is activated by the depolarisation of the cell membrane from the spreading 
action potential. The activated DHPR physically interacts with the ryanodine receptor 
(RyR) located in the junctional terminal cisternae of the SR. This interaction leads to 
the opening of the RyR and release of Ca+2 from the SR, which in turn, activates the 
myosin and actin filaments to interact. This process ends when Ca+2 is transported 
back into the SR by the calcium-ATPase pump ending the interaction between actin 
and myosin filaments and leading to muscle relaxation. 
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1.2.2 The ryanodine receptor type 1 
The ryanodine receptor which is a homotetrameric protein located in the junctional 
terminal cisternae of the SR membrane (Pessah et al., 1985) and it is the major Ca+2 
release channel in the SR of skeletal muscles (Otsu et al., 1990). It is named after the 
plant alkaloid ryanodine (Jenden and Fairhurst, 1969) which has a high affinity and 
specificity to binding with the receptor and it is used to evaluate the function of the 
receptor (Imagawa et al., 1987, Inui et al., 1987, Lai et al., 1988). The receptor exists 
in three isoforms RyR1, RyR2 and RyR3 (Lanner et al., 2010). The isoform RyR1 was 
detected in skeletal muscles first time by (Takeshima et al., 1989, Zorzato et al., 1990) 
while the RyR2 detected in cardiac muscles (Nakai et al., 1990, Otsu et al., 1990) and 
RyR3 in the brain (Hakamata et al., 1992). The RyR1 is also expressed in other tissues 
but at lower levels such as the brain and mononuclear blood cells (Furuichi et al., 
1994, Hosoi et al., 2001). The RyR1 is the largest known ion channel (Rossi et al., 
2002) and the gene encoding the RyR1 was located on chromosome 19q13.2 
(Mackenzie et al., 1990). 
1.2.3 The dihydropyridine receptor 
The receptor is a voltage dependant Ca+2 channel located in the cell membrane of 
skeletal muscles in the T-tubules region. It is also known as calcium channel, voltage-
dependent, L type, alpha 1 subunit or Cav1.1. Its function includes physically 
interacting with the RyR1 stimulating Ca+2 release from the SR after being activated 
by the transmitted action potential across the cellular membrane. The gene encoding 
this protein is located on chromosome 1q32.1 and is named CACNA1S. 
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1.2.4 Pathophysiology of MH 
The mechanism by which an MH reaction develops is depending on the sudden and 
progressive increase of intracellular Ca+2 leading to physiological and metabolic 
derangements. Triggering volatile anaesthetics and/or succinylcholine lead, in 
susceptible patients, to the abnormal release of high amounts of Ca+2 into the 
cytoplasm of skeletal muscle cells which leads to a sustained state of 
hypermetabolism. This mechanism is owed to defective forms of the Ca+2 regulating 
proteins; mainly the RyR1 and, to a less extent, the Cav1.1 which are mainly due to 
mutations on the RYR1 and the CACNA1S genes, respectively. The generated state 
of hypermetabolism leads to excessive CO2 production, which clinically presents as 
hypercapnia, increased O2 consumption which translates into hypoxia and excessive 
lactate production due to anaerobic metabolism. During the course of the reaction, 
depletion of adenosine triphosphate (ATP) affects the integrity of the cellular 
membrane, which leads to increased leakage of electrolytes such as Ca+2 and K+. 
Eventually, cell damage occurs leading to the release of enzymes such as creatinine 
kinase, previously known as creatine phosphokinase, and muscle proteins such as 
myoglobin. 
1.3 Genetics of MH 
Before establishment of the bases of molecular genetics of MH, reports about the 
mode of inheritance of MH in affected families provided convincing evidence that MH 
has an autosomal dominant mode of inheritance. In 1990, the RYR1 on chromosome 
19q13.1 was identified as the primary locus for the MH susceptibility trait (MacLennan 
et al., 1990, McCarthy et al., 1990). However, the molecular genetics of MH have 
shown marked locus and allelic heterogeneity (Robinson et al., 2003a). As ~50% of 
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MH families have been linked to mutations on the RYR1, other genes have been 
identified as possible loci for MH susceptibility such as CACNA1S, STAC3 and CSQ 
genes. 
1.3.1 The RYR1 gene 
The cDNA that encodes the Ca+2 release channel in the sarcoplasmic reticulum or the 
ryanodine receptor type 1 has been cloned to chromosome 19 (Zorzato et al., 1990) 
and subsequently localised to the position 19q13.1 (Mackenzie et al., 1990). 
Searching through this large gene that is composed of 106 exons using different DNA 
sequencing techniques, more than 300 mutations have been detected. Due to 
absence of high-throughput technique to confirm the causal association between this 
large number of mutations and the MH susceptibility trait, until now, only 48 mutations 
on the RYR1 have been functionally characterised and are currently used as 
diagnostic for MH susceptibility (https://www.emhg.org/genetics). The majority of 
these mutations are missense mutations, involving a single nucleotide change with a 
resulting change of one amino acid in the protein. On the EMHG list of diagnostic 
mutations, only one deletion mutation has been functionally characterised to be 
causative for MH, the RYR1 c.7042_7044del. 
1.3.2 CACNA1S gene 
The gene encoding the expression of the Cav1.1 protein is located on chromosome 
1q32.1. As this protein plays a crucial role in the excitation-contraction coupling 
process, mutations on this gene were suggested to be involved in the pathophysiology 
of MH (Monnier et al., 1997). The EMHG guidelines for genetic diagnosis of MH lists 
only two variants on the CACNA1S to be accepted for genetic diagnosis of MH 
susceptibility, the CACNA1S c.520C>T and c.3257G>A variants. Functional studies 
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(Weiss et al., 2004, Eltit et al., 2012) have confirmed the role of these two mutations 
on the excitation-contraction coupling mechanism and the pathogenesis of MH. 
1.3.3 STAC3 gene 
One of the proteins that are involved in the excitation-contraction coupling process is 
the SH3 and cysteine-rich domain 3 (Stac3). Its role in the process is not completely 
understood, but it is located in the T-tubules and believed to play an important role in 
the process by interacting with the RyR1 and Cav1.1 (Zaharieva et al., 2017). The 
gene encoding this protein has been localised to position 12q13.3 (Stamm et al., 
2008). Mutations in this gene have been reported to be causative for an autosomal 
recessive type of myopathy found in the Lumbee population, the Native American 
Myopathy (Horstick et al., 2013). It was also suggested to be associated with 
congenital myopathy and the MH susceptibility trait (Zaharieva et al., 2017). 
1.3.4 Other genes implicated in MH 
As shown in figure 1-1, other proteins play different roles in the Ca+2 homeostasis in 
skeletal muscles and the excitation-contraction coupling process. These proteins 
could also play a role in the pathogenesis of MH. As according to a recent estimate of 
the genetic background of MH, mutations on other genes apart from the three 
previously mentioned genes (RYR1, CACNA1S, STAC3) could account for 14-23% of 
MH families (Miller et al., 2018). Genes for other proteins that modulate the function 
of ryanodine receptors are considered as possible candidate genes for MH (Robinson 
et al., 1997). Calsequestrin (Casq-1) is a Ca+2 binding protein that acts as a regulator 
of RyR1-related Ca+2 release (Beard et al., 2002) and located in the terminal cisternae 
of striated muscles (MacLennan and Wong, 1971). The gene that control this protein 
is proposed as a candidate gene for MH (Protasi et al., 2009). Other proteins such as 
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junctin and triadin play a role in the interaction between Casq-1 and RyR1, hence 
affect the Ca+2 homeostasis in skeletal muscles. 
1.3.5 Discordance 
Genotype-phenotype discordance was observed in 26.2% of UK MH families found to 
harbour a familial RYR1 variant (Miller et al., 2018). Discordant cases in MH could be 
in the form of either a family member who is phenotype positive (MHS with IVCT) and 
genotype negative for a diagnostic RYR1 or CACNA1S variant or, to a less extent, a 
phenotype negative and genotype positive. It was first described with MH in a family 
with a functionally relevant RYR1 variant and the IVCT results (Adeokun et al., 1997). 
In some families with a phenotype positive-genotype negative discordance, the 
sequencing of the entire RYR1 gene has found other RYR1 variants that disapproved 
discordancy in these families (Robinson et al., 2000, Robinson et al., 2003b). Studying 
this discordancy, especially in the case of a phenotype negative-genotype positive 
discordance, is biased by the practice of not genetically testing patients who test MHN 
with IVCT. Of the possible explanations to this discordancy, is errors in either 
genotyping or phenotyping of affected patients. However, proved discordant cases 
add to the genetic complexity of the MH disorder that includes locus and allelic 
heterogeneity with the possibility of involvement of modifying loci in the development 
of clinical and diagnostic phenotypes. 
1.4 Congenital myopathies 
1.4.1 Overview 
Congenital myopathy (CM) is a group of clinically and genetically heterogeneous 
muscular disorders that present clinically with hypotonia and muscle weakness. The 
severity of weakness varies significantly between different subtypes and with age. 
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Different muscle groups are affected with marked overlap between clinical categories 
of the group. The course of the disease also varies from one type to another ranging 
from slowly or non-progressive course to severe affection of vital muscle groups such 
as respiratory muscles which mandates ventilatory support in some patients. Some 
musculoskeletal abnormalities have been described with different types of congenital 
myopathies such as congenital hip dysplasia and kyphoscoliosis. No myocardial 
involvement is usually described in association with congenital myopathies, but 
cardiac function may be affected secondary to other abnormalities such as scoliosis 
causing restrictive lung deficit (Klingler et al., 2009). 
The prevalence of congenital myopathies is estimated to be 1 in 26000 (Amburgey et 
al., 2011). Different types of congenital myopathies have been described and usually 
named after the predominant findings during the histopathological examination of 
muscle specimens from affected patients. Detection of central areas in muscle 
biopsies which are described as cores devoid of mitochondria that appear clear on 
oxidative enzyme staining, was first described by Shy and Magee (Magee and Shy, 
1956) and was given the name central core disease (CCD). When these cores are 
less defined, multiple and/or peripheral, muscle biopsies are described to have multi-
mini-cores (MmD) (Engel et al., 1971). In some muscle biopsies, no cores could be 
detected, and unevenness of oxidative enzyme staining is noticed (Morgan-Hughes et 
al., 1973b). This characteristic core formation has emerged to be the most prevalent 
histopathological change in congenital myopathies (Jungbluth et al., 2018). On the 
contrary to the previous estimate that nemaline myopathy, which is characterised by 
the detection of red staining rods or bodies with the modified Gömöri trichrome 
staining, is the most common pathological form (Sewry and Wallgren-Pettersson, 
2017). Other variants of myopathic changes include congenital fibre type disproportion 
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(Clarke, 2011), fibre type 1 predominance (Sato et al., 2008) and centronuclear 
myopathy (CNM) (Jungbluth et al., 2008). 
1.4.2 Different clinical presentations of CM 
Different types of congenital myopathies are labelled according to the predominant 
histological finding, though, a characteristic clinical pattern of clinical weakness has 
been described for each type. 
Central core disease 
The clinical presentation of CCD usually starts in infancy with floppy infant syndrome 
or during early childhood with delayed motor milestones with weakness, which is 
typically proximal affecting hip girdle and axial muscles (Dubowitz, 1995). Bulbar 
affection and ophthalmoplegia are not usually associated with CCD, and even they 
are considered as exclusion criteria (Middleton and Moser, 1998). The typical 
distribution of muscle weakness is the involvement of proximal muscle groups, 
including the hip girdle and axial muscles. CCD is commonly presented with 
orthopaedic complications such as congenital dislocation of the hips (Ramsey and 
Hensinger, 1975) and scoliosis (Merlini et al., 1987) and foot deformities (Gamble et 
al., 1988). Cardiomyopathy is not a feature of RYR1 inherited CCD (Jungbluth, 2007), 
although cardiac involvement secondary to restrictive lung disease due to scoliosis 
may be observed. Severe respiratory involvement presented in neonatal cases is 
described in association with recessive RYR1 mutations (Romero et al., 2003). 
Multi-mini-core disease 
MmD is diagnosed when muscle biopsies show cores that are less defined, multiple 
and peripheral. Different clinical presentations have been described in association with 
this histological pattern, including the classical form of axial muscle weakness and 
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severe scoliosis with respiratory impairment. This form may be associated with 
involvement of the extraocular muscles. Other forms include either hip involvement 
with arthrogryposis or distal weakness affecting the upper limbs (Engel et al., 1971, 
Jungbluth et al., 2000). 
Core myopathies 
Both previous subtypes showed a marked overlap in the clinical features. 
Furthermore, the histopathological finding of different forms of cores could be stages 
of the disease, a progression with age, or separate entities. However, due to this 
marked overlap, both subtypes are referred to as core myopathies. Mutations in 
several genes were associated with development of core myopathies that include 
ryanodine receptor 1, selenoprotein N 1 (SEPN1), actin alpha 1 (ACTA1), titin (TTN), 
cofilin 2 (CFL-2), dynamin 2 (DNM2), myosin heavy chain 7 (MYH7), and myosin 
heavy chain 2 (MYH2). With mutations in the RYR1, an autosomal dominant mode of 
inheritance is described with CCD while MmD myopathy is usually linked to autosomal 
recessive inheritance. However, due to the pathological, clinical and genetic overlap, 
it is more appropriate now to refer to these disorders as core myopathies (Sewry and 
Wallgren-Pettersson, 2017). 
Centronuclear myopathy 
Different clinical presentations have been described in association with CNM, and it 
mainly depends on the underlying genetic mutations (Jungbluth et al., 2008). The 
affected males of the X-linked form of the disease usually presented early during foetal 
life with reduced foetal movement, polyhydramnios and thinning of ribs (Osborne et 
al., 1983, Teeuw et al., 1993). Birth asphyxia and neonatal deaths may be the 
presenting features (Heckmatt et al., 1985, Barth and Dubowitz, 1998). Female 
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carriers of the X-linked form are usually asymptomatic with a few patients may have 
mild muscular weakness (Heckmatt et al., 1985, Sawchak et al., 1991, Hammans et 
al., 2000). Autosomal linked forms have been described with both recessive and 
dominant modes of inheritance with different clinical presentations (Jungbluth et al., 
2008, Wilmshurst et al., 2010) described in a large cohort of patients a consistent 
clinical pattern associated with RYR1 mutations. The clinical pattern described started 
in utero in some patients with reduced foetal movement and presented at birth with 
hypotonia and weakness. Delayed milestones have been described in all patients, and 
bulbar affection with feeding difficulties was common. Involvement of the respiratory 
muscle that mandated ventilatory support was described in three patients and 
scoliosis in another two patients. 
Genetic heterogeneity in this group of patients includes an X-linked mode of 
inheritance associated with mutations in myotubularin 1 (MTM1) (Longo et al., 2016, 
Savarese et al., 2016), autosomal dominant inheritance with mutations in DNM2 
(Bitoun et al., 2005, Bitoun et al., 2007, Koutsopoulos et al., 2013) and autosomal 
recessive with mutations in TTN, bridging integrator 1 (BIN1) (Schessl et al., 2007), 
coiled-coil domain containing 78 (CCDC78), striated muscle preferentially expressed 
protein kinase (SPEG) (Sewry and Wallgren-Pettersson, 2017), and RYR1. 
Histopathological findings and clinical features of CNM varies according to the mode 
of inheritance and the affected genes. X-linked CNM due to mutations in MTM1 lead 
to a generalised muscle weakness with wasting and severe respiratory insufficiency 
and feeding difficulties (North et al., 2014) with large centrally located nuclei 
surrounded by a pale halo (Sewry and Wallgren-Pettersson, 2017). 
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Congenital fibre type 1 predominance 
This type is described histologically when 99% of muscle fibres belong to type 1. The 
clinical course of the disease is usually non-progressive with early onset of symptoms. 
Weakness is mild with proximal involvement and associated with hyporeflexia or 
areflexia (Oh and Danon, 1983). In some patients, it could be the only pathological 
finding, and it is linked in these patients to mutations in ACTA1, tropomyosin 2 and 3 
(TPM2, 3), SEPN1, MYH7, 3-hydroxyacyl-CoA dehydratase 1 (HACD1), and RYR1. 
 
Myopathy Genes 
Cores RYR1, SEPN1, ACTA1, TTN, CFL-2, DNM2, 
MYH7, MYH2 
Central nuclei MTM1, DNM2, BIN1, RYR1, CCDC78, SPEG,  
TTN 
Fibre type 1 predominance ACTA1, TPM2, TPM3, SEPN1, MYH7, RYR1, 
HACD1 
Table 1-1: Genes associated with different congenital myopathies. 
 
1.4.3 Diagnosis of CM 
The diagnosis of CM requires a proper clinical examination to determine the degree 
and pattern of clinical muscle weakness, muscle biopsy and histological examination 
to identify the underlying pathology and genetic screening to detect the mutated 
genes. Patients who are found to have myopathic changes in their muscle biopsy 
without clinical weakness are not labelled to have CM. Additionally, due to the marked 
overlap between different types of congenital myopathies; clinically, histologically and 
genetically, it is sometimes challenging to ascertain the specific type of congenital 
myopathies. 
 22 
1.4.4 Anaesthetic implications in patients with CM 
The challenges of anaesthetising patients with CM include the predictable risk 
originating from the weakness of the affected muscle group such as respiratory 
muscles, bulbar muscles or myocardial involvement in rare cases. Other unpredictable 
risks include prolonged paralysis by muscle relaxing drugs used, abnormal response 
to succinylcholine in the form of rhabdomyolysis and hyperkalaemia. Therefore, 
thorough history and examination and a careful evaluation of the advantages and 
disadvantages of each anaesthetic technique in patients with myopathy are always 
required to ensure proper care is provided for patients with congenital myopathies. 
However, due to a marked clinical and genetic overlap between different entities of 
congenital myopathies, it is usually challenging to ascertain a definitive diagnosis. 
1.4.5 Association of CM with MH 
As shown in table 1-1, mutations in the RYR1 were described in association with four 
types of congenital myopathies. Different types of congenital myopathies were 
associated with different modes of inheritance. Clinical episodes of MH and positive 
response of the diagnostic IVCT in some patients diagnosed with CCD have been 
reported (Klingler et al., 2009). However, an inconsistency between CCD diagnosis 
and MH susceptibility diagnosis have been reported (Halsall et al., 1996, Curran et al., 
1999). No definitive reports of MH reactions in MmD patients were found (Klingler et 
al., 2009), on the other hand, histological features of MmD were reported in a family 
with many MHS members (Guis et al., 2004), together with clinical and histological 
overlap between CCD and MmD, extra care should be taken when anaesthetising 
patients diagnosed with MmD regarding the risk of MH. Regarding other types of 
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congenital myopathies, the uncertainty of the risk of MH in these cases and the overlap 
between different types mandates managing these patients with caution. 
1.5 Status of MH in Egypt 
1.5.1 Genetic disorders in the Arab world and the Middle East region 
The middle east and Arabic region are characterised by a high rate of consanguinity 
with an estimated rate of 10-60% (Al-Gazali et al., 2006). This high rate of 
consanguinity favours the spread of genetically inherited diseases. In addition, due to 
cultural, religious and legal considerations; certain procedures are of limited value 
during screening and/or investigation of different genetic disorders. The lack of public 
health measures and inadequacy of perinatal health care, especially in low income 
countries, lead to inappropriate control of genetic disorders. Despite these limitations, 
several Arab countries have endorsed an initiative to apply genetic prevention 
programmes; premarital, antenatal and neonatal. Nevertheless, these programmes 
are mainly directed to certain common genetic disorders due to the cost of 
implementing these programmes among populous, though low-income, countries. 
1.5.2 Reported cases of MH in Arab countries 
Searching for case reports and epidemiological data about MH in the Arab countries 
reveals minimal results. Nevertheless, as MH has been reported in all ethnic groups 
and due to the diversity of ethnic backgrounds of the population in these countries, we 
have little doubt that MH exists in the Arab countries. The Centre for Arab Genomic 
Studies in its report in 2016 (Centre for Arab Genomic Studies, 2016), listed three 
cases of suspected MH reaction that happened in Bahrain and another two cases in 
Saudi Arabia. The initial reports of these cases could not be traced due to poor 
referencing in the report. Only one case was reported to have died as a result of the 
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anaesthetic reaction while dantrolene was used in the other cases, and they were 
reported to survive the reaction. None of the reported cases had their MH susceptibility 
status confirmed, though, one of the relatives of the deceased case reported in 
Bahrain had the MH susceptibility status confirmed in the USA using CHCT. 
1.5.3 Challenges in the diagnosis and management of MH in Egypt 
The same population characteristics described early in the Arab world and the Middle 
East region that favour the spread of genetic disorders are presented among the 
Egyptian population. In addition, Egypt is the most populous country in the whole 
region with limited funding directed to health care programmes aimed at the screening 
of rare-occurring genetic disorders. Other limitations in the diagnosis and 
management of MH related to the health care systems operating in Egypt will be 
discussed thoroughly in the sixth chapter investigating the epidemiology of MH in 
Egypt. 
1.6 Thesis aims 
This study aims to investigate the incidence and prevalence of MH in the UK in recent 
years and to explore the genetic epidemiology of MH among the UK population. This 
research exploits the resources available at the Leeds MH Investigation Unit to explore 
the genotypic-phenotypic correlation of MH in the biggest cohort of patients who have 
had their susceptibility status confirmed using the gold-standard IVCT test after a 
suspected anaesthetic reaction or because of a clinical diagnosis of other MH-related 
muscular disorders. We also aim to define the extent of the problem of MH in Egypt in 
the absence of any referral or investigation centre in the region. Our long-term aim is 
to consolidate the use of the less-invasive genetic testing for the diagnosis of MH 
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susceptibility and to offer a base for future studies about MH in Egypt and the Middle 
East region. 
1.7 Thesis objectives 
1.7.1 Investigating the clinical epidemiology of MH in recent years 
The initial objective of this study is to review the clinical details of suspected 
anaesthetic reactions of MH susceptible proband who were investigated at the Leeds 
MH Investigation Unit over the last three decades. This will enable us to have a more 
comprehensive understanding of the clinical presentation of MH in the lights of modern 
anaesthetic practice. Therefore, we will be able to define the sex and age 
characteristics of this cohort of patients and categorise different clinical phenotypes of 
MH and understand the effects of different pharmacological agents on the 
development of these phenotypes. In addition to investigating how different 
management measures affect the outcome of the reaction. 
1.7.2 Correlation of RYR1 genotypes to the clinical and IVCT phenotypes of MH 
Subsequently, this understanding of the clinical epidemiology of MH among UK 
patients, and with the availability of genetic data for a vast majority of this cohort of 
patients, will enable us to correlate genotypic data to the clinical and IVCT phenotypes. 
The functionally characterised RYR1 variants will be investigated to explore its effects 
on the development and severity of different clinical features of MH. Furthermore, we 
will compare these genotypes against contracture strengths from IVCT lab results in 
order to quantify its laboratory effects. In addition, the IVCT data of first-degree 
relatives of the included probands will be retrieved in order to examine the effects of 
the suspected MH reactions on the in-vitro response of skeletal muscle to halothane 
and caffeine. 
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1.7.3 Investigate the association between MH and CM 
Clinical, genetic and histopathological details of the index cases of central core 
disease families will be reviewed in addition to their MH susceptibility status in order 
to identify variants that are causative of MH and lead to the development of CM. 
Details of other family members of CCD families who were tested at the unit will be 
reviewed to perform a segregation analysis of RYR1 genotype, myopathy phenotype 
and MH phenotype. Also, the histopathological examination reports of all index cases 
of MH families will be reviewed to investigate the incidence of RYR1-related 
histopathological changes in MH susceptible patients who do not suffer clinical muscle 
weakness. 
1.7.4 Explore the incidence of suspected MH reactions in Egypt 
An online questionnaire will be conducted on a local, then on a national perspective to 
collect preliminary data about MH in Egypt. We will try to explore the experience of 
Egyptian anaesthetists with MH, possible outcomes of suspected cases and available 
management measures and protocols in Egyptian hospitals. 
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2 Patients and methods 
2.1 Literature search strategy 
We used different search engines to search for the available literature about MH and 
its clinical and genetic epidemiology published by different research groups and labs 
interested in studying the condition around the world. Google Scholar and PubMed 
were the main search engines we used during our literature search for different 
keywords. The following table 2-1 shows a list of keywords and phrases we used 
individually and in combination during our search. Our review of the resulting literature 
enabled us to identify many of the limitations of previous studies that will be discussed 
thoroughly in the next chapters and to determine the gap in science that we aim to 
cover using the resources available for us. 
 
Anaesthetic deaths Epidemiology Myopathy 
Ca+2 homeostasis Excitation-contraction Pharmacology 
CACNA1S gene Fibre type Phenotype 
Calcium release channel Genotype Rhabdomyolysis 
Central core disease Halothane Ryanodine receptor type 1 
Central nuclei Inhalation anaesthetics RYR1 gene 
Congenital myopathy(-ies) Malignant hyperpyrexia RYR1 myopathy 
Contracture test Malignant hyperthermia Succinylcholine 
Cores MH Volatile anaesthetics 
Creatine kinase Muscle 
 Dantrolene Muscle relaxants 
Dihydropyridine receptor Myopathies 
Table 2-1: List of keywords used to search for published literature. Used individually or 
in different combinations. 
 
2.2 Identifying patients from the Leeds MH Investigation Unit database 
Using the Leeds MH Investigation Unit’s both databases, we identified patients to be 
included in different study cohorts. Index cases for each family were identified by 
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collecting IVCT numbers with the same family code, and as these IVCT numbers are 
assigned in chronological order, the patient with the lowest IVCT number is the index 
case for this family. As explained before in this study, we used the index case to refer 
to the first patient tested in each family while probands are the patients presented with 
the clinical phenotype and triggered investigation in their families. In some instances, 
probands were labelled on the database, however, we had to confirm their status by 
reviewing the reason for referral on the biopsy report stored in patients’ files at the unit 
archive. After identifying patients to be included in each group of our study cohorts, 
other information collected from the database included: patients’ date of birth, date of 
biopsy, MH susceptibility status, and basal serum CK level at the time of the biopsy. 
From the genetic table, we also collected information about genetic testing results for 
the included patients and any variants found in the three genes of interest; RYR1, 
CACNA1S and STAC3. 
The following figure 2-1 illustrates the different study populations and how they are 
related to each other. Of all patients tested at the unit, the index cases, as according 
to the previous definition, are the first member of their families to be tested. This 
includes the probands who have presented with the clinical manifestation and 
triggered investigation in their families. A portion of index cases who were first tested 
but did not present with the clinical manifestation, light blue colour in the diagram, are 
the first-degree relatives of probands that could not be tested as they were deceased, 
too young to be tested, or unfit for the procedure. The graph also shows some overlaps 
between study cohorts that need some clarification. Group A is a cohort of patients 
who developed an anaesthetic reaction and upon review of their clinical notes, they 
were found to have some degree of clinical muscle weakness related to congenital 
myopathy. Group B patients are index cases of known CM families that have been 
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referred to the unit to be tested for the risk of MH susceptibility, without any history of 
anaesthetic reaction. While group C patients are other members of CM families that 
were referred because of the risk of MH either due to a history of anaesthetic reaction 
in the proband or confirmed MH susceptibility in other family members. 
 
 
Figure 2-1: Different study groups illustrating the overlap between different cohorts. A) 
patients who developed a suspected anaesthetic reaction and were found to have CM related 
muscle weakness. B) Index cases of CM families and C) family members of known CM 
families whose index cases MH susceptibility status was previously confirmed. P.S. diagram 
proportions are not representative of actual percentages. 
2.3 IVCT measurements 
The IVCT traces for patients tested at the unit are kept in their corresponding files in 
the unit archive, in addition to an electronic version of the more recent traces kept on 
the unit lab computers. We have retrieved the IVCT traces from files and lab 
computers to measure the initial tensions, twitch heights, and tension differences to 
compare how muscles, from different groups of patients included in our cohort, react 










As shown in the following figure 2-1, two imaginary lines are drawn; one through the 
baseline at the start of the test and another one crosses the lowest point of the muscle 
contracture line. The initial tension is measured electronically, and this reading is used 
to define the scale of the graph. This scale is measured by dividing the electronic 
reading over the distance between the imaginary baseline and the initial stretch point. 
Using the resulting scale, the twitch tension and the contracture difference, in grams, 
are measured as follow: 
Ø Twitch tension = graph scale * twitch height in cm 
Ø Contracture difference = graph scale * distance between contracture line at 2% 
and the imaginary line crossing the lowest point 
  
Figure 2-2: IVCT trace of static halothane test showing a positive response. 0.5, 1 and 
2% halothane concentrations are added to the water bath. Tension difference is measured 




Figure 2-3: IVCT trace of dynamic halothane test showing a positive response. The trace 
shows repeated stretching and relaxation of the muscle specimen. 0.5, 1 and 2% halothane 
concentrations are added to the water bath. The tension difference is measured between the 
lowest point of the contracture line and its corresponding point at 2% halothane. 
The same measurements are applied for the dynamic halothane and the static caffeine 
tests as shown in these figures 2-2 and 2-3. 
 
Figure 2-4: IVCT trace of the caffeine test showing a positive response. 0.5, 1, 1.5, 2, 3, 
4, 32 mmol concentrations are added to the water bath. Tension difference is measured 
between the lowest point of contracture line and 2 mmol caffeine. 
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All the above figures are traces from positive tests for MH susceptible (MHS) patients, 
while in the case of a negative test, the contracture difference at 2% for either of 
halothane tests or 2 mmol for caffeine test, will be a negative value as the muscle 
specimens continue to relax and the contracture line slopes down. In this case, this 
particular test is labelled negative; however, the patient is not labelled as MHN unless 
the results from the three tests are all negative. If any of the tests were positive, the 
patient should be labelled susceptible to MH. Historically, a patient with a positive test 
and not the others used to be labelled as MHE. However, more recently, the following 
codes are used to indicate patients’ MH susceptibility status: 
Ø MHShc: all the halothane and caffeine tests are positive. 
Ø MHSh: only one or both halothane tests are positive, but the caffeine test is 
negative. 
Ø MHSc: the caffeine test is positive, but both halothane tests are negative. 
Ø MHN: all the halothane and caffeine tests are negative. 
In clinical practice, patients should be treated as susceptible to MH and anaesthetised 
with triggering-free anaesthetics if any of the tests were positive. 
2.4 Statistical analysis plan 
The Clinical and Genetic Epidemiology of Malignant Hyperthermia is designed as part 
of the study entitled: Human Tissues and Genomics Research in Malignant 
Hyperthermia with REC reference: 10/H1306/70, and the IRAS project ID: 60744. 
Ethical approval has been obtained for the original study from the University of Leeds 
ethics committee. It is designed as a retrospective study to review the clinical details 
available for patients tested at the Leeds MH Investigation Unit in patients’ files stored 
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at the unit archive and on the unit databases, while the patients have given their 
consent to use this data for future research at the time of the biopsy. 
Statistical analysis was performed using Prism 7 for macOS, © 1994-2017 GraphPad 
Software, Inc. Variables such as age, time in minutes, temperature in ℃, etCO2 in 
mmHg, and pH, were collected as continuous variables and tested for normality using 
the eyeball test and Shapiro-Wilk normality test when indicated. When data appeared 
to be normally distributed, parametric tests were used to compare between variables; 
student t-test for comparing between two groups and one-way ANOVA when 
comparing between more than two groups. When data appeared to be not normally 
distributed, data transformation was tried using the square root and Log 10 
transformation methods. If these methods produced normally-distributed data, 
parametric tests were used, and back transformation to produce the geometric mean 
was used. When these methods failed to produce normally distributed data, non-
parametric tests were used on the original data without any transformation; Mann-
Whitney test to compare between two groups and Kruskal-Wallis test to compare 
between more than two groups. 
When multiple comparisons were used to compare between each other group or 
between different groups and a control group, Fisher’s Least Significant Difference 
(LSD) test was used for normally distributed data and Dunn’s test for non-normally 
distributed data. No correction for multiple comparisons was performed, and the 
results were discussed accordingly. Chi-square test (X2) was used to test for 
association between categorical variables. The level of significance (p value<0.05) 
was considered statistically significant and is presented as a two-sided comparison, 
unless stated otherwise. Confidence interval (CI) of the mean is set at 95%.  
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2.5 Histopathological examination 
As mentioned before, during a muscle biopsy, a muscle specimen is harvested for 
histopathological examination. This specimen is sent to the Department of 
Neuropathology, Leeds Teaching Hospitals, NHS trust to be examined by the 
neuropathology team. A microscopic examination of the muscle biopsy is performed 
to describe the fascicular architecture of the muscle and muscle fibres distribution, 
size and shape. In addition, the muscle sample is stained with different stains to detect 
the presence of histopathological changes. The Hematoxylin and eosin (H&E) stain is 
used to detect any atrophy or hypertrophy of muscle fibres, and the percentage of 
centrally located nuclei in these fibres, the nicotinamide adenine dinucleotide (NADH) 
stain detects the presence of cores, their number and location within the muscle cells. 
The ATPase stain gives details about fibre types variation and if there is a 
predominance of one type over another, and the Gömöri stain describe the 
mitochondrial contents of the muscle fibres and the presence of inclusion bodies. 
2.6 Serum creatine kinase measurements 
When the patients attend for the biopsy list at St James’s University Hospitals, a 
routine procedure is to obtain a blood sample for measuring the basal serum CK level. 
The lab report of the results is kept in the patients’ corresponding files at the Leeds 
MH Investigation Unit archive and recorded on the unit database. The reference range 
for the lab differed over the years from 0-140 IU at the lower range and 90-280 IU at 
the upper range. The reference range was only available for patients whose lab reports 
were available in their corresponding files but not recorded on the unit database. For 
basal CK levels, we used the Log 10 transformed values to obtain a normally 
distributed data and compared the results as described in the statistical analysis plan. 
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2.7 Screening for genetic variants 
Since the establishment of the genetic background of MH, the Leeds MH Investigation 
Unit has started screening for genetic variants on the different genes involved in the 
pathogenesis of MH. The conventional methods used included Sanger sequencing 
(Sanger et al., 1977) and restriction fragment length polymorphism (RFLP). 
Nowadays, a panel of 50 genes are being screened at the DNA lab at St James’s 
University Hospitals for variants associated with MH using next-generation 
sequencing (NGS) including the three genes with approved association with MH; 
RYR1, CACNA1S, and STAC3. This method has widely replaced the conventional 
methods; however, Sanger sequencing is still being used to scan for variants in some 
RYR1 exons with inadequate coverage, e.g. exon 91, or to validate the results of NGS 
in some cases, and for in-house genetic testing. Patients tested using RFLP were 
screened for a list of RYR1 variants, the number of variants on this list has increased 
over the years, and patients tested with this method may be found to have other 
variants if re-screened using NGS. 
  
 36 
3 Investigating the clinical epidemiology of suspected MH 
reactions referred to the Leeds MH Investigation Unit 
3.1 Introduction 
The severe reactions to general anaesthetics that involved hyperthermia and led to 
death in many cases (Denborough et al., 1962, Cullen, 1966, Britt et al., 1969), was 
described first time by (Denborough and Lovell, 1960) and used the term malignant 
hyperthermia to name it. The term malignant was used to emphasise the high mortality 
rate of this condition at that time while the term hyperthermia, “hyperpyrexia” was used 
at that time, was used because of the progressive increase in temperature triggered 
by general anaesthetics and noticed in the affected patients. In these days, monitoring 
was depending mainly on clinical observation (Hopkins, 2000), but with the advances 
in monitoring equipment, the clinical picture of the reaction appeared to involve other 
manifestations that usually precede the development of hyperthermia. The classic 
fulminant form of the MH reaction became less prevalent as more anaesthetists 
became more aware of these other manifestations and with the introduction of 
advanced monitoring manifestations such as hypercapnia and tachycardia are now 
recognised as early indicators of a hypermetabolic reaction which enable the 
anaesthetists to early intervene and abort the development of a severe reaction. On 
the other hand, less severe forms of the reaction and early aborted cases are 
becoming more common to report. 
Without exposure to triggering agents, MH susceptible patients are usually 
asymptomatic. Basal serum CK level could be slightly elevated in some patients, but 
this is not specific to MH and varies with age, sex and physical activity. Additionally, 
other clinical features that could be indicative of MH susceptibility such as heat 
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intolerance, heat exhaustion (Tobin et al., 2001) or muscle cramps (Ogletree et al., 
1996), most of these indicators were found to be manifestations of other related 
muscular disorders such as central core disease or exertional heat illness that are 
often associated with MH and none of these indicators are considered specific to MH 
(Hackl et al., 1991, Hopkins et al., 1991). Even the association between MH and these 
diseases are not always consistent (Islander et al., 1995, Halsall et al., 1996, Curran 
et al., 1999). Other musculoskeletal abnormalities have been suggested to be 
associated with MH susceptibility such as scoliosis and hernias (Britt, 1979, Strazis 
and Fox, 1993). However, this association could not be approved after the analysis of 
the clinical details of a large cohort of MHS patients (Halsall et al., 1996). 
MH reactions are triggered in susceptible patients on exposure to anaesthetics; 
nevertheless, not all susceptible patients trigger a hypermetabolic MH reaction in their 
first exposure. An average of three previous uneventful exposure was reported in 
patients who developed an MH reaction. Previous exposures to anaesthetics prior to 
the reaction are usually uneventful or could be associated with some unspecific 
manifestations such as postoperative muscular pain or stiffness, particularly, if 
succinylcholine was used as part of the anaesthetic. Family history is the most 
indicative of MH susceptibility, as from the first reported case (Denborough and Lovell, 
1960), the anaesthetist was pre-alerted about a possible problem because of the 
family history of anaesthesia related deaths. Proper investigation of the family history, 
taking into consideration that MH is an autosomal dominant inherited condition, could 
alert anaesthetists about the possible risk and help to direct the patients for further 
investigation.  
The clinical manifestations of the MH reactions involve signs of hypermetabolism such 
as tachycardia, increased CO2 production, acidosis, which is mainly respiratory, and 
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hyperthermia. In addition, muscular features are also described as part of the 
anaesthetic reaction and include increased muscle tone either in a specific group of 
muscles, such as jaw muscle, leading to MMS, or in the form of generalised muscular 
rigidity. This continuous, uninterrupted muscular activity causes damage to muscle 
fibres and muscle breakdown. The results of this muscle breakdown include the 
release of muscle proteins in the blood (myoglobinaemia), which is excreted in the 
urine, causing myoglobinuria and an increased serum creatine kinase (CK) level. 
Additionally, the disruption of the membrane permeability leads to an increased 
release of potassium ions (K+) into the bloodstream leading to hyperkalaemia. None 
of these features is specific and could be signs of too many other conditions. Ellis and 
colleagues (Ellis et al., 1990) reviewed the clinical details of 402 patients who 
developed a suspected anaesthetic reaction and referred to the Leeds MH 
Investigation Unit to confirm their MH susceptibility status using the IVCT. They 
compared the different combinations of these clinical features to the results of the 
IVCT test and described eight different clinical categories and calculated the 
probability of MH susceptible diagnosis in each category. 
The anaesthetic practice including different pharmacological agents being used, 
monitoring equipment available, and standardisation of different management 
protocols and guidelines, in addition to the changes in surgical techniques and types 
of surgeries; should have an impact on the clinical presentation and management of 
an MH reaction. For instance, MH is known to be triggered by more potent volatile 
anaesthetics (Ørding and Bendixen, 1996), and with the cessation of use of halothane 
in the UK since the late 1990s and the use of less potent anaesthetics, it is expected 
for the incidence of MH to decrease or at least the fulminant form of the reaction. Also, 
the use of succinylcholine has diminished with the introduction of other muscle 
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relaxants that provides an accepted rapid onset of action for rapid sequence induction 
with fewer side effects; such as rocuronium. Additionally, the number of operations 
performed using other anaesthetic techniques such as regional anaesthesia and TIVA 
is increasing, with a reduction in the number of patients exposed to triggering agents. 
Patients undergoing certain surgical specialities are more commonly reported to 
develop MH reaction such as general surgery, E.N.T., and trauma. Also, management 
of MH crisis has been evolving with the availability of dantrolene, the establishment of 
guidelines and the introduction of activated charcoal filters as an alternative to gas-
free machines. 
The incidence of MH reactions was estimated to range between 1 in 15,000 to 1 in 
50,000 (Britt and Kalow, 1970, Ording, 1985), although an estimate of the incidence 
of genetic MH susceptibility trait was estimated to be 1 in 2,000 (Monnier et al., 2002), 
while the prevalence is estimated to be 1 in 8,500 (Robinson et al., 2002). Infants as 
young as one year old to elderly patients are reported to develop MH reactions, but 
the most affected age group is reported to be young people with a mean age of 18.3 
years (Rosenberg et al., 2015) with males being more susceptible than females. Male 
predominance in patients who tested susceptible to MH with disregard for the reason 
of referral is reported in several previous studies. In patients who were referred for 
diagnosis of MH susceptibility because of an anaesthetic reaction, this predominance 
was assumed to be due to males being more likely to have surgery associated with 
MH triggering agents (Ording, 1996). In Sweden, an analysis of 215 probands and 
1191 family members found a statistically significant male predominance in both 
groups (Islander et al., 2007). They proposed several theories to explain this male 
preponderance: the first explanation is related to the possible sex difference in the 
Ca+2 regulating proteins expression, which could be related to the effects of sex 
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hormones. Another explanation hypothesises a relatively lower penetrance in female 
patients who carry the MH genotype. This hypothesis, though, does not explain the 
male predominance of MHS diagnosis with IVCT in relatives. 
Different pharmacological agents are used during the anaesthetic practice, and it 
varies differently in the mechanism of action and the effects it has on the clinical status 
of the anaesthetised patient. These pharmacological agents have different effects on 
the triggering, course and management of a MH reaction. The different groups of drugs 
used during anaesthesia can be classified according to its effects on MH into three 
groups: the first group includes triggering agents, secondly is the group that may 
modify the response to MH, and the third group is the drugs used for management of 
a MH crisis. By definition,  is a pharmacogenetic disorder that is triggered in genetically 
susceptible patients by volatile anaesthetics and(or) succinylcholine. All the volatile 
anaesthetics in-use in the modern anaesthetic practice can trigger an MH reaction. 
This is on the contrary to a worryingly growing belief that MH does not exist anymore, 
as it is considered a disease of halothane anaesthesia (Sneyd, 2017). 
Neuromuscular blocking agents are split between the first and second groups as 
succinylcholine is considered by many to be a triggering agent for MH while non-
depolarising muscle relaxants (NDMR) could modify the clinical picture of an MH 
reaction. The role of succinylcholine in triggering a hypermetabolic MH reaction is still 
controversial. Its role was investigated in several studies on porcine MH. While two 
groups studying porcine MH (Hall et al., 1972, Nelson et al., 1973) were not able to 
trigger an MH reaction in susceptible pigs using succinylcholine alone, (Harrison, 
1971) found that the muscular rigidity induced by succinylcholine in susceptible pigs 
is prevented by prior curarisation. Reports about the development of a fulminant 
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hypermetabolic MH reaction with the use of succinylcholine alone either in humans or 
in pigs are not convincing (Hopkins, 2011). Most of the reported features of MH 
triggered by succinylcholine without the use of volatile anaesthetics can be otherwise 
explained due to other causes (Iaizzo and Wedel, 1994). Its combination with volatile 
anaesthetics is associated with a more exaggerated muscular response in the form of 
higher CK levels (Antognini, 1995) or marked rigidity (Aboelsaod et al., 2018). 
On the other hand, NDMR was found to be protective against the development of MH 
in 50% of susceptible pigs that received halothane (Hall et al., 1976) or at least delay 
the development of the reaction (Suresh and Nelson, 1985). Analysis of the clinical 
data of suspected MH reactions in humans revealed a significantly longer time of onset 
of the reaction with a lower postoperative serum CK levels (Young et al., 2010) when 
NDMR was used. Moreover, a recent study conducted by P.D. Allen and colleagues 
and presented at this year EMHG annual meeting found that complete neuromuscular 
blockade prevented, utterly, the development of an MH reaction in susceptible pigs 
that were exposed to halothane. Additionally, they found that complete blockade with 
pancuronium prevented Ca+2 increase in susceptible mice exposed to isoflurane, while 
when this blockade was reversed with neostigmine, in vivo Ca+2 measurements 
showed an increase in Ca+2 levels. 
Other drugs that belong to this second group of modifiers include IV agents and 
opioids. Few studies investigated the role of IV anaesthetics in MH triggering, and only 
thiopental was claimed to delay the onset of the reaction in susceptible pigs (Hall et 
al., 1972, Gronert and Milde, 1981, Suresh and Nelson, 1985). Studies of etomidate 
(Suresh and Nelson, 1985) and propofol (Raff and Harrison, 1989) could not find any 
similar effects to that of thiopental in swine MH. We could not find in literature enough 
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information about the possible effects of opioids on the development and severity of 
MH reactions. The third group of pharmacological agents include drugs used in the 
management of an MH crisis. The most important in this group that had a dramatic 
effect in reducing the mortality rate of MH reaction is dantrolene sodium. Since 
dantrolene was shown to treat an established MH reaction in pigs and was suggested 
to be used for treatment of MH in humans by (Harrison, 1975), its use in humans 
showed a marked improvement in survival after MH reaction (Kolb et al., 1982) and 
mortality rate of MH decreased dramatically from around 70% (Denborough, 1998) to 
less than 10% (Strazis and Fox, 1993). Other drugs that are used during the 
management of an MH reaction are not specific and only used as supportive or 
symptomatic treatment include sodium bicarbonate (NaHCO3), magnesium sulphate 
(MgSO4) and diuretics. 
Recrudescence of MH is defined as the rebound of clinical features of MH reaction 
after the initial episode has been resolved with adequate treatment and without any 
further triggering. The pathogenesis of this recurrence of symptoms and signs is not 
fully understood; however, patients’ body habitus, duration of anaesthesia and 
elevated temperature during the initial reaction were found to have been associated 
with a significantly higher rate of recrudescence (Burkman et al., 2007). This study 
found that, in patients referred to the North American Malignant Hyperthermia Registry 
(NAMHR), the recrudescence rate was reported to be 20% of patients whose CGS 
was >20, which reflects a likely diagnosis of MH. Previous case reports suggested that 
predictors of recrudescence of MH include persistent muscular rigidity (Mathieu et al., 
1979), shivering (Short and Cooper, 1999) or tachycardia (Fletcher et al., 1982, 
Morrison and Serpell, 1998), in addition to hyperkalaemia and oliguria (Mathieu et al., 
1979). 
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The clinical grading scale developed by Larach and colleagues (Larach et al., 1994) 
approved to be very helpful in determining the likelihood of the suspected anaesthetic 
reaction to be a true MH reaction. The opinions of a panel of experts were collected 
using the Delphi method to evaluate clinical details of patients who developed a 
suspected anaesthetic reaction. Scoring of different clinical indicators to generate a 
raw score that is ranked to describe the likelihood of MH diagnosis. The clinical 
indicators used were classified into six processes: the first process is related to the 
development of muscular rigidity, either generalised or MMS in relation to the 
administration of succinylcholine. The second process is dependent on manifestations 
of muscle breakdown such as elevated serum creatine kinase, myoglobinaemia or 
myoglobinuria, and increased serum potassium levels. Increased CO2 was described 
in the third process, which indicates respiratory acidosis. Inappropriate temperature 
increase, according to the anaesthesiologist’s judgement, is indicated in process 4, 
and cardiac involvement in the form of tachycardia or ventricular arrhythmias is the 
fifth process. A final process is described in relation to the family history of MH. A 
single indicator in each of the prescribed processes should be included to avoid double 
counting. However, other indicators such as arterial base excess, arterial pH, patients 
previous anaesthetic history, and the response of the reaction to treatment with 
dantrolene are added without taking double-counting into consideration. 
All the included patients in this study have had their MH susceptibility status already 
confirmed. However, we should distinguish between the susceptibility status and the 
adverse anaesthetic reaction being a true MH reaction. As none of the manifestations 
of MH is specific, besides, these manifestations could be due to other reasons such 
as adverse drug reactions, equipment malfunction, or human errors; it is essential to 
evaluate each referred clinical reaction to confirm the diagnosis of MH or to evaluate 
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the possibilities of other diagnoses. For example, masseter muscle spasm (MMS) is a 
frequently described sign of an MH reaction, and 50% of patients who develop MMS 
are tested susceptible to MH (Ellis et al., 1992), though, this sign could indicate only 
succinylcholine sensitivity (Carpenter et al., 2009). Another example is the 
hypercapnia that may result from a malfunction of a Bain’s circuit (Berner, 1987, Jellish 
et al., 2001), on the other hand, it could be a manifestation of an MH reaction. 
Therefore, we used the CGS to reassess the clinical details of the anaesthetic 
reactions of our MHS cohort of patients. 
Using the resources available for us at the Leeds MH Investigation Unit, we aim to 
explore the male predominance described to be associated with MH and to investigate 
if it is a true predominance of MH susceptibility comparing our results to the cohort of 
MHN probands and the general surgical population. We also aim to investigate further, 
the role of succinylcholine in triggering hypermetabolic MH reactions and its effect on 
the pathogenesis and severity of the clinical features of the MH reaction. Additionally, 
we will analyse the outcomes of the reported anaesthetic reaction regarding MH-
related complications, and MH-related deaths and investigate the role of different 
management measurers on these outcomes. 
3.2 Patients selection and methods 
3.2.1 Identifying MH susceptible index cases 
As we discussed early, the main target of this chapter is to collect and review the 
clinical details of all suspected cases of malignant hyperthermia who were referred to 
the Leeds MH Investigation Unit and tested MH susceptible using IVCT over the 30 
years period from 1988 to 2017, inclusive. We used the unit database to identify all 
MHS families that were tested at the unit during this period. The IVCT numbers, which 
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are assigned in chronological order, of all members of these families were sorted on 
an ascending order to identify the index case, the first patient to be tested, in each 
family. The files containing the IVCT biopsy report, medical and anaesthetic history, 
IVCT traces, clinical details of the suspected reaction, and laboratory reports of serum 
CK level of these cases are retrieved from the unit archive. These files were reviewed, 
and all the relevant information were collected for the purpose of this study. A 
spreadsheet was designed into different sections to collect all the relevant information 
to our study. 
The first section aimed to collect information about the included patients’ general 
characteristics including sex, date of birth, occupation, social history and sports 
activity. This section is aimed to compare these general characteristics to these of the 
general surgical population and to identify any specific characteristics of the MHS 
patients. A second section was designed to gather data about the medical history of 
any relevant condition, history of previous anaesthetics, including numbers and the 
type of anaesthetic used, and any complications that may be of relevant importance, 
in addition to a family history of anaesthesia related complications and/or deaths. 
These details are usually included in the IVCT biopsy report, included in patients’ files. 
A third section collected the additional information included in this report about the 
date of the biopsy and the tension threshold at which the muscle specimens reacted 
to different concentrations of halothane and caffeine in the three IVCT tests. 
The section for collecting information from anaesthetic charts and/or referral letters 
about the suspected anaesthetic reaction was designed to record the details of the 
anaesthetic technique used during the reaction including the pharmacological agents 
used: volatile anaesthetics, muscle relaxants (succinylcholine and non-depolarising 
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muscle relaxants), intravenous anaesthetics and opioids; in addition to the type of the 
circuit and the ventilation mode used in each patient when it was reported. We also 
recorded the first clinical sign of the reaction noticed by the attending anaesthetists, 
and the time in minutes from the induction of anaesthesia to the start of the reaction. 
Maximum derangement values of clinical signs such as temperature, etCO2, and heart 
rate, in addition to lab results such as pH, K+, and serum CK levels were also recorded. 
If the referral letter and/or anaesthetic chart included a mention about the occurrence 
of features such as MMS, generalised muscle rigidity, myoglobinuria, and 
coagulopathy, it was recorded as a binary yes or no variable, but it was left blank if it 
was not reported at all. 
Another section was designed to collect information about management measures 
used during the reported suspected reaction. The use of dantrolene, the time from the 
recognition of an MH reaction to the administration of dantrolene, the initial and the 
total dose used is recorded. In addition, we collected information about other specific 
management measures such as cooling techniques to reduce body temperature, the 
use of sodium bicarbonate (NaHCO3) for acidosis, replacement of anaesthetic 
machine with a gas-free machine. Any other management measures reported by the 
attending anaesthetist were also recorded, and this included the use of fluid boluses, 
diuretics and vasopressors. We also recorded if the surgery was abandoned or was 
allowed to continue; as this may provide an idea about the severity of the reaction in 
the anaesthetists’ judgement. 
The last section gathered details of the outcome of the suspected anaesthetic reaction. 
Possible complications related to muscle breakdown such as postoperative muscle 
pains, stiffness or weakness were described. The occurrence of compartment 
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syndrome was also described in a few patients. Severe rhabdomyolysis and renal 
complications such as acute kidney injury (AKI) and/or acute renal failure (ARF) were 
also reported, and we recorded if these complications required haemodialysis. In 
addition, we recorded if patients mandated an intensive care or high dependency unit 
admission, the length of stay, and any further complications reported if ICU notes were 
available for review. Recrudescence was reported in some patients, and we collected 
all the available clinical information about subsequent episodes. In the instance of 
index cases who were tested as family members of patients who did not survive the 
reaction, we collected clinical details of the suspected fatal anaesthetic reactions but 
will be presented separately in the results section of this chapter. 
3.2.2 Patients who had suspected anaesthetic reactions and tested MHN 
We had to compare our results to a control group. We used data from patients who 
have been referred to the unit for testing for MH susceptibility because of a suspected 
anaesthetic reaction and were tested MHN with IVCT. The clinical details of 
anaesthetic reactions of a total of 250 patients referred to the unit over the period 
between 1990 and 2009, were collected by medical students for a research project. 
We have retrieved these details after obtaining permission from the project 
coordinator. The data collected for this project included information about patients’ 
sex, the volatile anaesthetics used, the use of succinylcholine, and information about 
the clinical features of the reaction. Clinical features collected included the maximum 
derangement values of etCO2, temperature, heart rate, pH, postoperative serum CK 
levels and serum K+ levels. They also reported the occurrence of MMS as a sign of 
muscular rigidity. Some missing details compared to our dataset of MHS probands 
include the date of the reaction to determine patients’ age at the time of the reaction, 
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the occurrence of other muscular features such as generalised rigidity and 
myoglobinuria, and the outcome of the reaction including management measures. 
3.2.3 The general surgical population 
The denominator for our cohort to be compared against is the surgical population when 
comparing variables such as sex, age and surgical specialities. We were able to obtain 
this information from the data presented at the National Audit Project (NAP) reports 
(https://www.niaa.org.uk/NAP_home). The NAP is a project to study rare-occurring 
anaesthesia related complications with serious consequences. In addition to the 
information provided about the topic of interest for each project, the NAP offers 
valuable data on the numbers and age and sex characteristics of patients receiving 
anaesthetics for different procedures. The most recently published NAP report is the 
NAP 6 project (Harper et al., 2018) investigating the allergic reactions associated with 
anaesthesia and surgery. The majority of data collection for the NAP 6 project took 
place over a three-week period in October 2016. The annual caseload was estimated 
by multiplying the number of cases by a scaling factor. This project reported a 
reasonable return rate of the forms distributed to the 342 hospitals involved in the 
project. The estimated annual caseload was 3,126,067 cases. 
3.2.4 Data handling 
The sports activity that is recorded in the biopsy reports stored in patients’ files at the 
unit archive was categorised into three degrees: patients who reported no sports 
activity at all was given grade 1, while patients who mentioned they perform some 
sports activity to remain active were given grade 2 and patients who reported a 
professional athletic training were given grade 3. The history of cramps was also 
recorded as patients either reported suffering cramps or not. The age at which the 
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proband had the anaesthetic reaction is not routinely recorded in the IVCT biopsy 
reports that are kept in patients’ files in the unit archive. We recorded the date of birth 
and the age at the reaction for each proband included in this study. The first reported 
sign is recorded according to the reporting anaesthetist judgement. Through reviewing 
anaesthetic charts, we found that some signs could have been developed earlier and 
not noticed by the attending anaesthetist, though, for consistency, we included the 
signs reported by anaesthetists. Unless stated otherwise, we considered patients to 
have normal temperature before the procedure, and for statistical analysis, we 
recorded the difference between the highest reported temperature and 37℃. Similarly, 
for pH, we recorded the difference between the lowest recorded value and 7.4. 
As the etCO2 baseline is not routinely recorded, for statistical analysis, we recorded 
the maximum derangement value and as discussed earlier, we used a cut-off point for 
considering heart rate is inappropriately increased if it was >100 beats/minute in adults 
and >120 beats/minute in paediatrics and included the highest recorded value. For 
signs such as MMS, generalised muscular rigidity, myoglobinuria and coagulopathy; 
although the absence of these signs has been reported in few patients, we considered 
these signs as negative when it was not mentioned in other patients. K+ and serum 
CK maximum derangement levels were recorded as absolute values regardless of the 
baseline level before the reaction. In a few patients, the initial rise and the maximum 
value of serum CK level were recorded in addition to the time in minutes between the 
initial rise and the maximum value.  
3.2.5 Calculation of the Clinical Grading Scale 
Each of the clinical features that are listed in the clinical indicators used by Larach et 
al. was given points to calculate the CGS for each reaction. Unless stated otherwise 
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in the referral letters, all the described clinical features are considered as 
“inappropriate in anaesthesiologist’s judgement”. Some indicators such as generalised 
rigidity, MMS, the CK level in relation to the use of succinylcholine was clearly and 
easily interpreted. For indicators of the respiratory acidosis process, the mode of 
ventilation, as spontaneous or controlled, was not described in many patients. 
Therefore, when the ventilation mode was not mentioned, we used the cut-off point of 
8 KPa (~60 mmHg) for etCO2 and 8.65 KPa (~65 mmHg) to give this indicator the 15 
points for respiratory acidosis process. For temperature indicators, unless the baseline 
temperature, prior to the reaction, was recorded, we assumed a normal baseline 
temperature of 37℃ and that the recorded rise in temperature is considered 
“inappropriate in anaesthesiologist’s judgement”. 
Cardiac involvement indicators were the most challenging to assess in our cohort of 
suspected MH reactions. It was seldom mentioned in the referral letter if the 
anaesthetist considers this heart rate as inappropriately increased. In addition, when 
retrieving these data from the anaesthetic charts, it was not always clear the temporal 
relation between the heart rate and other factors that may have an influence on its 
pace, such as skin incision or other medications. We had to set our cut off point of 100 
beats/min for adults and 120 beats/min for children to be considered as inappropriate, 
regardless of the anaesthesiologist’s judgement and other factors. The family history 
process was not included in our calculation of the raw score for all anaesthetic 
reactions as all of our included patients are index cases for their families (first member 
of the family to be investigated) and although we recorded any relevant family history 
of anaesthesia related complications or deaths, all, but four, of our patients, had no 
family history of such complications. The clinical indicator with the highest points in 
each process was chosen and summed to produce the raw score for each patient. In 
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our statistical analysis, as will be discussed later, we used both the raw score and the 
MH rank or the likelihood description to compare between the groups.  
3.2.6 Special circumstances 
Index cases who have been referred because of a family history of anaesthesia related 
deaths identified and whenever the clinical details and anaesthetic notes of the 
deceased patient(s) were available, they were reviewed. The details of the fatal 
anaesthetic reaction will be reported with emphasis on the possible reasons for the 
failure of recognition and proper management of the suspected reaction. We also 
reported the characteristics of the deceased patients regarding age, sex and 
comorbidities, when these details were available to compare them against the 
characteristics of the general MH cohort. Another special group included in our cohort 
are patients who developed recrudescence of MH features after the resolution of the 
initial episode with proper treatment, and despite the cessation of any further 
triggering. Incidence of recrudescence, the number of further episodes and measures 
required for treatment of these further episodes, in addition to possible causes for this 
rebound are reviewed and reported. We also reviewed any available intensive care 
unit reports about further episodes to ascertain if it is a recrudescence episode or 
some other complications. 
The previous anaesthetic history of all the included patients was examined. We 
recorded the number of previous anaesthetics for each patient and any associated 
complications for patients who had previous general anaesthetics. We identified 
patients who had complications that could be relevant to MH but were not well-
evaluated before the current anaesthetic. By reviewing any available notes of previous 
anaesthetics, we tried to explore the nature of these complications and the possible 
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triggering agents used. In addition, we investigated the possible reasons why these 
complications were not adequately assessed before the current attack and to clarify 
any ambiguity that led to these details being overlooked. 
3.3 Results 
3.3.1 Summary of general characteristics of MH susceptible probands 
In total, 328 patients included in this cohort as they have been tested susceptible to 
MH with IVCT after a suspected anaesthetic reaction. These patients have been 
biopsied during the period between 1988 and 2017; nevertheless, the date of reaction 
spans between 1971 and 2016. The reason for patients who developed a reaction 
prior to 1988 not being tested during this period and not being included in (Ellis et al., 
1990) review, is beyond the scope of our study. Possible reasons may include delay 
in the referral to the unit or refusal of the muscle biopsy by the patients. As some of 
the patients who developed a suspected reaction before 1988 have been tested and 
included in Ellis 1990 review, we cannot rely on the numbers of patients per year 
during this period. During the period after 1988, 272 patients developed a suspected 
anaesthetic reaction and were tested MHS with an average of nine cases/year. The 
year 1992 was the year when the largest number of patients (25 patients) were 
reported to have developed a suspected MH reaction. Interestingly, the same year 
reported the highest rate of MH incidents reported to the NAMHR in a study of 
suspected MH reactions over the period between 1987 and 2009 (Visoiu et al., 2014). 
The age at which the patient developed the suspected reaction ranged between one 
year and 73 years old, with an average of 23.2 years old. The age distribution is shown 
in figure 3-1 with the most common age group is the young adults aged between 18 
and 40 years old (n. 145 patients) followed by children below the age of 18 years old 
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(n. 135 patients). Regarding sex distribution, males were predominant in our cohort 
(n. 217 patients), representing 66.2% of all MHS tested probands during this period. 
Apart from the group of three patients above the age of 60 at the time of the reaction 
who were all males, males were more predominant in the other three age groups, 
figure 3-1. About two-thirds of the included patients were tested for MH susceptibility 
at the Leeds MH Investigation Unit within the first two years after they developed the 
suspected anaesthetic reaction. The maximum difference between the year of the 




The most common surgical speciality reported was the orthopaedic surgeries, 
including trauma, in 87 patients. This was followed by general surgery operations in 
76 patients and E.N.T. surgeries in 73 patients. These three specialities represented 
two-thirds of all the reported reactions. Other specialities reported included, in a 
descending order: dental procedures in 29 patients, obstetrics and gynaecology in 23 
patients, urology in 15 patients, plastic in ten patients, ophthalmology in five patients, 
four patients during cardiothoracic surgery and one patient during neurosurgery 
procedure. Among the three major surgical specialities represented in our cohort, 
males were predominant within the same ratio for the whole cohort, except for 
orthopaedic and trauma surgery, as males represented 81.6% in this group. In 27.74% 
of the reported cases, the patients were anaesthetised for an emergency procedure. 
Figure 3-1: Distribution of age and sex in our cohort of MHS probands. Patients’ age is 
the age at which the patients developed the suspected anaesthetic reaction. 
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The past medical history of ten patients included in our cohort showed musculoskeletal 
abnormalities, and in five of these ten patients, a diagnosis of CM was established 
after the reaction, these five patients are discussed in the fifth chapter investigating 
the association between MH and CM. In the remaining five patients, four patients had 
some degree of scoliosis, and one patient had osteogenesis imperfecta. Another 
patient reported ptosis with no other muscular weakness. More than one-third of the 
patients, 135 of 328 patients reported no previous general anaesthetics prior to the 
reaction. The other 193 patients reported previous operations when triggering 
anaesthetics were used, and the number of previous anaesthetics ranged from one to 
a maximum of 11 previous anaesthetics. Apart from the 19 patients who will be 
discussed under special circumstances later on in this section, all the reported 
previous anaesthetics were uneventful. 
Information about the physical activity was available for 322 of the included patients, 
149 patients reported a mild to moderate degree of sports activity to remain active, 
while 135 patients reported not engaging in any sports activity at all. The remaining 
38 patients reported professional athletic training. Regarding muscle cramps, 67 
patients reported suffering from muscle cramps, while the other 261 patients reported 
no history of muscle cramps. No statistically significant association could be detected 
between the level of sports activity and the occurrence of muscle cramps, X2= 2.51, 2 
df., with p value=0.29. As a routine when patients come for their muscle biopsy, a 
blood sample is collected and sent to the lab at St James’s University Hospitals to 
measure the basal serum CK level. Using a student t-test to compare between the 
means of Log10 transformed values of serum CK level, males were found to have a 
statistically higher serum CK levels (geometric mean=232 IU/L) when compared to 
females (geometric mean=162 IU/L), p value<0.0001, 95%CI 0.586-0.833. While no 
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such difference was found when comparing between patients who reported muscle 
cramps and patients who did not, p value=0.73. Similarly, no such difference could be 
found when comparing between different age or sports activity groups using one-way 
ANOVA of Log10 transformed CK level values, p value=0.76 and 0.48, respectively. 
3.3.2 The MHN cohort and the general surgical population 
A cohort of 250 patients who developed an adverse anaesthetic reaction that was 
suspected to be an MH reaction, was referred to the Leeds MH Investigation Unit over 
the period between 1990 and 2009 and tested MHN using IVCT. Sex distribution in 
this cohort was not statistically different from our cohort of MHS probands with a male 
predominance of 60.8% (X2=1.72, 1df with p value=0.19). The male: female ratio in 
our cohort was significantly different from the general surgical population presented in 
the NAP 6 project with a female predominance of 58.7%, (X2=90.9, 1df with p 
value<0.0001). The exact dates when the reaction occurred have not been collected 
by the medical students for their research project. Therefore, a comparison of the 
mean age at the reaction between our cohort and the MHN cohort was not possible. 
Regarding the general surgical population, the exact data about the mean age of the 
sampled cohort was not available on the activity survey report (Harper et al., 2018). 
According to this report, the age distribution chart showed that the most common age 
group exposed to anaesthetics is the group aged 26-35 years old, followed by the 
group aged 66-75 years old. 
Comparing the basal CK level at the time of biopsy between our cohort of MHS 
probands and the MHN cohort using student t-test of Log10 transformed data, we 
found that basal serum CK level in MHS cohort (geometric mean=205 IU/L) was 
statistically significantly higher than the MHN cohort (geometric mean=112 IU/L), p 
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value<0.0001, 95% CI 0.488-0.615. Similar to the difference in our cohort of MHS 
probands, in the MHN cohort of patients, males were found to have higher basal serum 
CK level (geometric mean=127 IU/L) compared to females (geometric mean=92 IU/L) 
using student t-test comparing Log10 transformed data, p value<0.0001 95% CI 
0.635-0.84. 
3.3.3 Different anaesthetic techniques and the clinical presentation of the reaction 
Regarding the anaesthetic technique used including volatile anaesthetics, muscle 
relaxants, intravenous anaesthetics, the technique of airway management and mode 
of ventilation, and the available monitoring, this information was not always available, 
complete, nor consistent between the included patients. For example, information 
about monitoring was available for 73 patients, as temperature monitoring was used 
in 40 patients, and etCO2 monitoring was available for 41 patients according to the 
recorded information. Although we can determine the type of monitoring used from the 
reported clinical information for each patient, we cannot be confident whether this 
monitoring was used from the start of anaesthesia or only applied to the patient after 
suspecting an anaesthetic reaction. Noticeably, information about the use of 
succinylcholine was almost complete in all patients whose clinical details of the 
reaction were retrieved. On the contrary, information about NDMR, if it was used and 
which drug was used, was not always available. Similarly, no available information 
about whether a volatile anaesthetic was used, and which drug was used in 15 patients 
in our cohort. 
The following table 3-1 illustrates the trend in the use of different anaesthetic drugs in 
our cohort over the years between 1971 and 2017. Enough information about the 
triggering anaesthetics used in our cohort was available for 271 patients. Before 1988, 
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the most common triggering volatile anaesthetic was halothane, followed by 
isoflurane. Isoflurane was the most common triggering agent in all patients reported 
to have a reaction in or after 1988. The second most common trigger in the period 
from 1988 to 1997 was halothane and during the following years afterwards was 
sevoflurane. As shown in table 3-1, the number of patients reported in each decade 
after 1988 is decreasing, as well as the percentage of the use of succinylcholine. On 
the other hand, the percentage of the use of NDMR and opioids showed a steady 
increase over the years until the last decade, after 2008, when it slightly decreased for 
both groups of drugs. 
 








Volatiles Halo>Iso>Enf Iso>Halo>Enf Iso>Sevo>Des Iso>Sevo>Des 
Succinylcholine 27 (90%) 98 (79.7%) 34 (47.9%) 9 (21.95%) 
NDMR 0 32 (26%) 37 (52.1%) 19 (46.3%) 
Opioids 1 (3.3%) 41 (33.3%) 50 (70.4%) 25 (60.98%) 
Table 3-1: The trend of reported cases distributed according to the year at which the 
reaction had occurred. The most common volatile anaesthetics used in each time period 
and the number of cases reported the use of other pharmacological agents in each time 
period. Halo. --> halothane, Iso. à isoflurane, Enf. àenflurane, Sevo. à sevoflurane, Des. à 
desflurane, and NDMRà non-depolarising muscle relaxants 
 
In our cohort, we investigated the role of succinylcholine in triggering a hypermetabolic 
MH reaction. An anaesthetic reaction was reported after the use of succinylcholine 
without the use of volatile anaesthetics in 25 patients with enough clinical details. An 
anaesthetic reaction that involved both metabolic and muscular features were reported 
in ten patients with one patient reported to have appendicitis and preoperative fever. 
In the other 15 patients, no metabolic manifestations were reported, and the reaction 
was in the form of exaggerated muscular response. MMS was the first sign noticed by 
the reporting anaesthetists in 13 patients and the only sign in six patients of those. 
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MMS was reported with other muscular features in the form of generalised rigidity, 
myoglobinuria and/or elevated serum CK levels in seven patients. Of the remaining 
two patients, one patient presented with unexplained cardiac arrest and the other 
patient presented in the postoperative period with rhabdomyolysis. All these 15 
patients had made a full recovery without the need for ICU admission for the majority 
of them, and only two patients had been admitted to the ICU and dantrolene was used 
in only one patient. 
Administration of succinylcholine, in combination with volatile anaesthetics, was found 
to have marked effects on the muscular features and to a less extent on the metabolic 
features of the reported reactions in our cohort of patients. A statistically significant 
association between the use of succinylcholine and the development of muscular 
features in the form of MMS, generalised muscular rigidity and myoglobinuria can be 
found in our cohort, X2=79, 1 df., p value<0.0001. The development of MMS was 
strictly associated with the administration of succinylcholine. Also, none of the patients 
who received volatile anaesthetics only, developed muscular features-only reactions. 
Additionally, the maximum reported value of postoperative serum CK level was 
statistically higher in patients who received succinylcholine as part of their anaesthetic 
(geometric mean=10,964 IU/L), using student t-test of Log 10 transformed values of 
serum CK levels, compared to patients who did not receive succinylcholine (geometric 
mean=3,026 IU/L) p value<0.0001, 95% CI 0.167-0.53. 
Regarding the metabolic features of the reported suspected MH reactions, the use of 
succinylcholine was found to be associated with a statistically significant shorter time 
of onset of the hypermetabolic reaction (geometric mean=28.8 minutes), compared to 
when it was not used (geometric mean=52.5 minutes), student t-test comparing Log10 
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transformed data of time in minutes, p value=0.0005, 95% CI 1.31-2.54. Nevertheless, 
the use of succinylcholine was not associated with a statistically significant difference 
in the maximum derangement values of the metabolic features of the reaction 
including, etCO2, temperature and pH, table 3-2. Additionally, the use of 
succinylcholine was associated with a higher rate of postoperative complications, 




Volatiles without succinylcholine 
 
 
NDMR used NDMR not used 
etCO2 n.79- (Med. 10, IQR 8-12 kPa)  
n.46- (Med. 10.8, 
IQR 8.7-12.6 kPa)  
n.38- (Med. 10.6, 
IQR 8.5-13.9 kPa)  
Temperature n.107- (Med. 38.8, IQR 38.2-40 ℃)  
n.43- (Med. 39.1, 
IQR 38.6-39.9 ℃)  
n.37- (Med. 39.2, 
IQR 38.5-40 ℃)  
pH n.83- (Med. 7.19, IQR 7.06-7.260)  
n.34- (Med. 7.13, 
IQR 7.07-7.24)  
n.22- (Med. 7.13, 
IQR 7.00-7.21)  
Table 3-2: The effects of the use of different anaesthetic agents on the maximum 
derangement values of the hypermetabolic features of the MH reaction. N. à is the 
number of patients with valid clinical details for this feature. Med. à median, and IQR à 
interquartile range. 
 
Non-depolarising muscle relaxants were reported to be used in 92 patients in our 
cohort, and the most common NDMR reported to be used in our cohort was 
atracurium, followed by vecuronium and rocuronium. The use of NDMR was 
associated with a statistically significant lower serum CK levels (geometric 
mean=5,370 IU/L) compared to when NDMR not used (geometric mean=9,225 IU/L) 
using student t-test to compare between Log10 transformed values of maximum CK 
levels, p value=0.029 95% CI 0.98-3.04. When studying the association between the 
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use of NDMR and the development of muscular features, we excluded MMS as in all 
cases; MMS followed the administration of succinylcholine. No statistically significant 
association could be noticed between the use of NDMR and the rate of development 
of the other muscular features of the reaction, namely, generalised rigidity and 
myoglobinuria, X2=0.62, 1 df., p value=0.43. Additionally, regarding the metabolic 
features of the reaction, no significant effect of the use of NDMR on the time of onset 
(student t-test p value=0.279) nor the maximum derangement values of etCO2, 
temperature and pH, could be found, table 3-2. Opioids reported to have been used 
in our cohort in 125 patients included morphine, fentanyl, alfentanil and remifentanil, 
and their use was not associated with any significant effects on the development nor 
the severity of any of the reported metabolic and muscular features of the suspected 
reactions. 
Figure 3-2 shows the first clinical sign of the reaction noticed by the reporting 
anaesthetists. The most common sign reported was MMS that was preceded by the 
administration of succinylcholine in all patients. Of the metabolic features, elevated 
etCO2 was the most common hypermetabolic sign first noticed by the attending 
anaesthetists. To study the association between the mode of triggering: volatile 
anaesthetics only, succinylcholine only, and both drugs; and the clinical picture of the 
reaction, we categorised the reaction into muscular features-only reactions, metabolic 
features-only reactions, and both. Additionally, we used the categorisation described 
by (Ellis et al., 1990) of the clinical manifestation of the reaction. Table 3-3 shows the 
number of patients presented with each category of the clinical classification of the 
reaction and the triggering agents in each. We have discussed earlier the patients who 
reported an apparent hypermetabolic reaction triggered only by succinylcholine. On 
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the other hand, none of the patients who received volatile anaesthetics only, without 




Figure 3-2: The first clinical signs of the reaction reported by the referring anaesthetist. 
Other signs included hypoxia, generalised rigidity, arrhythmia and cardiac arrest. 
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The clinical picture of the 25 patients who received succinylcholine only without volatile 
anaesthetics have been discussed earlier, and the numbers in each category are 
shown in table 3-3. None of the patients who received volatile anaesthetics only 
without succinylcholine fell into clinical categories involved muscular features only: (d) 
and (f) nor into category (e): MMS with signs of metabolic disturbance. Ellis and 
colleagues compared these categories between patients who were tested MHS and 
MHN and estimated the incidence of MHS diagnosis in each category, as shown in 
table 3-3. However, all patients included in our cohort were tested susceptible; 
therefore, we are showing the clinical grading scale, medians and IQR, for each 














a) 3 29 37 0.96 40, 33.5-53 
b) 2 52 89 0.88 30, 25-45 
c) 1 12 8 0.14 18, 15-25 
d) 7 0 3 0.76 22, 15-30 
e) 3 0 3 0.57 18, 15-35 
f) 6 0 16 0.28 15, 15-15 
g) 2 1 3 0.66 34, 16-46.5 
h) 1 4 8 0.07 15, 10.75-20 
Table 3-3: Number of included patients in each clinical category. Patients are categorised 
according to the triggering anaesthetic agents used. CGS is the estimated clinical grading 
scale for each patient presented as median and interquartile range for patients included in 
each clinical category. 
 
In the MHN cohort of patients, no information about the triggering agents was available 
for eight patients. In another 34 patients, no volatile anaesthetic was reported to be 
used, and only succinylcholine was reported to trigger the reaction. The manifestation 
of the reaction in these 34 patients when only succinylcholine was used, included signs 
of hypermetabolism; hypercapnia, hyperthermia and/or acidosis, in 13 patients. On 
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the contrary to the observation noticed in our MHS cohort that MMS was always 
preceded by the use of succinylcholine, eight MHN patients reported MMS without the 
use of succinylcholine that was triggered by volatile anaesthetics only. The following 
table 3-4 shows the triggering agents used in the cohort of MHN patients and the 
nature of the reported anaesthetic reaction regarding metabolic and muscular 
features. The highest reported serum CK level in MHS patients (geometric 
mean=7,834 IU/L) was found to be statistically significantly higher than in MHN 
patients (geometric mean=1,606 IU/L), when comparing the Log10 transformed data 




Volatiles only Both drugs 
Metabolic-only 9 75 30 
Muscular-only 21 6 51 
Both clinical features 4 5 24 
Table 3-4: Number of MHN patients in each clinical phenotype. Categorised according to 
the triggering anaesthetic agents used. 
 
3.3.4 Different management measures and their effect on the outcome of the reaction 
The published EMHG guidelines for managing an MH crisis (Glahn et al., 2010) offers 
an easy step-by-step protocol to recognise and treat an MH reaction. In our cohort of 
patients, we noticed a discrepancy between the number of patients reported to have 
clinical features and the number who received a symptomatic treatment directed for 
these features. On the other hand, reporting of dantrolene use was consistent 
throughout our cohort with a precise record of its dose, when it was used, available for 
most of the patients. The following table 3-5 shows the number of patients presented 
with each of the clinical features of MH and the proportion who received symptomatic 
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treatment for these features. Although the change of the breathing circuit or the 
anaesthetic machine with a gas-free machine is not recommended according to the 
EMHG 2010 guidelines, it was reported to be changed in 53 patients. Additionally, the 
guidelines recommend discussing with the surgeon the termination or postponement 
of the surgery, though, the surgery was allowed to proceed in 226 patients in our 
cohort, although in 148 patients of them, anaesthesia was for an elective procedure. 
 
Clinical features Patients reported (n.) Treatment used (n., %) 
Hyperthermia ≥38.5℃ 149 109, 77.86% 
Hyperkalaemia 62 20, 32.26% 
Acidosis pH<7.2/NaHCO3 received 90 25, 27.78% 
Arrhythmias 21 0 
Urinary output - 46 
Dantrolene used/ dose recorded 188 148, 78.72% 
Table 3-5: The number of patients presented with each of the clinical features. 
Percentage of patients who were reported to have received treatment for these features 
according to the EMHG guidelines for management of MH crisis. In addition to the number of 
patients who were reported to have received dantrolene and the percentage of cases when 
the exact dose used was recorded. 
 
As shown in table 3-5, dantrolene was used in 188 patients in our cohort. In none of 
the included cases, dantrolene was reported to be unavailable. However, in patients 
when dantrolene was not used, no detailed explanation was provided for why it was 
not used. The use of dantrolene was associated with a lower rate of postoperative 
complications in the included cohort, X2=6.94, 1df, p value=0.0085. Treatment of 
hyperthermia included surface cooling, intravesical, intragastric irrigation with iced 
saline and iced IV fluids. Most of the patients who developed hyperthermia ≥38.5℃ 
received active treatment (77.86%). Even more, 25 of the 56 patients who reported a 
maximum temperature of <38.5℃, received active treatment to reduce their body 
temperature. Other drugs reported to be used in the management of MH crisis in our 
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cohort included dextrose/insulin infusion for the treatment of hyperkalaemia, steroids, 
and dopamine. NaHCO3 was reported to be used for the treatment of acidosis in 27% 
of patients who reported a pH <7.2 and in seven out of the 62 patients with a pH 
between 7.2 and 7.35. Diuretics, including mannitol or furosemide, was used in 41 
patients to maintain the urinary output and also for the treatment of hyperkalaemia. 
All of the patients included in this cohort have survived the current anaesthetic 
reaction, and as indicators of the outcome, we used the rate of postoperative 
complications reported, and the length of ICU stay. However, the latter is not very 
reliable in our cohort. In some occasions, the patients have not been admitted to the 
ICU because of unavailability of beds or due to causes related to logistics of 
transferring the patient to another hospital. Additionally, for the 189 patients who have 
been admitted to the ICU, the length of stay was reported in only 32 patients with very 
scarce clinical details about the ICU stay. Regarding postoperative complications 
reported, muscle-related complications and renal related complications were the two 
main groups reported. Muscle related complications were in the form of myalgia, 
weakness and stiffness and were reported in 85 patients in our cohort. Also, 
compartment syndrome was reported in eight patients. Acute kidney injury and/or 
acute renal failure was reported in seven patients. Other complications that have been 
reported and are mainly related to ICU stay included deep venous thrombosis, chest 
infection, and pulmonary oedema. Recrudescence, as one of the postoperative 
complications of an MH reaction, will be discussed later on. 
To categorise the severity of the reaction, we used both the clinical categories 
described by Ellis et al. and the CGS. In addition, we used the administration of 
dantrolene as an indicator of the anaesthetists’ judgement of the severity of the case. 
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We categorised patients into four different categories, table 3-6. Patients were 
classified first according to clinical categories and the use of dantrolene, then 
according to CGS raw score. Clinical categories (a), (f) and (h) are classified 
regardless of the use of dantrolene. We only included patients who had their reaction 
in or after 1981, as in our cohort, it was the year when dantrolene was first reported to 
be used. As according to this classification, lower severity grades were associated 
with a higher rate of complications, X2=11.83, 3df with p value=0.008. On the other 
hand, a strong association between high severity grades and the rate of admission to 
ICU, X2=73.5, 3df with p value<0.0001. 
 
 Severe Moderate Mild Less likely 




Category (b) Category (c) (d), (g) and (e)  
Dantrolene 
not used 
 Category (b) Category (c) Category (g) 
CGS raw sore ≥50 35-49 20-34 <20 
N. of patients 171 62 22 34 
Table 3-6: A proposed classification of the severity of suspected MH reactions. This is 
based on the clinical classification described by Ellis and colleagues in 1990, the raw score of 
the CGS (clinical grading scale), and the use dantrolene as an indicator of anaesthetist’s 
judgement of the severity of the reaction. 
 
3.3.5 Special circumstances 
MH and laparoscopic surgery 
In the five patients who developed the suspected anaesthetic reaction while having a 
laparoscopic surgery where CO2 insufflation was used, the first reported sign was 
hypercapnia. The reaction in these five patients was triggered by volatile anaesthetics 
only, and no succinylcholine was used. No muscular features were reported in any of 
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the five patients, but other hypermetabolic features were reported in the form of 
hyperthermia in all the five patients and tachycardia and acidosis in four of them. The 
time of onset of the reaction was recorded in three patients to be more than an hour 
from the start of the anaesthetic. In these five patients, the use of CO2 insufflation did 
not mask the hypercapnia as a manifestation of an MH reaction and delay the 
recognition of the MH reaction as the time of onset of the hypermetabolic reaction was 
recorded in three patients to range from 1-3 hours, while the average time of onset in 
other patients whom first reported sign was hypercapnia, was 68 minutes. 
Postoperative presentation 
In 17 patients included in our cohort, the reaction only presented during the 
postoperative period. The clinical presentation of 12 patients was related to muscular 
features in the form of rigidity in three patients, myoglobinuria in six patients, and 
rhabdomyolysis in another three patients. Hyperthermia was the only presenting sign 
in the postoperative period in four patients, and it was reported in two patients who 
presented with postoperative rigidity. The remaining patient presented with acute renal 
failure and high serum CK level. Dantrolene was only used in the management of the 
two patients presented with postoperative rigidity and reported hyperthermia. The only 
other feature of MH that was reported in eight patients in this group was elevated 
serum CK level. 
Patients with a relevant anaesthetic history 
We were able to identify 19 patients whom anaesthetic history revealed the 
development of some complications to previous anaesthetics that have not been 
mentioned by the patients, ignored by the anaesthetist as irrelevant, and/or not 
properly investigated before the current anaesthetic. In seven patients, the history was 
 69 
too ambiguous to be interpreted appropriately. This history that was told by the 
patients included phrases such as “feeling unwell after the operation”, “reaction to 
general anaesthesia”, “allergy to general anaesthesia”, and “feeling hot after the 
operation”. Details about the previous anaesthetics could not be retrieved for these 
patients, and the nature of previous reactions and the type of triggering drugs could 
not be clarified. Furthermore, in four of these seven patients, the anaesthetist was not 
informed by the patient about these vague complications, except during the discussion 
after the current reaction. In another three patients, fever in the perioperative period 
was reported. On two occasions, it was treated with antibiotics, and in the third patient, 
it was a late postoperative complication. 
Complications reported with previous anaesthetics were in the form of the muscular 
features of MH in another nine patients and in three of them, succinylcholine was 
known to be involved in the previous anaesthetics. The anaesthetists avoided the use 
of succinylcholine in two of these three patients, though, they developed a 
hypermetabolic reaction to volatile anaesthetics in the current anaesthetic. In the third 
patient, succinylcholine was used in the current anaesthetic, and the patient 
developed a muscular features-only reaction. A current reaction that involved 
muscular features only was reported in another three patients, and succinylcholine 
was used in all three of them. In the remaining five patients, the current reaction 
included hypermetabolic features of MH and according to the reporting anaesthetists; 




During our search for index cases of families that have been tested MHS at the Leeds 
MH Investigation Unit since 1988, we identified 22 index cases who did not report 
anaesthesia related complications in their history; instead, they were relatives of 
patients who died due to general anaesthesia related complications. We were able to 
retrieve the clinical details of the fatal anaesthetic reactions for only seven of the 
deceased patients. The index cases of families of these seven patients are all first-
degree relatives of the deceased probands. Of the remaining 15 index cases, five 
patients were told that their relative died due to MH, as a clinical diagnosis, but no 
further information about the suspected reaction could be retrieved. In another six 
patients, family history of anaesthesia related deaths, with no specific mention of MH, 
was the reason for their referral to the Leeds MH Investigation Unit for IVCT. The 
remaining four index cases were told that their relatives died due to an anaesthetic 
reaction that involved: high temperature in two cases, high etCO2 in one case, and 
MMS to succinylcholine followed by cardiac arrest in another case; with no further 
details available. 
After reviewing the available clinical details of the suspected anaesthetic reactions of 
the deceased probands, a typical fulminant clinical presentation of MH was reported 
in four patients. The triggering agents in these four patients included the use of volatile 
anaesthetics (isoflurane in two patients, sevoflurane in one patient and unknown agent 
in the fourth patient) and the use of succinylcholine in all of them. When the time was 
recorded, the start of the reaction was noticed by the anaesthetist after 2-4 hours after 
induction of anaesthesia. The management was commenced immediately after the 
recognition of the reaction in the four patients and dantrolene was used in early-stage 
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in all of them. The management measures followed the established protocol for MH 
crisis in all of these four patients and included dantrolene, ventilatory support, 
symptomatic treatment for hyperthermia and acidosis and supportive treatment for 
cardiovascular instability. In only one of these four patients, no clear information was 
noted about the early withdrawal of triggering volatile anaesthetics, though, it could be 
missed during reporting. 
In spite of the management measures described early, the reaction in all of these four 
patients progressed to cardiac arrest and cardiopulmonary resuscitation was 
commenced and patients were transferred to the ICU after the return of spontaneous 
circulation. Supportive and symptomatic treatment was continued in the ICU, however, 
all of the four patients developed multiorgan failure and disseminated intravascular 
coagulopathy (DIC). All of the four patients died within the first 24 hours after the 
reaction. 
In the other three patients, a female patient had a history of dilated cardiomyopathy at 
the age of one year, for which she received a cardiac transplant. The reaction was 
reported later during an E.N.T procedure for which the patient received isoflurane and 
succinylcholine and developed cardiac arrhythmia followed by cardiac arrest. 
Laboratory results showed an elevated K+ (9.7-12.1 mmol/L) levels and high CK levels 
(5,500 IU/L). The patient was treated for cardiac arrest with no dantrolene reported to 
be used and the post-mortem examination indicated severe rhabdomyolysis. In 
another patient, the reaction developed during a thyroidectomy operation. Although 
laboratory results indicated that the patient during the preoperative period was in an 
euthyroid state, the patient had an increased heart rate. During the operation, the 
patient developed a hypermetabolic reaction and was treated as a case of thyroid 
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crisis, without the use of dantrolene, but eventually developed DIC and cardiac arrest. 
Laboratory results showed myoglobinuria and a CK level of 15,000 IU/L. The third 
patient had a history of musculoskeletal abnormalities including limb contractures, 
arthrogryposis and hypotonia. Anaesthesia for a pyloroplasty at the age of five years 
old was uneventful, however, 48 hours after the procedure, the patient developed 
breathing difficulties, hypoxia, severe acidosis and progressed to cardiac arrest. No 
dantrolene was used during the management of this case and the patient was 
pronounced dead in the ICU. 
Recrudescence episodes 
A group of eight patients included in our cohort reported a rebound of the clinical 
features of the suspected MH reaction after the resolution of the initial episode. All, 
but one, of these patients, were males and all of them had an age range from 13 to 20 
years old. The triggering agents of the initial episode included both volatile 
anaesthetics and succinylcholine in three patients, while the other five patients 
developed the reaction in response to volatile anaesthetics only. The clinical picture 
of the initial reaction included hypermetabolic features in the form of hyperthermia and 
hypercapnia in all patients, in addition, acidosis was reported in three patients. 
Muscular features such as MMS, generalised rigidity was reported in five patients but 
no myoglobinuria in any of them. All patients received dantrolene as part of the 
management of the initial reaction and seven of them received repeated doses for 
treatment of subsequent episodes. 
Although all of these eight patients have been admitted to the ICU the clinical notes 
from their ICU stay were available for only two patients. In the remaining six patients, 
details of the recrudescence attacks were obtained from the referral letters. In six 
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patients, the subsequent episode was in the form of a rise in temperature that was 
subsided spontaneously in one patient, treated with oral dantrolene in another patient, 
and IV dantrolene in the other four patients. A rise in etCO2 with tachycardia reported 
in one patient and was treated with IV dantrolene. Two recrudescence attacks were 
reported in the remaining patient: the first attack involved a rise in temperature and 
etCO2 and the second attack involved a rise in temperature with normocapnia. Both 
episodes required treatment with IV dantrolene. 
3.4 Discussion 
This study exploits the biggest and most consistent resource for MH reactions in the 
world. This project is based on the Leeds MH Investigation Unit archive and database, 
which is the principal and only national centre for investigating MH in the UK and 
provides a vast and invaluable set of information about the MH disorder. Our study 
overcomes some of the limitations of previous epidemiological studies that were based 
on information collected from administrative databases; such as poor validation of the 
MH diagnosis and entries being not always patients but admissions, giving a 
misestimate of the incidence. We were able to validate the diagnosis of MH 
susceptibility from IVCT reports and review the details of the clinical reaction to confirm 
the diagnosis of the anaesthetic reaction to be a true MH reaction. Of these studies 
that were based on the North American MH Registry (NAMHR); (Larach et al., 2010) 
that investigated the clinical presentation and possible complications of MH and 
(Larach et al., 2008, Larach et al., 2014) that studied MH-related deaths. 
MH is a rare-occurring condition, though it is potentially fatal which makes conducting 
case-control studies unethical and impractical. However, we were able to compare our 
results of confirmed MHS cases to another group of patients who tested MHN. We 
 74 
also used the information available on the NAP 6 activity survey report to compare our 
results to the general surgical population. Of the advantages of using this cohort as a 
denominator to compare between the characteristics of the patients included in our 
cohort and the general population, is the relative homogeneity of these general 
characteristics regarding ethnicity, age and sex with our cohort as both are based on 
the UK population. Additionally, the NAP 6 activity survey report offered a valuable 
nationwide estimate of the anaesthetic caseload to compare against the number of 
suspected anaesthetic reactions reported to the Leeds MH Investigation Unit. It also 
provided an insight on the compliance of anaesthetists to the standard monitoring 
guidelines, which has an important impact on the early recognition of a suspected 
hypermetabolic anaesthetic reaction. 
On the other hand, the data available from the NAP 6 activity survey has its own 
limitations when used as a representation of the general surgical population and a 
denominator for our comparison study. Firstly, the anaesthetic caseload in this report 
is an estimate of a sample of UK hospitals over a limited time period. Secondly, this 
estimated anaesthetic caseload reflects modern anaesthetic practice, in comparison 
to our cohort of suspected anaesthetic reactions that span a period of more than 30 
years with a marked variability in the number of cases reported per year. And thirdly, 
as the NAP 6 project was investigating the perioperative anaphylaxis, it included 
patients who received other types of anaesthetics that are irrelevant when studying 
MH, such as regional anaesthesia and TIVA. 
During the period of the last 30 years, an average of nine cases/year were reported to 
have a suspected anaesthetic reaction and tested MHS with IVCT. A surge in the 
number of reported cases was noticed during the year of 1992 and the number of 
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reported cases during the decade between 1988 and 1997 was nearly twice the 
number reported in the following decade, and three times the number in the last 
decade between 2008 and 2017. The possible reasons for that surge in the early 
1990s, depend on the change of the anaesthetic practice and the pharmacology of 
triggering. The introduction of volatile anaesthetics such as sevoflurane for clinical use 
in the 1990s (De Hert and Moerman, 2015) with its safer pharmacodynamic and 
pharmacokinetic profile in comparison to halothane may have led some anaesthetists 
to consider the drug as a safer option with regard to MH. Additionally, as we have 
noticed in our cohort, the rate of use of succinylcholine was high during the early 1990s 
and declined over the years with the introduction of NDMR such as rocuronium that 
offers intubating conditions similar to succinylcholine with a safer pharmacodynamic 
profile. 
It is crucial to stress again that our study shows that all volatile anaesthetics currently 
in use can trigger a hypermetabolic MH reaction. Furthermore, in the last two decades, 
isoflurane was the most common volatile anaesthetic involved in triggering MH 
reactions. On the other hand, we could not confirm or dismiss the role of 
succinylcholine alone in triggering a hypermetabolic MH reaction due to some missed 
information about anaesthetic drugs used and the clinical details of the anaesthetic 
reaction. However, we illustrated that the combination of succinylcholine with volatile 
anaesthetics was associated with a more rapid onset time of the reaction. The lack of 
statistically significant difference in the severity of hypermetabolic reaction could be 
because of lack of power due to small sample size, or due to the effect of other drugs 
used, such as NDMR or opioids. These latter two groups of drugs are used as 
anaesthetic adjuvants to maintain balanced anaesthesia and reduce the dose of 
anaesthetics used and are known to affect signs such as heart rate and respiratory 
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rate. Although we could not find a statistically significant effect of these drugs on the 
severity of metabolic features of MH reaction, the timing of administration of these 
drugs; before or after the start of the reaction, may have confounded this analysis. 
In this study, we were able to illustrate the association between the use of 
succinylcholine and the shorter time of onset of the hypermetabolic MH reaction when 
combined with volatile anaesthetics. We also demonstrated the effect of the use of 
succinylcholine on the rate of development of the muscular features of the MH reaction 
and the highest reported value of postoperative serum CK level. On the other hand, 
we could not find a significant effect of the use of succinylcholine in the degree of 
derangement of metabolic features of the MH reaction regarding temperature, etCO2 
and acidosis. This lack of significance could be due to lack of power because of a 
relatively small sample size to elaborate a difference, or the effects of other 
confounding factors related to other drugs being used during anaesthesia. For 
example, as NDMR has been suggested to be protective against MH (Harrison, 1971), 
it may also play a role in reducing the effect of succinylcholine on the clinical features 
of MH. Additionally, the timing may also play a role as early recognition and cessation 
of triggering agents lead to abortion of the reaction and mild degrees of derangement 
are reported. 
Succinylcholine was described in the literature to be associated with poorer survival 
rates from MH (Britt and Kalow, 1970). Apart from the fatal cases described, all the 
included patients have survived the anaesthetic reaction. However, our data showed 
that the use of succinylcholine was associated with a higher rate of postoperative 
complications supporting the earlier observation. On the other hand, although the role 
of succinylcholine as a solo trigger of a hypermetabolic MH reaction is still 
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controversial (Hopkins, 2011), in this study we reported ten cases who developed an 
anaesthetic reaction involved metabolic features, while no volatile anaesthetics were 
reported to be used. A classic form of MH reaction was reported in three of these ten 
patients. However, the majority of these reactions occurred in the early 1990s and 
information about the reaction was available only from referral letters. In none of these 
referral letters, the anaesthetist actively mentioned that volatile anaesthetics were not 
used. Therefore, we cannot be totally confident that no volatile anaesthetics was 
involved in the pathogenesis of these reactions. Additionally, the reaction in one 
patient can be explained otherwise as the patient was diagnosed with appendicitis and 
reported a preoperative fever. 
When medical students collected information about anaesthetic reactions in MHN 
probands, they only recorded MMS as a sign of muscular rigidity. An interesting 
observation was the reporting of MMS without the use of succinylcholine in the cohort 
of MHN patients, while in our cohort of MHS patients, MMS exclusively followed the 
use of succinylcholine. Medical students may have labelled some patients to have had 
MMS as part of generalised muscular rigidity or misinterpreted reports of difficult 
intubation due to other causes as a result of MMS. The highest postoperative serum 
CK level was significantly different between both groups. Although serum CK level is 
not a specific feature of MH reactions, our data indicate that high levels of serum CK 
is a useful indicator of MH susceptibility in combination with other indicators. 
Age at reaction was not easily compared against the group of MHN patients as this 
information was not collected by the medical students. Also, we could not compare 
the average age at the reaction to the age of the general surgical population at which 
patients included in the report had their anaesthetics. Therefore, we cannot confirm 
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any marked difference between our cohort and the other two groups regarding age. 
Sex distribution was markedly different between our cohort and the general surgical 
population. As the NAP 6 project was investigating the perioperative anaphylaxis 
under anaesthesia, it included patients who had regional anaesthesia and local nerve 
blocks. These patients should be excluded from our denominator when comparing sex 
distribution as for example, the number of caesarean sections performed under spinal 
anaesthesia may skew our data. However, female predominance was also noticed in 
the general surgical population in the NAP 5 project (Sury et al., 2014) that 
investigated awareness under general anaesthesia. Different explanations have been 
proposed for the male predominance of the MH cohort of patients (Islander et al., 
2007) including the difference in Ca+2 homeostasis between males and females, the 
influence of sex hormones on the Ca+2 regulating proteins in muscle fibres, and the 
lower penetrance of MH in females. 
We can confirm that this observation of male predominance is not specific for MHS 
patients as no significant difference was noticed between our cohort and the MHN 
cohort of patients who developed an anaesthetic reaction, though tested not 
susceptible to MH. This indicates that males present with the non-specific features of 
MH more than females and the difference regarding MH susceptibility may not be a 
true difference. A possible explanation is related to the body habitus of male patients 
with a bigger muscle bulk that makes the exaggerated muscular response to 
succinylcholine more obvious in male patients. Another explanation that has been 
proposed before by (Islander et al., 2007), is the effect of sex hormones on Ca+2 
regulating proteins which affect how males and females react differently to volatile 
anaesthetics and succinylcholine. The influence of age on the male: female ratio is not 
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significant in our cohort as male predominance was noticed in all age groups, including 
the group of patients above the age of 65 years old who were all males. 
On the other hand, a preliminary analysis of the MH susceptibility status of the first-
degree relatives of our included probands showed a slightly higher ratio of MHS cases 
within each male category i.e. fathers, brothers and sons in comparison to their female 
counterparts i.e. mothers, sisters and daughters; respectively. We have not conducted 
a proper statistical analysis nor compared the IVCT results between these cases to 
draw a definitive conclusion. However, further analysis of these data may provide us 
with a better understanding of the effects of different triggering agents on the in vitro 
responses of muscle from both sexes. 
In our cohort, patients who were classified into one of the clinical categories described 
(Ellis et al., 1990) where a probability of MHS diagnosis was more than 50%, had a 
median CGS raw score >20, indicating a greater than likely diagnosis of MH, except 
for patients classified into category (e) with incidence of MHS diagnosis of 0.57 where 
patients had a median CGS=18 i.e. less than likely MH. The clinical features of 
category (e) include MMS with signs of metabolic disturbance such as arrhythmia or 
rising core temperature. However, Ellis and colleagues did not indicate a cut-off point 
for temperature in this category, on the contrary to Larach and colleagues who stated 
a cut-off of >38.8℃. Patients included in this clinical category had a maximum 
temperature of 38.5℃; this may explain the discrepancy between the likelihood of MH 
diagnosis and the probability described by Ellis and colleagues. 
According to our proposed classification in table 3-6, severe forms of the reaction was 
significantly associated with higher ICU admission rates, giving reliability to our 
proposed classification. However, we should take into consideration that in some 
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patients, ICU admission was dependant on the availability of beds rather than the 
severity of the reaction. On the other hand, the rate of complications was higher in low 
severity scores. This can be explained by the inclusion of dantrolene as an indicator 
of severity. As we have illustrated in the results section, the use of dantrolene was 
associated with a statistically significant lower rate of complications in our cohort, and 
in our proposed classification, lower severity grades were associated with lower rate 
of dantrolene use. This could explain the higher complication rate in low severity 
grades. 
When evaluating the management measures used in our cohort of patients, we should 
take into consideration several factors; for example, some of the reported reactions 
occurred before the approval of dantrolene for treatment of MH in humans (Kolb et al., 
1982) and a management protocol was not established and available for use in all the 
reported cases. Additionally, the emergency nature of the reaction creates a challenge 
for anaesthetists involved in treatment and reporting of the suspected reaction. 
Furthermore, management of particular clinical features is dependent on the available 
monitoring facilities to recognise the derangement, and on the available treatment for 
this particular feature. The most efficiently treated clinical sign was hyperthermia in 
~77% of patients presented with this feature, which reflects how hyperthermia is still 
perceived as the most important clinical sign of MH. Other signs such as acidosis and 
hyperkalaemia were reported to be treated in less than half of the patients presented 
with these features. This could be due to incomplete reporting of the management 
measures used, or due to prioritisation of the preparation of dantrolene. 
The postoperative complications were mainly related to muscle breakdown leading to 
pain, weakness and stiffness. Additionally, the resulting degraded muscle proteins led 
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to the development of acute kidney injury and acute renal failure in some patients. We 
found a statistically significant association between the development of postoperative 
complications and the reporting of muscular features of the reaction. Only four of the 
53 patients who had a metabolic features-only reaction developed postoperative 
complications, while more than one-third of the 200 patients who reported muscular 
features in their anaesthetic reaction, developed postoperative complications, 
X2=18.44, 1df, p value<0.0001. Information about postoperative complications in the 
MHN cohort of patients was not precisely collected by the medical students and we 
could not effectively relate our findings to the findings in the MHN cohort. This 
information would help us to understand whether these complications are related to 
the development of an MH reaction in susceptible patients, or it is considered as a 
continuation of the abnormal response to the anaesthetic drugs used e.g. 
succinylcholine and not related to the background MH susceptibility trait of the affected 
patients. 
The incidence of recrudescence in our cohort is less than a previous retrospective 
study base on the NAMHR database (Burkman et al., 2007). Only eight patients in our 
study reported recrudescence which represents ~2.5% of our MHS cohort, in contrast 
to the 20% incidence reported in the previous study. Our study, though, is based on 
reviewing the clinical details of the suspected reactions obtained from the patients’ 
files stored at the Leeds MH Investigation Unit archive, on the contrary to the previous 
study that obtained all its information from an administrative database. These 
administrative databases have its own limitations towards the validity of the obtained 
information as discussed earlier. In our study we have not collected information about 
the body habitus of the included patients to assess its association with the rate of 
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recrudescence, nor were we able to perform statistical analysis comparing the clinical 
variables in the recrudescence group to the included MHS cohort. 
All the eight patients who reported recrudescence have been admitted to the ICU and 
the management included the use of dantrolene in all of them. As ~40% of our MHS 
probands have not been admitted to the ICU, there is a possibility that a number of 
patients who developed recrudescence have not been detected in the recovery room 
or in the postoperative wards. Additionally, one of the reasons dantrolene was not 
used in the treatment of the initial episode of MH in the ~40% of patients who did not 
receive dantrolene, is that the attending anaesthetist was not totally convinced that 
the reaction is a true MH reaction. Therefore, they may have ignored any subsequent 
related manifestations and missed detecting a recrudescence episode. 
In the reported fatal reactions when we were able to retrieve clinical details, the 
reaction can be explained otherwise in three cases due to the preoperative medical 
condition of the patient. In the four cases in whom the clinical details of the reaction 
were convincing to be a true MH reaction, succinylcholine in combination with volatile 
anaesthetics was used. The clinical picture of the reaction in these four patients was 
the classical presentation of fulminant MH reactions, though the first reported sign was 
atypical in the form of hypoxia in all the four patients. We could not identify any 
shortcomings in the management measures used in these four cases and dantrolene 
was reported to be used in all four of them once the possibility of MH was suspected. 
However, the recorded time of the start of the reaction was more than two hours, which 
may indicate a delay in the recognition of the adverse anaesthetic reaction, possibly, 
due to the atypical first reported sign. Hypoxia is not a classical presenting sign of MH 
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reaction and it is usually a delayed manifestation, which indicates that other features 
of the reaction may have started to develop earlier and were not recognised. 
The social history of the included patients did not show any interesting features and 
no association was noticed between the basal CK level and physical activity or the 
development of cramps. The medical history of ten patients included musculoskeletal 
abnormalities and CM in five of them. The anaesthetic history also confirmed the 
observation of incomplete penetrance of MH as more than half of the patients reported 
uneventful previous general anaesthetics that involved the use of triggering agents 
without developing an MH reaction. Factors related to the potency of volatile 
anaesthetics, duration of exposure to the triggering agents, preoperative physical 
status, and the combination of volatile anaesthetics and succinylcholine have been 
proposed as possible causes for this incomplete penetrance. Due to the lack of clinical 
details of the previous anaesthetics in almost all patients in our cohort, we were not 
able to investigate this topic further. However, ~10% of the 193 patients who had 
previous general anaesthetics prior to the reaction, reported anaesthesia related 
complications that were overlooked at the time of the current episode. This indicates 
that an MH reaction may start to develop in some patients but abort early after 
cessation of anaesthesia in short procedures and muscles are sensitised for further 
exposures. Due to the non-specific features of MH manifestations, it is hard to 
ascertain how many patients could have a subclinical form of MH during previous 
anaesthetics. 
In our study, we were not able to overcome one of the main limitations of previous 
studies related to the assessment of the temporal relations between the clinical 
features of MH. We obtained most of the information about the included patients in 
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our cohort from the referral letters of the attending anaesthetists. The information 
included in these letters is usually dependant on the judgement of the attending 
anaesthetist and the first reported sign is not always the first sign of the reaction to 
develop. Signs such as MMS or exaggerated muscular response to succinylcholine 
are easier to be observed by the anaesthetist and this explains why MMS was the 
most common first reported sign in our cohort. MMS was usually reported by the 
anaesthetist when attempting to intubate the patient or by the E.N.T. surgeon or the 
dentist when attempting to open the mouth to start the procedure. The degree of 
change in signs such as heart rate, temperature or etCO2 is more critical in early 
recognition of an MH reaction, though, these signs are markedly affected by other 
factors related to the depth of anaesthesia, pain control and ventilation mode. 
Anaesthetists should be educated the importance of the degree of change in these 
signs when reporting an MH reaction for better recognition and proper reporting. 
The clinical details of the suspected anaesthetic reaction were collected in a separate 
section. This section was markedly dependant on the original source of information as 
in some patients, the full-detailed anaesthetic chart was available, which enabled us 
to reassess the temporal relations between the development of the clinical features 
and to have a more accurate idea about the baseline of each clinical sign to determine 
the degree of change. However, in the majority of patients, these clinical details were 
obtained from the referral letters of the attending anaesthetists who experienced the 
suspected anaesthetic reactions. These referral letters although being more organised 
and clearly written than the anaesthetic charts, made most of the recorded clinical 
features highly-dependant on the judgement of the attending anaesthetists. We had 
to assume that when a sign was not reported, it was within the normal range. However, 
to have a more accurate analysis of these clinical signs, we included only the 
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difference between the maximum reported value and the physiological value unless 
reported otherwise. 
When referring a suspected MH case for diagnosis, anaesthetists should include all 
the available clinical notes about the ICU stay including the length of stay, any 
recurrence of the clinical features of the reaction and any complications that have 
occurred during the ICU stay. In our cohort, although 189 of patients have been 
reported to be admitted to the ICU, only a limited number of files, less than 20%, 
contained the full details about the ICU stay and any relevant information to the initial 
reaction. Our proposed classification of severity was based on a combination of an 
established clinical classification and the CGS that has been used by several studies 
to diagnose MH reactions and assess its severity. We also included the use of 
dantrolene as an additional indicator of the anaesthetist judgement of severity. In many 
referral letters of the reactions included in our study, the anaesthetists reported that 
dantrolene was sent for or was prepared but not used, because the reaction started to 
subside with symptomatic treatment and supportive measures. That is why although 
the use of dantrolene is not necessary a very reliable indicator as some suspected 
reactions included in this study occurred before the availability of dantrolene, we 
included it in our severity classification. 
In conclusion, this study added to the ongoing research to better understand the 
clinical epidemiology of MH and explore the interacting effects of the many 
pharmacological agents used during anaesthesia on the different clinical 
presentations of MH reactions. The observation of male predominance in relation to 
MH is shown to be related to the clinical features of the MH reaction, which are not 
specific to MH; instead, it may be related to other factors such as muscle bulk of 
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patients and the preoperative physical status. However, a male predominance in MH 
susceptibility was noticed in the first-degree relatives of our included probands, 
though, proper statistical analysis is needed to confirm this observation. We 
demonstrated that succinylcholine accelerated the development of the MH reaction 
and influenced the severity of some of its features, however, its role in the 
pathogenesis of MH and its effect on the metabolic features is still considered as an 
ongoing dilemma that needs further investigation. Last but not least, this type of 
retrospective studies of rare occurring disorders such as MH, is highly dependent on 




4 Correlation between RYR1 genotypes, IVCT phenotypes and 
clinical phenotypes of MH susceptible probands 
4.1. Introduction 
The relationship between the genetics of MH and its clinical presentation under 
general anaesthesia and the laboratory results of the diagnostic test could offer us a 
better understanding of the epidemiology of MH. Three directions of correlations: 
genotype-clinical phenotype, genotype-IVCT phenotype and clinical-IVCT 
phenotypes, are meant to provide us with a more defined statistical relationship 
between the three components. This statistical relationship could help us to predict 
how different mutations lead to the variability in the clinical presentations of the MH 
disorder and how muscles from the affected patients respond differently, ex vivo, to 
ryanodine receptor agonists. 
The ryanodine receptor isoform 1 protein is a tetramer with its amino terminal and 
central regions located intracytoplasmic and its carboxyl end in the transmembrane 
region. The ryanodine receptor 1 gene is located on chromosome 19q.13.1 and was 
identified as the primary locus for MH by (MacLennan et al., 1990). It is believed that 
the intracytoplasmic regions of the receptor host the ligand-binding sites (Stokes and 
Wagenknecht, 2000). In the past, it was believed that mutations leading to MH trait 
are clustered in three hotspots on the RYR1 gene. However, with the development of 
genetic sequencing techniques, new variants are being found scattered across the 
gene, and the list of functionally characterised diagnostic RYR1 variants 
(https://www.emhg.org/diagnostic-mutations) is growing bigger and containing more 
variants beyond these three hotspots. 
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Several factors complicate the analysis of the genotype-phenotype correlation in MH: 
firstly, the low incidence of the condition 1: 15,000 to 1:200,000 general anaesthetics 
lead to a lack of power in many of the statistical analyses. Secondly, the high degree 
of clinical variability of the reaction due to different penetrance between susceptible 
individuals, in addition, none of the clinical manifestations is specific to MH, and the 
severity of these features largely depend on the stage at which an MH reaction was 
suspected, and treatment was initiated. Thirdly, factors related to the urgency of the 
condition and problems with monitoring patients under anaesthesia. These factors 
were associated with incomplete reports of the clinical details of the reaction in many 
of the referred cases. Fourthly, the genetic test results are not necessarily always 
complete and/or consistent for all of the affected patients due to differences in the 
genetic testing methods used. On the other hand, despite these limitations, our study 
is relying on the most extensive available database for this condition in the world as 
~7000 individuals have been tested for MH susceptibility with the gold standard IVCT 
and with genetic testing results available for ~3000 of the IVC-tested individuals. In 
addition, the unit archive holds records of the available clinical details of suspected 
MH reactions. 
Previous studies explored this correlation between the MH genotypes and 
phenotypes. Manning and colleagues (Manning et al., 1998) established a correlation 
between the caffeine threshold and caffeine tension in different genotypes found in 
families from different European countries, for instance, the RYR1 c.487C>T genotype 
was associated with low caffeine threshold and a stronger tension, while RYR1 
c.6617C>T was associated with a weak reaction and a high caffeine threshold. No 
such correlation was found with the halothane test. A study of the correlation between 
RYR1 genotypes and IVCT phenotypes in the Swiss population (Girard et al., 2001) 
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concluded that different RYR1 mutations lead to different IVCT phenotypes with the 
RYR1 c.7300G>A has a weak IVCT response. Fiege and colleagues (Fiege et al., 
2002) found a more subtle difference between the studied MH mutations in a German 
cohort with the ryanodine test, compared to halothane and caffeine, as patients with 
mutations c.487C>T, c.1840C>T and c.7300G>A developed faster response 
compared to patients with c.1021G>A mutation or without a detected mutation. 
However, they owed some of these differences between tests to other possible factors 
such as patients age, muscle specimen size and fibre type composition. 
Studies based on the UK population such as (Robinson et al., 2002) established a 
positive correlation between the pre-drug twitch height of muscle samples and the 
severity of the IVCT response in each test, based on the tension difference at 2% 
halothane or 2mMol caffeine. They observed the same strong response to caffeine in 
patients with the RYR1 c.487C>T mutation, in addition in this study, patients with the 
same mutation had a strong IVCT response to both halothane tests, static and 
dynamic, when compared to muscle samples from patients with the RYR1 c.7300G>A 
that was found to have a weaker IVCT response. Furthermore, (Carpenter et al., 2009) 
studied a larger number of mutations and again used the RYR1 c.7300G>A as a 
comparator, as it is the most prevalent mutation among the UK population, and found 
a statistically significant stronger response in muscle samples from patients with a 
number of different mutations as shown in table 4-1. They also compared the highest 
serum CK level after the anaesthetic reaction between the genotype groups. 
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Variants Caffeine S halothane D halothane CK 
c.487C>T *** * *** *** 
c.1021G>A *** - - - 
c.1840C>T - - - * 
c.5183C>T - - * - 
c.6488G>A ** - *** * 
c.7007G>A - - - * 
c.7304G>A *** *** *** *** 
c.7361G>A *** * - *** 
c.11958C>G ** - - ** 
c.11969G>T ** - * - 
c.14477C>T ** * ** *** 
Table 4-1: Statistical differences of RYR1 genotypes reported in Carpenter et al. 2009. 
Statistical comparisons of tension differences of the three IVC-tests and the highest serum CK 
level after anaesthetic reactions between different variants and the most common RYR1 
variant among the UK population the c.7300G>A. Level of significance: (-)à no significance, 
(*)àp value<0.05, (**)àp value<0.01, (***)àp value<0.001, and (****)à p value<0.0001 
 
Most of the previous correlation studies focused on the statistical relation between 
different mutations and the laboratory IVCT response of muscle samples from affected 
patients. These statistical differences have given us an idea about how different RYR1 
mutations affect the function of the ryanodine receptor and Ca+2 homeostasis in 
skeletal muscles although other factors may confound these findings (Fiege et al., 
2002). Apart from postoperative serum CK levels differences discussed in (Carpenter 
et al., 2009), the majority of previous work focused on the correlation between RYR1 
genotype and IVCT phenotype, although a correlation to the clinical phenotype could 
give us an insight on the effects of different mutations on the clinical presentation of 
the reaction and explain the variability in penetrance of MH. We were able to study 
this correlation between genotype and clinical phenotype because of the availability of 
resources at the Leeds MH investigation unit.  
We also were able to use these available resources to perform a further correlation 
between clinical phenotype and IVCT phenotype that would enable us to relate 
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between the presentation in a clinical setting and the response of muscle under 
laboratory conditions. In order to be able to perform this clinical phenotype-IVCT 
phenotype correlation study, we grouped patients into three clinical groups depending 
on the main features of the clinical reaction and the use of succinylcholine as part of 
the triggering anaesthetic. As discussed in the general introduction, previous attempts 
to classify patients presented with suspected MH reactions depended mainly on the 
presence of muscular manifestations; rigid and non-rigid (Britt and Kalow, 1970) and 
the presence of MMS with some other metabolic features (Ellis et al., 1990). We re-
stated this concept and additionally, highlighted the more recent understanding of MH 
as a state of hypermetabolism. We also included the use of succinylcholine, as part of 
the triggering anaesthetic, to the grouping factors. Consequently, we had three clinical 
groups: muscular-only presentation, manifestations of hypermetabolism triggered by 
anaesthetics that involved the use of succinylcholine, and manifestations of 
hypermetabolism triggered by inhalation anaesthetics only. We only included 
probands who had a suspected anaesthetic reaction and have been confirmed to be 
MHS using IVCT. 
The quantitative difference of IVCT results between patients with different RYR1 
variants has been studied before (Manning et al., 1998, Girard et al., 2001, Fiege et 
al., 2002, Robinson et al., 2002, Monnier et al., 2005, Carpenter et al., 2009), we will 
readdress the topic in our cohort of included MHS probands. However, our primary 
aim of this study is to assess if there is any quantitative difference of the clinical 
features of MH reactions between patients with common RYR1 variants in comparison 
to the most common RYR1 variant in the UK populations; the c.7300G>A. We will also 
assess the correlation between different clinical presentations of MH reactions and the 
IVCT laboratory results of muscle specimens of the affected patients, to test the 
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hypothesis that muscles from patients who develop severe forms of anaesthetic 
reactions, react differently to ryanodine receptor agonists ex vivo. 
4.2. Materials and methods 
4.2.1. Study design 
This correlation study was designed as a retrospective observational study reviewing 
data of patients who were tested at the Leeds MH investigation unit. This study is 
covered by the same ethical approval mentioned earlier as it is a part of the study 
“Human Tissues and Genomics Research in Malignant Hyperthermia”. All patients 
selected for this study were referred to the unit for diagnosis of MH susceptibility and 
their clinical data, IVCT traces and genetic testing results are saved at the unit archive. 
Inclusion criteria for patients to be recruited for this study were a proband who 
developed a suspected MH reaction under general anaesthesia, was tested 
susceptible using IVCT, and genetic testing identified a variant in one of the three 
genes of interest that are known to be associated with MH susceptibility. 
Patients’ selection process included using the unit database to identify the 649 index 
cases of all MH susceptible families at the unit by selecting patients with the smallest 
IVCT number, as it is assigned in chronological order, within each family code. As this 
study is aiming to correlate clinical and IVCT phenotypes to RYR1 genotypes, the 
identified list of MH susceptible index cases was filtered for patients who were 
genetically tested and a variant or more was found in one of the three genes; RYR1, 
CACNA1S and/or STAC3. Consequently, the files containing clinical data of those 379 
patients were reviewed to identify patients who had an anaesthetic reaction and the 
clinical details of their reaction were retrieved and recorded. Clinical data collected 
included patients’ sex and age at the reaction and previous anaesthetic history in 
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addition to the details of the anaesthetic reaction. IVCT traces are retrieved from files 
and measured as described later. 
4.2.2. Importing genetic testing results for the included probands 
In addition to the details collected as mentioned earlier, results of genetic testing of 
the 379 genotype-positive probands were imported from the unit genetic database. 
The genetic database is populated on the MH unit public database uploaded on the 
University of Leeds secure server using the FileMaker Pro 16Ó with secure login 
credentials to ensure patients’ confidentiality. As some patients had more than one 
variant detected, we included all the variants detected in any of the three genes of 
interest and consequently ordered them descending according to the detection rate in 
the MHS probands. Selection of variants to be included in this correlation study 
followed the inclusion criteria discussed later on. Worth mentioning that different 
genetic sequencing methods were used during genetic testing of the identified MH 
susceptible probands. 
4.2.3. Genotype-negative patients 
The genetic testing of 41 MHS index cases could not define a variant in the RYR1 in 
these patients. These negative results are of limited value in our genotype, clinical and 
IVCT phenotype correlation analysis. The main reason is that, the method of genetic 
testing was not consistent in all of the tested patients as in the majority of these 
genotype-negative patients, a restriction fragment length polymorphism (RFLP) 
sequencing method was used to search for a list of RYR1 variants that were believed, 
at that time point, to be pathogenic for MH. Over the years, new variants have been 
added to this list, and these variants cannot be excluded in patients who were tested 
prior to the identification of these new variants. In only eight patients of the 41-
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genotype negative MHS index cases, an NGS method was used to search for RYR1 
variants. Although these NGS methods offer a more thorough search of the RYR1 for 
variants, problems of sequencing certain exons on the RYR1 have been reported in 
addition to issues with the depth of coverage in some areas of the sequenced gene, 
related sometimes, to the quality of DNA used. Therefore, we cannot exclude the 
possibility of the presence of a pathogenic, or at least potentially pathogenic, variant 
in these patients. 
4.2.4. Inclusion criteria for different genotypes 
The number of variants detected in the three genes RYR1, CACNA1S and STAC3, 
was too huge to be easily interpreted as seen in tables 9-1 and 9-2 in the appendix. 
In addition, some variants were detected in only one or two probands making statistical 
analysis of their results meaningless. Moreover, some of these variants are 
considerably common in the general population with a minimum allele frequency of 
more than 1:1000, decreasing the possibility of deleteriousness of these variants. 
Furthermore, the IVCT data and clinical details of the suspected anaesthetic reaction 
are not necessarily complete in all probands due to shortcomings in reporting and 
referrals of these probands to the unit. Therefore, we set some criteria for the variants 
to be included in our analysis. 
For the purpose of this study, a variant was included in the analysis only if it was found 
in at least ten probands who had a suspected anaesthetic reaction and tested 
susceptible to MH using the IVCT test. In addition, sufficient clinical details about the 
anaesthetic reaction and IVCT traces should be available for at least six patients in 
each genotype group to allow meaningful interpretation of the statistical analyses. The 
estimated prevalence in the general population should be low; therefore, we included 
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variants with a minimum allele frequency (MAF), on the ExAC browser 
(http://exac.broadinstitute.org), less than 1:1000 in the European non-Finnish cohort, 
as a low-risk general population. This mainly because our cohort of probands is 
considered predominantly white European. 
Additionally, we included the RYR1 c.529C>T, p.177Arg>Cys variant, that was found 
in only nine probands with sufficient clinical details about their reaction. However, this 
variant is considered the most common among a group of non-functionally 
characterised variants found in the UK MH population. Additionally, it is considered a 
rare variant with ExAC MAF of 0/64006. The C-score, derived from Combined 
Annotation-Dependent Depletion score that is used to predict the most deleterious 
variants in the human genome, was calculated to be 32 for this variant, using 
(http://cadd.gs.washington.edu) (Miller et al., 2018). Variants with C-score>15 include 
the 5% predicted most deleterious substitutions in the human genome. 
4.2.5. IVCT traces measurements 
The IVCT measurement method was described early in the general methods chapter. 
However, as more patients included in this study from the era before the 
standardisation of the IVCT techniques, some of the patients included in this study 
had old IVCT traces where adjustments had to be made to match the recording of the 
more recent traces. These adjustments include for example, excluding the results of 
the static halothane test for some patients when the practice was to add only a single 
concentration of 2% halothane to the water bath where the muscle is strung, to ensure 
consistency of the included data, while including the results of the dynamic halothane 




We identified the MHS index cases of 649 families tested at the unit after a suspected 
anaesthetic reaction. Positive genotype data was available for 379 individuals on the 
unit genetic database who were tested inhouse for diagnostic variants or sequenced 
using the NGS facility at St. James’s University Hospitals for a panel of genes including 
our genes of interest, the RYR1, CACNA1S, and STAC3. Table 9-1 in the appendix 
details all the RYR1 variants detected, their detection rate and the minimum allele 
frequency (MAF) for each variant found in more than one index case in our cohort, 
using the European non-finish population, as a low-risk general population, as a 
denominator. Table 9-2 details the variants detected in the CACNA1S and number of 
individuals found to carry each of these variants. In addition, in one patient with three 
RYR1 variants detected, a STAC3 c.842A>G, p.281Asn>Ser variant was found. 
Another STAC3 deletion mutation, c.226_228del, p.76Glu-del, was detected in a 
patient with the RYR1 c.7300G>A, p.2434Gly>Arg variant. 
According to the criteria we stated earlier (a missense mutation with a MAF on ExAC 
database of <1:1000 and was found in ten or more unrelated probands from our 
cohort), four functionally characterised variants as causative for MH were included in 
the analyses: c.487C>T, c.1021G>A, c.6617C>T, c.7300G>A, in addition to the non-
functionally characterised RYR1 c.529C>T, p.177Arg>Cys genotype group, as stated 
earlier. The sex distribution for this group of 118 probands was not significantly 
different compared to the cohort of all 649 MHS index cases; X2=0.66, 1df. with p 
value=0.42. In addition, the age at the reaction and sex distribution were not 
significantly different between the included genotype groups; one-way ANOVA, p 
value= 0.6236 and X2=5.9, 4df with p value=0.2, respectively. 
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4.3.1. Genotype-clinical phenotype correlation 
The clinical features of the anaesthetic reaction of this cohort of patients were 
categorised into three clinical groups: exaggerated muscular response to 
succinylcholine only, a hypermetabolic reaction triggered by anaesthetics involved the 
use of succinylcholine, and a hypermetabolic reaction triggered by volatile 
anaesthetics only. The following table 4-2 shows different clinical categories in each 
genotype group. Regarding the c.7300G>A, p.2434Gly>Arg variant, which is the most 
common in the UK MH population, only six patients carrying this variant have triggered 
an anaesthetic reaction that included metabolic features without the administration of 
succinylcholine. In addition, half of the patients with the same variant triggered a 
reaction in their first anaesthetic. The number of previous anaesthetics, in the other 
half, ranged from one up to elven previous uneventful anaesthetics before they 
developed a reaction. For the RYR1 c.6617C>T, p.2206Thr>Met that was found in 
twelve patients included in our cohort, seven patients developed metabolic features 
after succinylcholine use, and seven developed a reaction in their first anaesthetic. 
For patients who were found to have the second most common RYR1 variant among 
the UK MH population, the c.1021G>A, p.341Gly>Arg, only three out of fourteen 
patients included in our cohort triggered a reaction in their first anaesthetic, and a 
hypermetabolic reaction in eight patients with this variant was triggered by 
anaesthetics that did not include succinylcholine administration. Another group with 
11 patients found to have the RYR1, c.487C>T, p.163Arg>Cys, shared similar figures 
with the c.1021G>A genotype group; regarding more patients have developed a 
hypermetabolic reaction to volatile anaesthetics without the use of succinylcholine 
(eight out of eleven), and less than half of the eleven patients triggered a reaction in 
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their first anaesthetic (four out of eleven patients). In addition to the group with the 
RYR1 c.529C>T, p.177Arg>Cys variant that was found in nine patients, seven of them 
developed a hypermetabolic anaesthetic reaction without the use of succinylcholine 
and all but one patient had a history of uneventful anaesthetics.
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Total 1st anaesthetic 
vs. previous 
anaesthetics 
Time to develop 1st 
hypermetabolic sign 




1 2 8 11 4: 7(1-3) 52.5, 20-77.5 min. 
c.529C>T, 
p.177Arg>Cys 
0 2 7 9 1: 8(1-4) 72.5, 30-88.75 min. 
c.1021G>A, 
p.341Gly>Arg 
2 4 8 14 3: 11(1-3) 77.5, 48.75-135 min. 
c.6617C>T, 
p.2206Thr>Met 
2 7 3 12 7: 5(1-3) 42.5, 18.75-112.5 min. 
c.7300G>A, 
p.2434Gly>Arg 
17 49 6 72 36: 36(1-11) 52.5, 22.5-67.5 min. 
Table 4-2: The number of patients included in each of the common genotype groups included in this study. The nature of the anaesthetic 
reaction regarding metabolic and muscular features in relation to the use of succinylcholine. Anaesthetic history in each genotype group and the 
time in minutes to the appearance of the first metabolic sign of the reaction, presented as median and interquartile range (IQR). 
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We studied the maximum derangement of the hypermetabolic features recorded 
during the reaction, including temperature, pH and etCO2, and compared them 
between the genotype groups. For temperature and pH, we analysed the difference 
between the maximum recorded value and 37℃ and 7.4, respectively, unless stated 
otherwise, e.g. if the patient had fever prior to the operation, we used the difference 
between the baseline temperature and the maximum recorded value during the 
reaction. We used the recorded value for etCO2 for comparison, as it proved difficult 
to identify the baseline for every patient as it varies highly depending on the patient’s 
medical condition, the ventilation technique and when the measurement starts. In 
addition, some reports did not include information about etCO2; instead, the PaCO2, 
available from an arterial blood gas (ABG), was recorded. To match these recordings 
with our data, we converted the PaCO2 to etCO2 by subtracting 5mmHg. We also 
included the time in minutes to the development of the first hypermetabolic sign of the 
reaction. 
The time in minutes from the start of anaesthesia to the development of the first 
hypermetabolic sign of the reaction was recorded. In the majority of patients, this time 
was reported by the attending anaesthetists. This time was dependent on the 
anaesthetist judgement of the starting point of the hypermetabolic signs. In the 
remaining patients, when anaesthetic charts were available, we re-evaluated the 
anaesthetic charts and identified the time at which the hypermetabolic sign started to 
develop. We also recorded serum CK levels and used the highest reported value for 
comparison between the included genotype groups. 
The data of the four studied variables (pH, temperature, etCO2 and time in minutes) 
followed a normal distribution and passed the Shapiro-Wilko normality test with a p 
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value>0.05. One-way ANOVA comparing data from the five genotype groups showed 
no statistically significant difference in change in pH, etCO2 highest values, and timing 
to the onset of metabolic features with p values=0.13, 0.12, 0.2, respectively. Only the 
change in temperature was significantly different between the studied genotype 
groups with a p value= 0.016. When compared different genotype groups to the group 
of patients with the RYR1 c.7300G>A using uncorrected Fisher’s LSD multiple 
comparisons testing, only patients with the RYR1 c.1021G>A variant showed a 
consistent statistically significant higher pH and temperature difference and etCO2 
value and longer time to onset. None of the other genotype groups showed a 
significant difference with the RYR1 c.7300G>A, figure 4-1, except for patients with 
the variant c.529C>T as the change in temperature was statistically higher with a p 
value=0.043. 
The Log 10 transformed data of the highest postoperative serum CK levels recorded 
were compared using one-way ANOVA and showed a statistically significant 
difference between the studied genotype groups with a p value=0.014. Using 
uncorrected multiple comparisons Fisher’s LSD test to compare individual groups with 
the c.7300G>A, patients with the RYR1 c.487C>T and c.529C>T variants had a 
statistically significant lower postoperative serum CK levels with a p value=0.0036 and 







































































































































































Figure 4-1: Comparing the studied metabolic features and time of onset between different 
genotype groups and the RYR1 c.7300G>A group. A) Time in minutes to the start of the 
hypermetabolic reaction, B) end tidal CO2 in KPa, C) pH difference from 7.4, and D) temperature 
difference in from 37℃. Using Fisher’s LSD test comparing each genotype group to the c.7300G>A 




4.3.2. Genotype-IVCT phenotype correlation 
The IVCT traces of the included patients were retrieved from the patients’ files stored 
at the unit archive, and the twitch height and tension difference for each of the three 
tests were measured as described before. The average twitch height from the three 
specimens of the IVCT test for the included probands passed the normality testing 
according to Shapiro-Wilko normality test with a p value>0.05. The average pre-drug 
twitch height was significantly positively correlated with the tension difference from the 
three IVCT tests, as shown in the following figure 4-3. Between the five different 
genotype groups, there was no significant difference in the average twitch height, one-











































Figure 4-2: Comparing the Log 10 transformed data of the highest postoperative 
serum CK level between different genotype groups and the RYR1 c.7300G>A group. 
Using Fisher’s LSD test. Uncorrected p values are labelled above each group. (*)àp 
value<0.05 and (**)à p value<0.01. 
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Kruskal-Wallis non-parametric test was used to compare the mean ranks of the three 
components of the IVCT test between the five different genotype groups. A significant 
difference was found between groups with the caffeine and dynamic halothane but not 
the static halothane test (p value= 0.0046, 0.041, and 0.10.9, respectively). Then we 
used multiple comparisons uncorrected Dunn’s test to compare between the different 
genotype groups and the c.7300G>A. This variant was described in the previous 
literature to have a weaker contracture (Carpenter et al., 2009). Comparison of the 
IVCT data of patients with the RYR1 c.7300G>A showed that patients with the variant 
c.487C>T had a significantly stronger IVCT response (higher tension difference) in the 
caffeine and dynamic halothane tests. In addition, patients with the variant c.1021G>A 
had a significantly higher tension difference to the caffeine but not the other IVCT 
tests.























Figure 4-3: The correlation between the average twitch height and the tension 
differences of the three IVC-tests. A positive correlation was found with using 

































































































































Figure 4-4: Comparing the tension differences of the IVCT between different genotype groups and the c.7300G>A group. Using multiple 
comparisons Dunn’s test. The tension differences at 2 mmol caffeine for the caffeine test and at 2% halothane for the static and dynamic halothane 
tests. Uncorrected p values are labelled above each genotype group. (*)à p value<0.05 and (**)à p value<0.01. 
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4.3.3. Clinical phenotype-IVCT phenotype correlation 
For patients with the four most common RYR1 genotypes in the UK MH population in 
addition to patients with the RYR1 c.520C>T genotype, we correlated the clinical 
pattern of the suspected anaesthetic reaction to the IVCT lab results of these patients. 
We tested the relationship between a stronger clinical phenotype and whether this 
might have any reflection on the in vitro response of muscle samples to halothane and 
caffeine. As we thoroughly investigated the clinical and IVCT patterns in these five 
genotype groups early in this chapter, we only included patients from this cohort in this 
correlation analysis. 
The viability of muscle specimens as indicated by the average pre-drug twitch height 
showed no significant difference between the three clinical groups, one-way ANOVA 
p value=0.74, nor when used uncorrected Fisher’s LSD test to compare the mean of 
each clinical category with the mean of each other category. As the tension differences 
of the three IVCT tests were not normally distributed, we used Kruskal-Wallis non-
parametric test to compare between the mean ranks of the different clinical groups 
included, a statistically significant difference was found in the three tests, caffeine p 
value=0.0004, static halothane p value=0.0058 and dynamic halothane p 
value=0.0057. We then used the uncorrected Dunn’s test to compare the mean ranks 
of tension differences of the three IVCT tests between each clinical category with each 
other category. As shown in figure 4-5, a consistent statistically significant difference 
was found between the group of patients who had a muscular only reaction to 
succinylcholine and the group of patients who had a hypermetabolic reaction to 
triggering volatile anaesthetics without the use of succinylcholine. A significant 
difference was found between the two groups of patients who developed a 
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hypermetabolic reaction with and without succinylcholine, with the caffeine test but no 
such difference was noticed with both halothane tests. Also, the tension difference of 
the static halothane test was statistically significant between patients who developed 
muscular features only reaction and patients who developed a hypermetabolic 
reaction with the use of succinylcholine. We were not able to identify any correlation 
between the hypermetabolic features of the reaction and the tension differences of 
any of the three IVCT nor the average twitch height of the three muscle specimens 
used in the tests.
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ID V1 V2 V3 
1 c.1021G>A CACNA1S, c.1817G>A, p.606Ser>Asn 
 
2 c.6617C>T RYR1, c.14344G>A, p.4782Gly>Arg 
 
3 c.6617C>T RYR1, c.8327C>T, p.2776Ser>Phe 
 
4 c.7300G>A CACNA1S, c.1817G>A, p.606Ser>Asn 
 
5 c.7300G>A CACNA1S, c.1817G>A, p.606Ser>Asn 
 
6 c.7300G>A CACNA1S, c.1817G>A, p.606Ser>Asn 
 
7 c.7300G>A CACNA1S, c.4060A>T, p.1354Thr>Ser 
 
8 c.7300G>A CACNA1S, c.4060A>T, p.1354Thr>Ser 
 
9 c.7300G>A RYR1, c.10097G>A, p.3366Arg>His 
 
10 c.7300G>A RYR1, c.5033A>G, p.1678Asn>Ser RYR1, c.5360C>T, p.1787Pro>Leu 
11 c.7300G>A STAC3, c.226_228del, p.76Gludel 
 
Table 4-3: Additional variants found in our cohort of patients. V1à the variant included 
in our list of studied genotype groups, V2 and V3 are additional variants. 
 
4.3.4. Patients with multiple variants 
When retrieving the genetic testing results from the unit genetic database, we found 
that 44 index cases were found to have more than one variant during genetic testing. 
Different combinations of variants were detected in these patients with one patient was 
found to have up to three RYR1 variants with an additional STAC3 variant. This was 
not particularly reported in previous studies as the genetic testing in the past was 
targeted to certain regions and/or exons of interest using RFLP or Sanger sequencing. 
Conversely, in recent years, NGS methods are able to sequence the whole gene 
and/or panel of genes of interest boosting the number of variants detected in tested 
patients. Table 4-3 lists the patients included in our analysis who were found to have 
more than the variant of interest. No combination between two or more of the included 
variants in this study was found. In addition, due to the small number of the patients 
included in our study found to have additional variants, we were not able to study the 
possible confounding effects of these variants on the correlation between genotype 
groups and clinical and IVCT phenotypes. 
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4.4. Discussion 
We applied stringent inclusion criteria for different genotypes to be included in this 
study. However, the 118 patients, from the five genotype groups, who were included 
in this study, represent nearly one-third of the 379 genotype-positive MHS index 
cases. Our main aim of these strict criteria was to ensure more homogeneity of 
patients’ data within each genotype group in an attempt to eliminate confounding by 
other factors such as sex, age, and muscle viability-related factors. The number of 
probands included in each genotype group in relation to the total number of 
independent UK families found to have the variant of interest, differed as follow: 
c.487C>T (52.83%, 95% CI 31.02%-73.74%), c.1021G>A (45%, 95% CI 34.8-
69.96%), c.6617C>T (42.85, 95% CI 24.52%-61.18%), c.7300G>A (61%, 95% CI 
52.2%-69.8%) and c.529C>T (90%, 95% CI 71.41%-108.59%). The low percentage 
of inclusion in some genotype groups led to a lack of power in some of the analyses. 
Table 4-3 shows a list of another six RYR1 variants that have been reported in ten or 
more UK MH families. However, we have not included these variants in our study 
mainly because the number of patients for whom we were able to retrieve the clinical 
details of their reaction with too small to perform statistical analysis. Additionally, to 
ensure homogeneity in our cohort, we only included probands who have been 
genetically screened and tested susceptible to MH with IVCT. 
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codon protein No. of UK families Segregation 
c.1840C>T p.614Arg>Cys 14 7 
c.7304G>A p.2435Arg>His 11 10 
c.7361G>A p.2454Arg>His 14 11 
c.7373G>A p.2458Arg>His 15 12 
c.11969G>T p.3990Gly>Val 11 7 
c.14477C>T p.4826Thr>Ile 10 10 
Table 4-4: List of other RYR1 variants that have been detected in ten or more UK MH 
families. They were not included in our genotype-phenotype correlation study due to missed 
information in some patients. 
 
Discussing our primary aim regarding the relation between different genotypes and 
the clinical presentation of MH reactions, a crucial point to address is the possible 
effects of different genotypes on the penetrance of MH. More patients in the genotype 
groups c.487C>T, c.529C>T, and c.1021G>A had uneventful previous anaesthetics 
before they develop the suspected reaction. Coincidently, more patients in these 
groups developed a reaction triggered by volatile anaesthetics only. On the other 
hand, more patients in the genotype group c.6617C>T developed a reaction in their 
first anaesthetic, and more patients developed a reaction triggered by anaesthetic that 
involved the use of succinylcholine. This may give the impression that the former three 
genotype groups have a lower penetrance compared to the c.6617C>T group. 
However, this observation is confounded by the controversial role of succinylcholine 
in triggering an MH reaction (Hopkins, 2011). Another confounding factor is the 
duration of exposure to, and the potency of different volatile anaesthetics. These 
factors may play a role in triggering a reaction from the first exposure or sensitise the 
muscles for further exposures. Therefore, as we could not retrieve information about 
the anaesthetic agents used during previous occasions, we cannot assess the 
possible effects of these confounding factors. 
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When compared to the c.7300G>A genotype groups, patients from the c.1021G>A 
genotype group had a consistent statistically significant higher degree of derangement 
of the metabolic features studied; etCO2, pH and temperature. This may indicate that 
this genotype group produce a stronger clinical phenotype. On the other hand, the 
time of onset of the hypermetabolic reaction was significantly longer in the c.1021G>A 
group. This observation is confounded by the fact that more patients in the c.7300G>A 
group received succinylcholine during their anaesthetic and as we have illustrated in 
the previous chapter, the use of succinylcholine was associated with a shorter time of 
onset of the hypermetabolic MH reactions. No statistically significant difference could 
be found with other genotype groups, except for patients in the c.529C>T group who 
had a statistically higher temperature but no difference in the other features. 
Regarding the difference in the highest postoperative serum CK level between the 
c.1021G>A and c.7300G>A groups, no statistically significant difference could be 
found. An interesting observation is that patients in the genotype group c.487C>T who 
were reported in a previous study (Carpenter et al., 2009) to have a statistically higher 
basal serum CK level compared to patients in the c.7300G>A group, however in our 
study, these patients had a statistically lower postoperative serum CK level. This 
observation could be again due to more patients in the c.7300G>A group have 
received succinylcholine compared to the c.487C>T genotype group. We have 
illustrated in the previous chapter that the use of succinylcholine was associated with 
statistically higher postoperative serum CK levels (Aboelsaod et al., 2018). 
Comparing the IVCT tension difference of the included patients, the difference 
between genotype groups was similar to the previous study that included a smaller 
number of patients and the cohort in that study included both probands and index 
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cases; who did not develop anaesthetic reactions, instead investigated because of 
family history of MH. However, the difference between genotype groups in our cohort 
was less evident than in the previous study. Different genotype groups did not have 
any significant effect on the viability of the three muscle specimens used in the IVCT 
test, as indicated by the pre-drug twitch height. Though, muscle viability is affected by 
other factors such as the surgical technique, the time the muscle kept on the bench 
and any underlying muscle pathology. A positive correlation was noticed between the 
average pre-drug twitch height and the tension difference of the three IVCT tests. This 
correlation was more evident with the dynamic halothane test, which may be due to 
the longer duration of the test and repeated stretching and relaxation of the muscle 
specimen that may affect its viability. 
To our knowledge, our study is the first attempt to correlate between the clinical 
presentation of MH reactions and the IVCT results of the affected probands. All 
patients included in this study reported an anaesthetic reaction, and we classified 
these reactions according to the predominant clinical features; muscular or metabolic 
in relation to the use of succinylcholine. We hereby report a novel observation that the 
IVCT results from patients who developed a hypermetabolic MH reaction triggered by 
volatile anaesthetics only, showed a stronger response to both halothane tests and 
the caffeine test compared to patients who developed a muscular-only reaction 
triggered by anaesthetics involved the use of succinylcholine. Furthermore, the former 
group of patients showed a higher tension difference in the caffeine tests, but not the 
halothane tests, compared to the group of patients who developed a hypermetabolic 
reaction triggered by anaesthetics involved the use of succinylcholine. This 
observation suggests an association between how patients develop different clinical 
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presentations of MH reactions and how their muscle would react to ryanodine receptor 
agonists under laboratory conditions. 
However, although all the included patients have tested susceptible to MH with IVCT, 
we should deal with the results from the group of patients who developed a muscular-
only reaction with caution as it is considered by some literature to be an exaggerated 
muscular response to succinylcholine rather than a true MH reaction. Especially with 
the specificity of the IVCT of ~93%, as it takes a more conservative approach to 
include false-positive patients to avoid the possible fatal outcome of suspected MH 
reaction, some of the included patients may not be susceptible to MH. Another 
argument is that an RYR1 variant has been found in all the included patient, four of 
these five variants are on the EMHG list of diagnostic variants, which consolidate the 
MH susceptible diagnosis. However, discordance has been reported in all the included 
genotype groups according to the recent study based on the UK MH population (Miller 
et al., 2018). Furthermore, we have not corrected for multiple comparisons which may 
abolish the difference we noticed between different groups. Therefore, further analysis 
based on a larger cohort of patients is needed to confirm, or exclude, our observation. 
We could not study the possible effects of multiple interacting variants on the clinical 
phenotype or the IVCT phenotype due to the small number of patients who were found 
to have more than one variant during genetic screening. In our cohort, eight of the 11 
patients who had an additional variant in one of the three genes of interest, were in 
the c.7300G>A genotype group. This group was described to have a weaker IVCT 
phenotype (Carpenter et al., 2009, Robinson et al., 2002) and our data illustrate that 
it has a weaker clinical phenotype compared to the c.1021G>A group. These 
additional variants may play a modulatory role in the expression of the clinical or IVCT 
 115 
phenotype in these patients. However, this role cannot be detected statistically due to 
the small number of patients; instead, functional studies may help to elaborate the 
effect of these additional variants on the process of the pathogenesis of MH in HEK-
293 cells or knock-in mice. 
This study was limited by the small number of included patients in each genotype 
group, in addition to the inconsistency in the reported clinical information about the 
anaesthetic reactions despite our strict criteria to include only patients with available 
clinical information. Furthermore, as some of the included patients had their IVCT test 
in the 1970s and early 1980s when the protocol for IVCT has not been standardised 
until 1984 (Ellis, 1984), some of the data from IVCT traces were not interpretable for 
our statistical analysis. In the meanwhile, the introduction of NGS method for genetic 
screening will help detect a more significant number of patients who have the variants 
of interest that will improve the statistical power of future studies. We are also aware 
of ongoing projects that study the biochemical changes in muscle cells and myotubes 
from patients diagnosed with different IVCT phenotypes. We recommend that more 
studies investigating these biochemical changes in muscles from patients presented 
with different clinical phenotypes, as it may help to understand the possible 
biochemical mechanism behind different clinical presentations. 
Overall, we reported a statistically significant difference in the maximum derangement 
values of the metabolic features of the MH reaction between one of our studied 
genotype groups and the most common genotype group among the UK MH 
population. This difference indicates that the underlying genetic mutation influences 
how susceptible patients react to triggering agents in the clinical session. We restated 
the same observation reported previously about a difference in the IVCT results 
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between different genotype groups but in an exclusive cohort of MHS probands who 
developed an anaesthetic reaction. A novel observation of a possible association 
between the clinical phenotypes of MH reactions and the IVCT results is also reported 
in this study. However, more studies, including larger cohorts of patients, are needed 
to explore this association further. 
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5 Investigating the association between CM and MH 
susceptibility 
5.1 Introduction 
The congenital myopathies, a class of neuromuscular disorders, is of pivotal 
importance when studying the clinical and genetic epidemiology of MH. This group of 
clinically and genetically heterogeneous disorders are usually presented with an early 
onset characteristic clinical muscle weakness with different severity and course of 
progress patterns. The subtypes of this group overlap with each other on a clinical, 
histopathological, and genetic levels. Clinically, many patients are presented at birth 
with a severe phenotype, while others may develop mild or moderate forms of muscle 
weakness that could start in early childhood or later on in their life. The course of these 
disorders varies from non- or slowly progressive to severe and rapid affection of vital 
muscle groups, such as respiratory muscles. The pattern of distribution of clinical 
muscle weakness is characteristic for each subtype, although overlap is frequently 
noticed between the different clinical phenotypes. Genetically, mutations in several 
genes were linked to the pathogenesis of one or more category of the group of 
congenital myopathies with a dominant, recessive, or X-linked modes of inheritance 
described. The histopathological examination of muscle biopsies from patients 
diagnosed with these disorders shows a spectrum of pathology featuring different 
stages of core formation, central nucleation, fibre type 1 predominance and the 
presence of nemaline rods or bodies. 
Core myopathy, the most common of congenital myopathies, is characterised by the 
formation of a well-demarcated central core that lacks oxidative enzyme activity and 
is usually devoid of mitochondria (Sewry et al., 2002). These cores could be less 
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defined, peripheral and/or multiple in some patients or in the form of unevenness of 
the oxidative staining, or the motheaten appearance (Morgan-Hughes et al., 1973a). 
Conventionally, patients with well-demarcated central cores in their muscle biopsies 
are diagnosed with central core disease (CCD) and clinically presented with a non- or 
slowly progressive course of muscle weakness that starts at birth or in early childhood, 
usually with respiratory muscle sparing (Romero et al., 2003). When cores are less 
defined and multiple, patients are usually diagnosed with multi-mini-core or mini-core 
myopathy (MmD). According to the (Jungbluth et al., 2005), the underlying genetic 
variation leads to different clinical pictures in the form of the classic axial phenotype, 
MmD with predominant hip girdle involvement and MmD with marked distal weakness 
and wasting. Extraocular muscle involvement has also been reported in some families 
(Romero et al., 2003).  
The presence of central nuclei in muscle biopsies from patients with clinical features 
of CM led to the diagnosis of centronuclear myopathy (CNM) (Jungbluth et al., 2008). 
The clinical features in a group of patients with RYR1-related congenital myopathy 
with central nuclei showed an early onset severe form of muscle weakness starting 
from birth with recurrent respiratory tract infections and extraocular muscle 
involvement (Wilmshurst et al., 2010). Nevertheless, the histopathological feature of 
central nucleation is not a rare finding in other types of congenital myopathies such as 
core myopathies (Sewry and Wallgren-Pettersson, 2017). 
Fibre type 1 predominance is another pathological feature of congenital myopathies 
that is seen in muscle biopsies from patients with different types of congenital 
myopathies. Four out of six patients from a UK cohort with fibre type 1 predominance, 
as the only abnormality detected in their muscle biopsies, were found to have 
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pathogenic RYR1 mutations (Maggi et al., 2013). The clinical features of myopathy in 
these six patients overlapped with that of other types of congenital myopathies 
including extraocular muscle involvement, bulbar affection and orthopaedic 
deformities. RYR1 variants were detected in 4 out of ten Japanese patients who were 
found to have isolated fibre type 1 predominance in their muscle biopsies (Sato et al., 
2008). 
In this study we will explore the association between all the previously mentioned 
histopathological changes and MH susceptibility. To sum up different definitions of CM 
subgroups; the diagnosis of each subtype is dependent on the most prevalent 
histopathological changes, clinical presentation of the muscle weakness and affected 
muscle groups, and the underlying genetic variation. The main reason for referral of 
patients with clinical muscle weakness without any adverse anaesthetic history to the 
Leeds MH Investigation Unit, is the diagnosis of these patients with CCD according to 
the treating clinician judgement and the association between the two disorders 
(Klingler et al., 2009). However, due to the marked clinical, histopathological, and 
genetic overlap between the different subgroups of CM, according to the literature 
discussed earlier, we referred to all the patients who were tested at the unit and 
included in this study as CM patients, and explored the association between the 
histopathological findings, the genetic results and MH susceptibility status, regardless 
the clinical diagnosis made by the treating clinician. It is also worth mentioning that we 
cannot make an assumption on the exact proportion of patients diagnosed with 
different subtypes of CM who were referred for diagnosis of MH susceptibility as it is 
mainly dependent on the judgement of the treating clinicians and their understanding 
of the association between the different CM subtypes and MH. 
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Anaesthesiologists dealing with patients with congenital myopathies face many 
apparent challenges (Klingler et al., 2009), related for example to the clinical muscle 
weakness, which makes it difficult to assess the patient’s reserve capacity and 
exercise tolerance. Also, respiratory muscle involvement could worsen after 
anaesthesia mandating postoperative ICU admission and ventilatory support. 
Moreover, the involvement of bulbar muscle has been reported in association with 
different types of congenital myopathies in 46.4% of cases reported by (Colombo et 
al., 2015). Bulbar palsy carries its own risks during anaesthesia in the form of 
increased risk of aspiration due to attenuated upper airway reflexes, requiring closer 
monitoring of the patient during the perioperative period.  
In addition to the previously mentioned risks, the molecular mechanism behind the 
pathogenesis of CM, i.e. the mutated channels, has the potential risk of other 
anaesthesia-related disorders, e.g. MH. Mutations in the RYR1 was described as a 
possible cause in all of the previously mentioned subtypes of congenital myopathies. 
The same gene is identified as the primary locus for mutations causing MH in 70% of 
susceptible families (Robinson et al., 2006). More than 300 variants have been 
detected in the RYR1 with only 48 mutations have been functionally characterised as 
causative for MH and meet the criteria for genetic diagnosis of MH susceptibility 
(www.emhg.org). The abundance of variants detected in the RYR1 gene and the lack 
of a high-throughput method to functionally establish the pathogenicity of these 
variants make it mandatory to treat patients who have a medical personal or family 
history suggestive of MH with caution until their susceptibility status is confirmed using 
the gold standard IVCT (Klingler et al., 2009). 
 121 
MH susceptibility risk in patients with core myopathies originates from the effects of 
some RYR1 mutations linked to CCD on the Ca+2 homeostasis. These effects are in 
the form of excitation-contraction uncoupling and depletion of sarcoplasmic reticulum 
Ca+2 stores because of a constant leak (Treves et al., 2008). Patients diagnosed with 
MmD have not been reported to develop a clinical hypermetabolic MH reaction 
(Klingler et al., 2009). However, repeatedly, due to the marked overlap between core 
myopathies and some reports of alterations in Ca+2 homeostasis in fibres from MmD 
patient (Osada et al., 2004) and in human embryonic kidney cells (HEK293) with 
MmD-associated RYR1 mutations (Zorzato et al., 2007), it is wise to treat patients with 
MmD diagnosis with caution regarding the MH susceptibility risk. With regard to CNM, 
as mutations in the RYR1 have been identified as a common cause of CNM 
(Wilmshurst et al., 2010). Although none of the patients reported in this study 
developed an MH reaction, there is still a potential risk of MH, especially with a 
previous report of an MH reaction in a patient diagnosed with CNM (Quinn et al., 
1992), though the diagnosis of MH susceptibility was not confirmed using IVCT in this 
patient. 
It is noticed that most of the work done before to study the association between CM  
and MH was concerned with CCD diagnosis in particular. On a histopathological level, 
a study of the association between different RYR1 variants detected in a dominantly 
French cohort and the number and nature of cores, could not find any correlation 
between the RYR1 genotype and the pathological phenotype (Monnier et al., 2005). 
The same study estimated the detection rate of cores during pathological examination 
of muscle biopsies of IVC-tested patients without clinical muscle weakness, to be 
~27.5% of MHS patients and 2.5% in MHN individuals. Based on the UK population, 
several studies correlated histopathological detection of cores to the RYR1 variants 
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detected. Subsequently, the different RYR1 variants were categorised according to 
the association with a CCD diagnosis and the detection of cores in muscle biopsies. 
Hence, the categorisation of RYR1 variants into MH/CCD vs non-MH/CCD variants 
(Carpenter et al., 2009) or CCD associated mutations vs non-CCD mutations 
(Manning et al., 1998, Tong et al., 1999). Quantitative analysis of receptor function 
found that resting cytoplasmic Ca+2 concentrations in cells expressing CCD-
associated channel mutants were higher than for non-CCD associated channel 
mutants (Robinson et al., 2002). In addition, patients with MH/CCD variants were 
found to have a stronger response to the caffeine and dynamic halothane tests of the 
IVCT (Carpenter et al., 2009). 
Shepherd and colleagues (Shepherd et al., 2004) reported that all the clinical variables 
between CCD and MH phenotypes were noticed in a cohort of 21 UK families in the 
form of:  
• Patients tested MHS and had clinical muscle weakness. 
• Patients tested MHS, and myopathic features were found on histology but no 
clinical myopathy. 
• Clinical myopathy patients with histopathological changes but tested MHN. 
The possible theories behind this variation include incomplete penetrance of the CCD 
phenotype (Gillard et al., 1991), the slow progression of clinical myopathy (Patterson 
et al., 1979) or the independent segregation of MH and CCD (Shepherd et al., 2004). 
On the other hand, other studies were concerned with the histopathological findings 
in patients tested susceptible to MH without the presence of clinical muscle weakness. 
The same pathological spectrum of congenital myopathies is not a rare finding in 
patients tested MHS with IVCT without clinical muscle weakness, ranging from 
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unevenness of oxidative stain to the formation of cores, fibre type 1 predominance and 
central nucleation. A study that included a Canadian cohort of patients who were 
tested susceptible to MH with the Caffeine Halothane Contracture Test (CHCT), the 
American equivalent of IVCT but with no dynamic halothane test and the static 
halothane is performed through by single addition of 3% halothane, (Orlov et al., 2013) 
reported a 22% incidence of histopathological abnormalities in muscle biopsies of 
MHS patients. Although this study could not identify a consistent histological pattern 
in MHS patients, it reported that the incidence of histological abnormalities was higher 
in probands (patients who experienced a suspected anaesthetic reaction) more than 
other family members. However, it is unclear if these abnormalities are due to the 
effects of the anaesthetic reaction on muscle histology or these patients are more 
predisposed to trigger a reaction because of abnormal muscle histology.  
More recently, the same broad spectrum of histopathological findings observed in 
patients with congenital myopathies, ranging from non-specific isolated abnormalities 
to core formation, was also described in muscle biopsies of patients presented with 
MH or rhabdomyolysis, either exertional, viral or drug-induced (Knuiman et al., 2019). 
This multicentre study, repeatedly, reported the lack of correlation between the 
presence and severity of histological abnormalities and the degree of clinical muscle 
weakness. This study was more focused on genetically confirmed cases of RYR1-
related MH and RM, though, the presence of cores did not correlate with the detection 
of likely pathogenic RYR1 variants. 
Variants that have been described with both the CCD and MH phenotypes were 
reported (Carpenter et al., 2009) to have a statistically higher dynamic halothane 
tension and a shorter static ryanodine response time, ryanodine is another Ryr1 
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agonist that was used in some patients as part of the IVCT for research purposes, 
when compared to variants that have been described with the MH phenotype only. 
While a prior study (Robinson et al., 2002) found that variants that have been found in 
CCD patients were associated with a significantly more severe static halothane, 
dynamic halothane and caffeine test but not ryanodine test. Both previous studies 
have not reported the clinical myopathy phenotypes of the included patients. Although 
these studies were based on the UK MH population, the variants reported to be 
associated with CCD was described in previous studies that were not based on the 
UK population: c.487C>T and c.1565A>C were reported by (Quane et al., 1993, 
Quane et al., 1994), c.6488G>A by (Manning et al., 1998) and c.14693T>C reported 
by (Lynch et al., 1999). The RYR1 c.487C>T and c.6488G>A variants are on the list 
of the diagnostic variants for MH, while the other two variants have not been found in 
the UK MH population (Miller et al., 2018). 
RYR1 mutations lead to the development of different muscular related disorders due 
to their implication on the function of the ryanodine receptor. Four categories of RYR1 
mutations were described depending on how these mutations affect receptor function 
(Treves et al., 2008, Loy et al., 2011). The first category of mutations is associated 
with increased probability of receptor activation through fibre depolarisation or by 
receptor agonists and usually lead to the development of MH phenotype. Secondly, 
mutations that lead to Ca+2 leak through channels and depletion of Ca+2 stores in the 
sarcoplasmic reticulum and these mutations lead to the CCD phenotype. Other forms 
of CCD are associated with the third category of RYR1 mutations that lead to 
excitation-contraction uncoupling due to deficits on the Cav1.1-mediated voltage-
dependent activation of SR Ca+2 release. The fourth category of mutations leads to 
decreased RyR1 channel expression and results in multi-mini-core disease. A 
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compound effect of these mutations on the RyR1 channels’ activity is seen as some 
mutations lead to hypersensitive and/or leaky channels with the development of 
RYR1-related MH and CCD, while other CCD-causing mutations lead to excitation-
contraction uncoupling. The mechanism of this complexity is unclear (Dowling et al., 
2014). 
Rhabdomyolysis is a condition associated with muscle breakdown, and it is the leading 
cause of acute renal failure in 7% of cases (Dlamini et al., 2013). It is being reported 
in some patients who develop an MH reaction or found to have one of the 
neuromuscular disorders described earlier. The index cases of 14 families with no 
clinical muscle weakness presented with exertional rhabdomyolysis were found to 
have RYR1 mutation on genetic analysis, and the histopathological examination of 
their muscle biopsies showed some of the spectra described with different types of 
congenital myopathies (Dlamini et al., 2013). The cause of rhabdomyolysis in this 
studied cohort was mainly related to exertion, heat or alcohol intake. In one family, the 
trigger to this condition was an intercurrent infection. The spectrum of pathology in this 
cohort of patients ranged between fibre type 1 predominance, increased internal 
nucleation, and unevenness of oxidative staining. These patients usually presented 
with exertional myalgia and mild to moderate elevation of serum CK levels. 
This study aims to investigate the prevalence of MH susceptibility in known CM 
families that were referred to the Leeds MH Investigation Unit because of a diagnosis 
of myopathy or were investigated because of a suspected anaesthetic reaction and 
the medical or family history revealed clinical myopathy. In addition, we aim to study 
the incidence of MH reactions among members of these families. Furthermore, we are 
interested in investigating the prevalence of histopathological features of myopathy in 
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patients who were tested at the Leeds MH Investigation Unit for MH susceptibility 
because of personal or family history of anaesthetic reactions suggestive of MH, in the 
absence of clinical muscle weakness. As routinely during IVCT, a muscle specimen is 
sent to the Neuropathology lab at Leeds Teaching Hospitals to be examined by a 
pathologist, hence, we were capable of reviewing the histopathological examination 
reports of index cases of all families who were tested at the Leeds MH Investigation 
Unit. Last but not least, we explored the association between the findings in both 
cohorts included in this study and the genetic testing results available for those 
patients in an attempt to investigate the correlation between both disorders. 
5.2 Methods 
5.2.1 Study design 
This study consisted of two main parts; the first one is to collect the available 
information about the MH susceptibility status of all CM index cases who were tested 
at the unit and collecting information about family members of those index cases. 
Secondly, reviewing histopathological examination reports of MH index cases who 
were tested at the unit because of anaesthetic history suggestive of MH. Furthermore, 
we will import all the available results of genetic testing of the included patients to 
correlate this data to clinical and IVCT data of those patients. 
Index cases of CM families 
Using FileMaker Pro 16©, we selected the lowest IVCT number in each family code, 
as it is assigned in chronological order, to identify index cases of all families tested at 
the unit. Secondly, we filtered the results using the “reason for referral” field to patients 
who are labelled as referred because of CM. As the “reason for referral” field was not 
complete for all the patients due to some shortcomings when creating the database 
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and uploading the data from patients’ files to the database, we ensured to check the 
reason for referral in the IVCT biopsy report for each index case while we were 
reviewing the histopathological reports of all the index cases as will be described later 
in this section. Additionally, some patients were referred because of an anaesthetic 
reaction suggestive of MH. By reviewing their medical history, they were found to have 
CM or belong to a family known to have the condition. Those patients were also 
included in this group. 
Other members of myopathy families who were tested at the unit 
After identifying index cases to be included in the CM group, we used their family 
codes to search for other members of these families who were tested at the unit. Using 
FileMaker Pro16 program to search the database, we collected information about 
these families including the number of members in each family who were tested with 
IVCT and/or genetic screening for one of the RYR1 variants, the MH susceptibility 
status for each member tested with IVCT, and the results of genetic screening for the 
members who were tested genetically. For each member of these families, we 
additionally collected data about the degree of kinship to the index case of the family, 
medical history of CM, and any history of suspected MH reactions. 
Index cases of families tested for MH susceptibility 
In order to study the prevalence of histopathological myopathic changes in muscles of 
individuals who were tested for MH susceptibility because of anaesthetic history, 
personal or familial, of a suspected MH reaction, we selected the index cases for more 
than 1900 family codes for which the Leeds MH Investigation Unit archive holds files 
for at least one member of these families. We, consequently, reviewed the 
neuropathology lab examination reports of all these index cases and identified reports 
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indicating the presence of one or more of the histopathological changes of RYR1 
myopathy: core formation, fibre type I predominance, and/or increased percentage of 
central nucleation. The pathological changes detected in these reports were recorded 
in addition, we collected information about the MH susceptibility status of the identified 
index cases, results of genetic screening, if performed, and the medical and 
anaesthetic history. 
For all the included cases, we collected patients’ data including, sex, date of birth, date 
of biopsy, and body measurements. From the IVCT biopsy reports of these cases, we 
recorded the information available about their MH susceptibility status, previous 
medical and anaesthetic history, and the reason for referral. We also recorded the 
serum CK level at the time of biopsy. As we stated earlier, the results of the 
histopathological examination were also recorded for all the included cases, and the 
genetic screening results available on the unit database were imported. 
5.2.2 Genetic testing results 
We used the Leeds MH Investigation Unit database to collect the results of genetic 
testing for the included patients. The method of sequencing was different over the 
years, and between the patients, though, we only collected the available information 
about variants detected in RYR1. In addition to the available genetic information on 
the database for the patients included in the CM group of patients, including patients 
with a clinical or family history of clinical muscle weakness with or without a history of 
suspected MH reaction, we submitted a request to the DNA lab at St. James’s 
Hospitals, Leeds Teaching Hospitals to perform NGS screening for the available DNA 
samples for the remaining patients with no available information on the unit database. 
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5.2.3 Muscle biopsies and muscle histology 
As a rule, all patients included in this study have had their muscle biopsy obtained for 
IVCT diagnosis of MH susceptibility at the Leeds MH Investigation Unit at St. James’s 
University Hospital. All but three patients had their muscle biopsy obtained from the 
quadriceps muscle. In the remaining three patients, a muscle biopsy was obtained 
from the palmaris longus muscle, and all of them had their muscle biopsy in 1973, 
before the standardisation of IVCT procedure. Two of these patients were referred 
because of a family history of CM and the third patient had a suspected anaesthetic 
reaction. In only seven patients who were referred because of CM, a previous muscle 
biopsy was obtained for the diagnosis of CM. According to the available reports, the 
site of the previous biopsy was not the quadriceps muscle in three patients; instead, 
the muscle biopsy was obtained from, the biceps, deltoid and trapezius muscles. 
5.2.4 Categorisation of histopathological findings 
The spectrum of pathology in patients with CM is broad and very variable, making the 
categorisation of these patients and the severity ranking of the histopathological 
findings very difficult. Additionally, the formation of cores is believed to be age-related 
and varies from one individual to another even within the same family. We aimed to 
rank the severity of histopathological findings to enable us of easy categorisation of 
the included patients and to facilitate investigating the relation between the 
histopathological findings during pathological examination and the laboratory findings 
of the IVCT. We categorised the histopathological features according to the findings 
during each staining stage of the histopathological examination. During oxidative 
staining, the following features are commonly seen in these patients: unevenness of 
the oxidative stain or the motheaten appearance, formation of mini-cores that are 
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usually multiple, and the formation of a well-demarcated central core. Central cores 
are usually single but can be multiple or even located peripherally in the cell. As we 
stated earlier, it is not completely understood if these findings are stages of the disease 
that progress with age or with the progression of the disease, separate entities of the 
disease features, or different severity stages of the disease. However, we endorsed 
the assumption that these findings are different levels of severity of the pathological 
changes. As shown in table 5-1, each level of core formation stages, mentioned 
earlier, is given a rank that sums up for the severity score of the histopathological 
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Nucleation Normal Central 
 
Pathology 
score No pathology Mild Moderate Severe 
Table 5-1: A proposed severity scoring of the RYR1-related histopathological findings. 
The pathological features detected in our cohort of patients presented with MH or CM 
phenotype. 
 
Additionally, the fibre type distribution found using pH-specific adenosine 
triphosphatase (ATPase) stain is given a rank of 1 if fibre type 1 predominance was 
found and rank of 0 if the biopsy preserved its normal pattern of fibre types distribution. 
The percentage of central nucleation in muscle fibres that is assessed using H&E stain 
also contributed to our severity score of myopathic changes. We considered central 
nucleation as a pathological finding if its percentage was 10% or more of the observed 
nuclei in the muscle biopsy. Although according to personal communication with the 
Neuropathologists at the Neuropathology lab at Leeds Teaching Hospitals, indicating 
that some pathologists consider central nucleation as a pathological finding if it is 
spotted more than 5% in the given muscle biopsy, we endorsed stricter inclusion 
criteria, especially in patients presented with no clinical muscle weakness. 
5.3 Results 
5.3.1 MH susceptibility in CM families 
We identified 38 cases who were referred to the unit for diagnosis of MH susceptibility 
because of a CM diagnosis. An additional nine patients were selected as they were 
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referred because of a suspected MH reaction and after reviewing their medical files, 
they were found to have CM. In 28 of the 38 families included in this study, the first 
patient to be tested was the proband who reported clinical CM, while in the remaining 
ten families, the first patient to be tested did not have clinical muscle weakness but 
was referred because of a family history of CM, i.e. index case, while the probands of 
these families could not be tested because of being too young, deceased or unfit for 
the procedure. In total, a cohort of 47 cases was included, of those cases, 26 were 
females, and the average age at biopsy for this cohort is ~31.5 years with a minimum 
age of 7 years and maximum of 70 years old. 
Histopathological examination of muscle biopsies of the 47 cases ranged from no-
pathology detected in seven patients to the detection of severe myopathic changes in 
20 patients with the histopathological report missing for one patient. Apart from the 
patient with a missing pathology report, all patients who were referred because of 
clinical CM showed myopathic changes in pathological examination with only two 
patients had a mild form of myopathic changes in the form of motheaten appearance 
in one patient and fibre type 1 predominance in the other patient. The remaining 25 
patients had moderate to severe forms of pathological changes. Histopathological 
examination of muscle specimens from either index cases of CM families, or patients 
who had a CM and were referred because of a suspected MH reaction, showed a 
variety of results of histopathological changes ranging from no myopathic features to 
severe forms of pathological changes. 
Regarding MH susceptibility status in this cohort of patients, more than half (26 of 47 
patients) were tested not susceptible to MH and seven of the 21 patients who tested 
MHS with IVCT, were susceptible to halothane only during the IVCT. Moreover, the 
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nine patients who were referred because of an anaesthetic reaction and were found 
to have CM, three of them tested not susceptible using the IVCT. By reviewing the 
clinical notes for the three MHN patients who were referred because of a suspected 
anaesthetic reaction, no anaesthetic records could be retrieved for one patient with a 
vague history of reaction to general anaesthetic in the form of delayed recovery and 
the patient has described feeling weak after the operation. Another patient with no 
anaesthetic records but a letter from the referring anaesthetist described a low-grade 
fever with the use of halothane that was reversed rapidly and easily with surface 
cooling. The third patient’s file contained the full report of the anaesthetic reaction in 
addition to the referral letter from the attending anaesthetist. This patient’s anaesthetic 
included the use of isoflurane without the administration of succinylcholine, and after 
45 minutes of the seven-hour operation, the patient developed a temperature increase 
from 37.5°C to 39°C with unexplained tachycardia of 150 beats/minute. However, the 
maximum recorded etCO2 was <6.1kPa and the highest CK level recorded was 285 
IU/L. In addition, the pH was within normal range with no acidosis, and a urinary 
sample showed the absence of myoglobinuria. 
On the other hand, the six patients who were referred because of either a clinical or 
family history of myopathy and tested MHS with IVCT had previous general 
anaesthetics without developing an MH reaction. In only one patient who is an index 
case of a CM family, an MH trigger-free anaesthetic was used as the anaesthetist was 
aware of the possibility of MH due to the family history of CM. In the other five patients, 
triggering volatile anaesthetics were used without the use of succinylcholine. The 
number of previous anaesthetics, before the diagnosis of MH susceptibility was 
established, ranged from one up to six previous operations where triggering volatile 
anaesthetics were used. All five patients showed myopathic changes during 
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histopathological examinations of their muscle biopsies ranging from mild to severe 
changes. Regarding the reason for referral for these five patients, two patients had the 
clinical phenotype of CM while the other three patients were index cases of CM 
families. 
Family study 
It is essential to restate the definitions of an index case and a proband when we report 
this study of CM families. Throughout this study, we used the term index case to 
indicate the first member of the family to be investigated, while proband is used to 
indicate the member of the family who presented with the clinical phenotype and 
triggered an investigation of this family. Although the proband and index case could 
be the same person, in this part of the study, we will refer to an index case as the first 
member of the family who has been tested without being affected by the clinical 
phenotype. Of the 47 family codes identified, 30 index cases were singletons with no 
other family members tested at the unit, and consequently, no additional clinical, IVCT 
or genetic information was available. For family codes with other family members who 
were tested at the unit ranging in number from two to 21 family members. Of the 17 
CM families with more than one member tested at the unit, the index cases of four 
families were tested for MH susceptibility with IVCT but did not have any clinical 
muscle weakness. In the remaining 13 families, the first member to be tested was the 
proband who presented with the clinical phenotype of CM or developed an anaesthetic 
reaction and was found to have clinical muscle weakness. 
Two large families with 14 and 20 members tested with IVCT, in addition to the CM 
proband in each family, were included in our study. Genetically, a different familial 
RYR1 variant was found in each family, and in both families, matching results of the 
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RYR1 genotype, myopathy phenotype, IVCT phenotype and histopathology were 
found. In the first family MYO-1, five members, including the proband, reported some 
degree of clinical muscle weakness and all of them were found to carry the familial 
variant RYR1 c.13913G>A. In these five patients, in addition to another clinically-free 
genotype-positive patient, the histopathological examination of their muscle biopsies 
showed some features of CM. On the other hand, the other nine MHN members of 
this family, who were tested genotype negative for the familial variant, reported no 
muscle weakness and no abnormality was detected in their muscle biopsies. The other 
family MYO-2 with 21 members tested at the unit, including the myopathic proband, 
showed the same degree of segregation between myopathy, IVCT, and 
histopathology phenotypes and the RYR1 genotype, but the familial variant that was 
found in this family was the RYR1 c.14814C>G. Regarding numbers in this family: 15 
members, including the proband, tested MHS with IVCT, some degree of clinical 
muscle weakness and myopathic changes were reported, and 14 of them were 
genetically tested, and the familial variant was detected in all of them. The other six 
members tested MHN, no clinical nor histopathological features of CM were reported, 
and the familial variant could not be detected in the five members who were genetically 
tested. 
The genetic testing of members of three families; MYO-3, MYO-4, MYO-5, in whom 
more than one member in addition to the proband or index case have been tested with 
IVCT and genetically, a familial RYR1 variant was detected in all MHS members, while 
MHN members of these families were not genetically tested. In another two families; 
MYO-6, MYO-7, no such segregation could be found between IVCT and genetic 
results. In the first family, an MHS patient and two MHN members were found to have 
the RYR1 c.2320G>A variant and another MHN did not have this variant. The other 
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family’s proband tested MHS and the RYR1 c.14582G>A variant was found while his 
father tested MHS, but no variant was found. Four families included in our study had 
only one member, in addition to the proband or the index case, tested with IVCT. In 
one family; MYO-8, the proband who had clinical myopathy and moderate myopathic 
changes, in addition to another clinically-free relative and no histopathological 
abnormality detected, both tested MHN with IVCT. Only the proband of this family was 
genetically tested and the RYR1 c.14591A>G variant was detected. The probands of 
another two families; MYO-9 & MYO-10 tested MHS, the additional member of both 
families tested MHN. However, the additional member of one of these families, MYO-
10, the sister of the female proband, complained of scoliosis but no pathological 
abnormality was detected in her muscle biopsy. Both members of the last family; MYO-
11, including the proband who had a suspected MH reaction, tested MHS with IVCT. 
Nevertheless, the sister of the male proband had no clinical muscle weakness and her 
muscle biopsy showed no pathological abnormalities. 
5.3.2 Histopathological findings in MH index cases 
Reviewing the histopathological examination reports of all MH index cases who have 
been tested at the unit for MH susceptibility and had a muscle specimen examined by 
the neuropathology lab at Leeds Teaching Hospitals, we identified 120 reports with 
histological changes of CM detected in their muscle biopsies. None of these 120 cases 
had any medical history of clinical muscle weakness as the nine patients who 
experienced a suspected MH reaction and were found to have muscle weakness were 
included in the former group of congenital myopathies. The reason for referral for 
diagnosis of MH susceptibility in these 120 selected cases was a suspected 
anaesthetic reaction in 106 patients, while the remaining 14 individuals were relatives 
of patients who experienced an anaesthetic reaction and could not be tested being too 
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young, abroad, deceased or unfit for the procedure. The average age at the biopsy of 
the included 120 cases was 34 years, with a minimum of 5 years and a maximum of 
75 years old, and 51 cases were females. 
All the selected cases were included in this cohort because of the detection of 
myopathic changes during the histopathological examination of their muscle samples. 
Mild myopathic changes were detected in more than half of the patients (63 out of 120 
patients) with the most common change detected is the motheaten appearance during 
NADH reductase staining. In the remaining patients, moderate to severe myopathic 
changes were detected: either a more severe form of core formation, mini-cores or 
well-demarcated central cores, with or without fibre type 1 predominance, and/or 
increased percentage of central nucleation. All the 12 patients who presented with a 
severe form of myopathic changes, tested MHS and all, but one case, were referred 
because of a suspected anaesthetic reaction. On the other hand, 22% of the 45 
patients who had a moderate form of myopathic changes and 39% of the 63 patients 
with mild myopathic changes, tested not MHN. 
5.3.3 The relation between histopathological findings and the IVCT results and CK 
level 
As the severity of myopathic changes differed between patients in our cohort, we 
tested the association between different histopathological severity scores and the 
basal serum CK level at the time of the biopsy and the results of the three IVCT tests. 
We excluded seven patients with no pathology detected from this analysis as their 
number in each sub-category was too small to be statistically interpreted. The basal 
serum CK level was available for 127 patients, and we used the uncorrected Fisher 
LSD test to compare the mean of Log 10 transformed serum CK levels in each severity 
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category with that of each other category, and no statistically significant difference 
could be found between groups, figure 5-1. For IVCT results, we compared the 
average twitch height of the three tests using uncorrected multiple comparisons 
Dunn’s test and no significant difference was found between the groups. 
Regarding the tension difference for the three IVCT tests, we only included in this 
analysis the available results for patients who were tested susceptible to MH, as MHN 
patients would have a negative tension difference value. The available numbers were 
not consistent in each test due to the unavailability of the test traces for some patients. 
We used the uncorrected Dunn’s test for multiple comparisons, and as shown in figure 
5-2, the only significant difference that could be noticed was in dynamic halothane 
test, as patients with severe myopathic changes in their muscle biopsies showed a 
small but significant higher tension difference when compared with patients with mild 
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Figure 5-1: Comparing the log 10 transformed data of basal CK level between 
different pathology severity groups. No difference could be found between the 
























































Figure 5-2: Comparing tension differences of the three IVCT tests between different pathology severity grades. Statistically significant 
difference was found in DH test between patients with severe pathology compared to the other two groups using the uncorrected Dunn’s test. 
P values are labelled above brackets connecting with significant values labelled with *. SH= static halothane, DH= dynamic halothane 
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In addition, the numbers of patients who were found to have an isolated feature of the 
RYR1-related myopathic changes are shown in table 5-3. Motheaten appearance is 
the most common isolated histopathological feature found in our patients. Only one of 
those patients who were found to have an isolated motheaten appearance in their 
muscle biopsies presented with clinical muscle weakness. Motheaten appearance 
was found in all patients reported in this table to have an isolated fibre type 1 
predominance or central nucleation. Nonetheless, we included these patients as to 
have an isolated fibre type 1 predominance or central nuclei because of the 
controversy about motheaten appearance being a nonspecific feature or a stage of 
core formation process (Sewry et al., 2002). 
 















2 1 0 1 1 
MHN 
n.5 





10 5 39 2 12 
MHN 
n.36 
2 4 25 4 1 
Table 5-2: Patients with isolated RYR1-related histopathological changes. Patients are 
distributed according to their clinical myopathy status and MH susceptibility phenotype. MHS= 
malignant hyperthermia susceptible. MHN= malignant hyperthermia not susceptible. 
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5.3.4 Genetic findings 
Information about the genetic testing results was available for 104 patients of the 
whole cohort included in this study. In the group of patients who were referred because 
of an anaesthetic or a family history of suspected MH without any medical history of 
CM and their muscle biopsies showed some myopathic changes, at least one variant 
was found in 51 patients. Additionally, nine patients from the same group were not 
genetically tested, but we included the variant that was detected in other MHS 
members from their families. In the CM group of patients, including patients with a 
clinical or family history of clinical muscle weakness with or without a history of 
suspected MH reaction, information about genetic testing results on the Leeds MH 
Investigation Unit database was available for 19 patients. The other 28 patients, in this 
group of congenital myopathies, for whom we submitted an NGS request to the DNA 
lab, we found that no DNA sample was available for analysis for nine patients and 
another patient declined to provide consent for genetic testing. DNA samples of the 
remaining 18 patients were genetically tested using NGS, and at least an RYR1 variant 
was detected in 11 patients, while no variant could be detected in seven patients. 
Genetic testing of the whole cohort of patients detected 60 different RYR1 variants. 
As we stated earlier, sequencing techniques were different over the years and 
between patients. Table 5-4 lists all RYR1 variants found in this cohort of patients and 
their detection rate, in addition to the MH phenotype of patients with each variant and 
their clinical myopathy phenotype. Variants that are on the EMHG list of diagnostic 
variants are labelled in the table. Of the variants detected in this cohort, 42 variants 
were detected in only one patient each, while the most common RYR1 variant among 
the UK population, the c.7300G>A, was detected in 12 patients in our cohort, all of 
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them were tested because of a history of MH without clinical muscle weakness. 
Another ten variants were detected in two patients, each, while three variants detected 
in three patients and four variants detected in four patients, each. An additional RYR1 
variant was detected in five patients in our cohort and in another four patients, we 
included the variant that has been detected in an MHS member of their families, as 
the four included patients have not been genetically tested. All, but two, variants 
detected in our cohort of patients are missense mutations, and the two exceptions are 
deletion mutations, variants ID# 48 and 55.
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phenotype MH Pathogenicity Notes 
1 c.38T>G p.13Leu>Arg 1 MHS    
2 c.178G>A p.60Asp>Asn 1 MHS    
3 c.251C>T p.84Thr>Met 1 MHS    
4 c.325C>T p.109Arg>Trp 1 MHN   With variant #10 
5 c.479A>G p.160Glu>Gly 2 MHS CM Likely-pathogenic 
6 c.487C>T p.163Arg>Cys 3 MHS  Diagnostic  
7 c.742G>C p.248Gly>Arg 1 MHS  Diagnostic  
8 c.1021G>A p.341Gly>Arg 2 MHS  Diagnostic  
9 c.1201C>G p.401Arg>Cys 1 MHS  Diagnostic  
10 c.1453A>G p.485Met>Val 1 MHS   Additional variant 
11 c.1615T>G p.539Phe>Val 1 MHS  Likely-pathogenic 
12 c.1840C>T p.614Arg>Cys 2 MHS  Diagnostic 1 Family variant 
13 c.2320G>A p.774Gly>Arg 1 MHS    
14 c.3535C>T p.1179Arg>Trp 1 MHS    
15 c.4178A>G p.1393Lys>Arg 1 MHS    
16 c.4405C>T p.1469Arg>Trp 1 MHN    
17 c.4711A>G p.1571Ile>Val 2 1MHS/*1MHN CM  *1 with variant #39 
18 c.6488G>A p.2163Arg>His 1 MHS  Diagnostic Family variant 
19 c.6502G>A p.2168Val>Met 1 MHS  Diagnostic  
20 c.6587A>G p.2196Asn>Ser 1 MHN CM  With variant #53 
21 c.6617C>T p.2206Thr>Met 4 MHS  Diagnostic 1 with variant #47 
22 c.7036G>A p.2346Val>Met 1 MHS   With variant #60 
23 c.7043A>G p.2348Glu>Gly 1 MHS    
24 c.7048G>A p.2350Ala>Thr 2 MHS  Diagnostic  
25 c.7063C>T p.2355Arg>Trp 1 MHS  Diagnostic  
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phenotype MH Pathogenicity Notes 
26 c.7089T>G p.2363Cys>Gly 1 MHS    
27 c.7093G>A p.2365Gly>Arg 1 MHS    
28 c.7291G>T p.2431Asp>Tyr 2 MHS  Likely-pathogenic 
29 c.7300G>A p.2434Gly>Arg 12 MHS  Diagnostic  
30 c.7304G>A p.2435Arg>His 1 MHS CM Diagnostic  
31 c.7304G>T p.2435Arg>Leu 1 MHS    
32 c.7354C>T p.2452Arg>Trp 2 MHS  Diagnostic  
33 c.7361G>A p.2454Arg>His 2 MHS  Diagnostic  
34 c.7373G>A p.2458Arg>His 3 MHS  Diagnostic  
35 c.7523G>A p.2508Arg>His 4 MHS 2CM Diagnostic  
36 c.11132C>T p.3711Thr>Met 1 MHS    
37 c.11315G>A p.3772Arg>Gly 1 MHS CM Likely-pathogenic 
38 c.11752A>C p.3918Thr>Pro 1 MHS    
39 c.11798A>G p.3933Tyr>Cys 1 MHS   Additional variant 
40 c.11958C>G p.3986Asp>Glu 1 MHS  Likely-pathogenic 
41 c.11969G>T p.3990Gly>Val 2 MHS  Diagnostic  
42 c.13513G>C p.4505Asp>His 1 MHS    
43 c.13913G>A p.4638Gly>Asp 4 3MHS/1MHN CM   
44 c.14201G>A p.4734Gly>Glu 1 MHS   Family variant 
45 c.14209C>T p.4737Arg>Trp 1 MHS   Family variant 
46 c.14210G>A p.4737Arg>Gln 1 MHS  Likely-pathogenic Family variant 
47 c.14344G>A p.4782Gly>Arg 1 MHS   Additional variant 
48 c.14419_14421del 1 MHS    
49 c.14440C>T p.4814Leu>Phe 1 MHN CM   
50 c.14458G>T p.4821Gly>Trp 1 MHS CM   
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phenotype MH Pathogenicity Notes 
51 c.14471T>C p.4824Leu>Pro 1 MHS  Likely-pathogenic 
52 c.14477C>T p.4826Thr>Ile 4 MHS  Diagnostic 2 Family variants 
53 c.14522C>A p.4841Thr>Asn 1 MHS   Additional variant 
54 c.14582G>A p.4861Arg>His 2 1MHS/1MHN CM Diagnostic  
55 c.14588_14605del 1 MHN CM   
56 c.14591A>G p.4864Tyr>Cys 1 MHN CM   
57 c.14678G>A p.4893Arg>Leu 3 2MHS/1MHN* 1CM Likely-pathogenic *The CM patient is MHN 
58 c.14814C>G p.4938Ile>Met 1 MHS CM   
59 c.14815G>T p.4939Asp>Tyr 1 MHN CM   
60 c.14817C>A p.4939Asp>Glu 1 MHS   Additional variant 
Table 5-3: RYR1 variants detected in our cohort, the number of patients included in our cohort who were found to have these variants and 
their MH susceptibility status using IVCT and CM phenotype. Variants found in the EMHG list of diagnostic RYR1 variants for MH are labelled as 
diagnostic. The six variants in red cells are variants found in the family members of nine patients included in this cohort but were not genetically 
tested. The five variants in yellow cells were found in association with other RYR1 variants, each labelled in the notes’ column.
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Most of the patients (78 out of 89) who were found to have an RYR1 variant, were 
tested susceptible to MH with IVCT. Nine of the 11 patients who were tested MHN 
have presented with clinical CM, while the other two patients were tested because of 
a family history of CM without clinical muscle weakness, nor anaesthesia related 
complications in their anaesthetic history. The RYR1 variants c.4711A>G, 
c.13913G>A, c.14582G>A, c.14678G>A were found in both MHS and MHN tested 
patients. All the MHN patients who were found to have one of these variants are CM 
patients. The RYR1 c.14582G>A variant is on the EMHG list of diagnostic variants. 
We reviewed the IVCT traces of the MHN CM patient who were found to have the 
diagnostic RYR1 14582G>A variant and found that the three muscle specimens used 
for the IVCT tests were viable at the time of the test, and for the static halothane test 
the muscle contracture line continued to relax with the addition of 0.5, 1, 2% 
concentrations of halothane, while for the dynamic halothane test the muscle 
contracture line plateaued. For the caffeine test, the muscle specimen reacted to the 
application of 2 mmol, but the tension difference was 0.05 g (below the cut-off point of 
0.2 g) 
In our list of variants, 19 diagnostic mutations were functionally characterised as 
causative for MH (https://www.emhg.org/diagnostic-mutations). These mutations were 
found in 50 patients included in our cohort and apart from the MHN CM patient 
discussed early, all other 49 patients were tested susceptible to MH. In addition to the 
MHN CM patient with the RYR1 c.14582G>A mutation, another three patients 
presented with clinical CM were found to have diagnostic RYR1vriants: one patient 
with c.7304G>A mutation and two patients with c.7523G>A mutation, and all of the 
three patients tested MHS. Another list of non-functionally characterised RYR1 
variants that are considered by the EMHG as likely pathogenic for MH can be found 
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on (www.emhg.org/genetic-scoring-matrix). In our cohort, 12 patients were found to 
have one of these likely-pathogenic variants. Of these 12 patients, four had the clinical 
CM phenotype, and two of them were tested MHN with IVCT. The likely-pathogenic 
variant RYR1 c.14678G>A was found in an MHN CM patient and also found in another 
two MHS patients, one was referred because of an MH reaction, and the other patient 
is a family member of a CM family but without any clinical muscle weakness. 
Investigating the incidence of clinical myopathy and/or histopathological features of 
myopathy in different genotype groups, we found that the 12 patients who were found 
to have the most common RYR1 variant among the UK population, the c.7300G>A, 
and were found to have myopathic features on histology, none of them had any clinical 
features of clinical muscle weakness. Histologically, NADH staining of all 12 patients 
showed a motheaten appearance, and one patient had also an increased percentage 
of central nucleation and another patient had also fibre type 1 predominance, while 
the remaining ten patients had no other pathological abnormalities. These 12 
unrelated patients represent 10.17% of all the 118 UK families who were found to have 
the RYR1 c.7300G>A. The second most common RYR1 variant, the c.1021G>A, that 
was found in 31 UK families, was found in only two index cases of MH families included 
in our cohort. Both cases did not report clinical CM nor anaesthesia related 
complications but were tested as relatives of patients who had a suspected MH 
reaction. The histological examination of their muscle biopsies revealed only 
motheaten appearance in one case and multi-mini-cores plus central nucleation in the 
other case and both cases were tested MHS. 
Of the 28 UK families who were found to have the third most common RYR1 variant, 
the c.6617C>T, four index cases (14.29%) of these families were found to have 
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histopathological features of CM. All these four patients were referred because of a 
history of anaesthetic reaction with no clinical muscle weakness reported in their 
history. A severe form of myopathic changes on histology was reported in one patient 
with well-defined central cores can be detected in the muscle biopsy in addition to fibre 
type 1 predominance. The other three patients had motheaten appearance with one 
patient found to have an increased percentage of central nucleation. In our cohort, 
three out of 21 UK families with the RYR1 variant c.487C>T were found to have some 
myopathic changes in their muscle biopsies with a severe form of pathology in one 
patient with central cores and increased percentage of central nucleation. All the three 
patients were tested MHS because of an anaesthetic reaction, and none of them 
reported clinical muscle weakness. 
These discussed four variants were found in >50% of all the UK families who were 
found to have one of the diagnostic RYR1 variants. These 21 unrelated patients 
included in our cohort and were found to have one of these four variants, represent 
just above 10% of the UK families with these variants. None of these patients has 
reported any clinical features of CM. Histologically, only two patients of this group were 
found to have severe myopathic changes with well-demarcated central cores in their 
muscle biopsies, while the remaining had mild to moderate myopathic changes. 
Clinical CM with a diagnostic RYR1 variant was reported in four patients with the 
variants c.7304G>A, c.7523G>A and c.14582G>A. These three variants were found 
in 16 UK families (~4.5% of UK families with diagnostic variants). The CM patient with 
the RYR1 variant c.14582G>A was tested MHN with IVCT, discussed earlier. 
Of the variants that are not on the EMHG list of diagnostic variants, nor on the list of 
likely-pathogenic variants for MH, the RYR1 variant c.13913G>A that was found in two 
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MHS, and two MHN patients included in our cohort. None of these four patients had 
any history of anaesthesia related complications, and all of them were referred 
because of clinical muscle weakness. This variant could be of particular interest with 
regard to the CM phenotype. It was found in one of the big CM families described 
earlier MYO-1, five members of this family who were found to carry the genotype 
reported clinical muscle weakness and histopathological changes. Only one 
discordant member of this family who is genotype positive but clinically free and the 
muscle biopsy showed histopathological abnormalities. It was also found in the 
proband of another two families, and a singleton; however, we have not included these 
two families in the family study as only the probands were genetically tested. 
5.4 Discussion 
The widening histopathological spectrum of congenital myopathies and the growingly 
accepted concept of marked overlap between different types of congenital myopathies 
mandate a proper investigation of the association between the whole group of 
congenital myopathies and MH. The current practice is to refer patients who have a 
confirmed diagnosis of CCD for diagnosis of their MH susceptibility status using IVCT, 
a decision usually made by the neuropathologist or the paediatrician reviewing the 
case. We believe that the 47 index cases of CCD families referred at the unit and 
included in this study, including those who developed an anaesthetic reaction, are 
considered a relatively small sample representing the number of families that have a 
confirmed diagnosis of CCD and even a smaller sample of families that have a 
confirmed diagnosis of other congenital myopathies. We summarised in this study the 
work done to study the overlap between different types of congenital myopathies, 
though, our main aim is to highlight to the anaesthetists the potential risk of MH in 
patients with the broader, clinical and histopathological, spectrum of CM. 
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As RYR1 mutations are now recognised as the most common genetic cause for 
congenital myopathies (Jungbluth et al., 2018) and it has been associated with 
different subtypes of congenital myopathies including the two most common variants 
of the disease CCD (Haan et al., 1990, Mulley et al., 1993) and MmD (Ferreiro et al., 
2002, Jungbluth et al., 2002), in addition to other subtypes of CM including fibre type 
1 predominance (Clarke et al., 2010) and centronuclear myopathy (Wilmshurst et al., 
2010). The histopathological features of these subtypes are referred to as RYR1-
related myopathic changes (Sewry et al., 2002, Sewry and Wallgren-Pettersson, 
2017). Mutations in the same gene were identified as the causative mutations for MH 
in >50% of UK MH families, and if variants that have not had its pathogenicity 
confirmed are included, this percentage rises to >70% (Miller et al., 2018). However, 
due to the marked clinical, histopathological and genetic heterogeneity of these two 
disorders, the management of both disorders in relation to each other is too complex. 
Therefore, it is reasonable to treat patients diagnosed with one of these conditions as 
at risk of developing complications due to the other disorder until a definitive diagnosis 
is confirmed. 
Of the different subtypes of congenital myopathies, CCD patients were suggested to 
be at risk of MH (Shuaib et al., 1987, Brownell, 1988), though, this association is not 
always consistent (Curran et al., 1999). Considering the clinical and histopathological 
overlap between different subtypes of CM, it is crucial to assess the associated risk 
between MH and CM, regardless of the subtype diagnosis. However, this association 
is complicated by factors such as the incomplete penetrance of MH, the observation 
that not all MH susceptible patients develop a reaction in their first anaesthetic, and 
the specificity of the IVCT of ~93%. Additionally, different molecular mechanisms have 
been proposed to explain how different RYR1 mutations affect Ca+2 homeostasis 
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leading to the MH susceptibility phenotype (Hirata et al., 2007, Maclennan and 
Zvaritch, 2011) in one hand, and the CCD phenotype (Treves et al., 2008), on the 
other hand. In our cohort, three patients with clinical myopathy who had an adverse 
anaesthetic reaction tested MHN with IVCT. The reaction of one of these three 
patients, where the details were available, mounts to be diagnosed clinically as a 
hypermetabolic MH reaction, though, considered a mild to moderate form of 
anaesthetic reactions. This could question the sensitivity of IVCT of 99%, especially 
in patients with CM. Unfortunately, these three patients were not tested genetically for 
variants in the RYR1. 
In our cohort, the majority of patients presented with clinical muscle weakness, 
excluding those who developed an anaesthetic reaction, tested MHN with IVCT (21 of 
28). Some of these 21 patients were genetically tested when a DNA sample was 
available, and they have consented for genetic testing. Of the 14 patients who were 
genetically tested, an RYR1 variant was found in nine patients, and one of these 
variants is on the EMHG list of diagnostic variants for MH, representing another 
possible challenge for the sensitivity of the IVCT in patients who present with clinical 
myopathy. Although, the in vitro response of muscle samples depends on other factors 
related to the viability of the muscle and surgical techniques during the biopsy, the 
background pathology in these muscles could influence their response to the 
ryanodine receptor agonists used, halothane and caffeine. We have not analysed the 
difference of contracture strength in IVCT traces from our patients. This was mainly 
because of the small sample size and the fact that these biopsies have been taken 
during different time periods, with the changes in the surgical techniques and the IVCT 
protocols over the years. However, we noticed that the tension differences for the two 
halothane tests and the caffeine test were just slightly higher than the cut-off point in 
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most of the patients. It could be an observation bias; however, further statistical 
analysis of larger sample size is needed to test the possible effects of the underlying 
muscle pathology on the IVCT results. 
Our study of family members of probands and index cases who have been tested at 
the unit because of a clinical or a family history of CM, reinstated the same observation 
found before in a previous study (Shepherd et al., 2004). This study reported patients 
who had clinical myopathy and tested MHS, patients who had no clinical myopathy 
but tested MHS and their muscle biopsies showed RYR1-related myopathic changes, 
and patients who had clinical myopathy with histopathological changes in their muscle 
biopsies but tested MHN. Additionally, we report further variations in the association 
between clinical myopathy, MH susceptibility and RYR1-related myopathic changes: 
• Patients who reported an adverse anaesthetic reaction and tested MHN, but 
their muscle biopsies showed histopathological changes. 
• Patients who presented with clinical muscle weakness and had a 
hypermetabolic anaesthetic reaction, but tested MHN. 
• Patients who presented with clinical muscle weakness, reported an adverse 
anaesthetic reaction but tested MHN, and no pathological changes were found 
in their muscle biopsies. 
This complicates more our standing of the link between the two phenotypes, however, 
as a possible explanation; the different molecular mechanisms leading to the clinical 
myopathy and/or myopathic changes, which is different from that causing the MH 
phenotype (Jungbluth et al., 2018), may alter the response of muscle samples to 
ryanodine receptor agonists used during the IVCT. Another explanation is that the 
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viability of muscle samples from these patients may be compromised due to the 
underlying pathology that leads to false-negative responses. 
The high segregation found in two of our large families, MYO-1 and MYO-2, between 
the different studied features; the myopathy phenotype, the MH phenotype, and the 
histopathology in association to the two RYR1 variants c.13913G>A and c.14814C>G, 
respectively; highlights a significant and promising background for future studies. 
Functional characterisation studies of these two variants could offer a better 
understanding of their effects on the excitation-contraction coupling and Ca+2 
homeostasis. On the other hand, no segregation between the studied features and 
genetic testing results were found in most of the other families. This adds more to the 
complexity of the association between the two conditions. In particular, in one of the 
families; MYO-7, an RYR1 variant was found in the MHS proband, while not found in 
the MHS father of this proband. The same variant, the diagnostic RYR1 c.14582G>A 
variant, was found in another CM proband who was tested MHN. Of the limitations of 
this study that it is limited to patients who were referred to the Leeds MH Investigation 
Unit for IVCT, and when the proband or index case of a family is tested MHN, usually 
other members of the family are not referred for the invasive biopsy. However, to better 
understand the complexity of the association between the two disorders, it would be 
beneficial to test a larger number of members of these families for MH susceptibility 
and genetically, in different generations of the family. This could be practically difficult 
due to the long waiting list at the unit, in addition to the ethical dilemma of exposing 
some patients to the probably unnecessary invasive biopsy procedure. 
Several studies have reported the spectrum of histopathological changes associated 
with MH susceptibility without clinical muscle weakness (Reske-Nielsen et al., 1975, 
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Gullotta and Spiess-Kiefer, 1983, Harriman, 1988, Mezin et al., 1997, Orlov et al., 
2013). Unspecific changes were described in the form of areas of necrosis or fibre 
degeneration, while other literature reported the presence of “frank” myopathic 
changes such as motheaten appearance and well-demarcated cores. We only 
included in this study the features that have been described in association with RYR1-
related congenital myopathies. We have examined all the index cases and probands 
of families who have been tested at the Leeds MH Investigation Unit because of 
anaesthetic reactions. Of the 795 independent MHS families, 86 probands or index 
cases were found to have RYR1-related myopathic changes in their muscle biopsy, 
(10.8%, 95% CI 0.087-0.132), compared to 34 MHN probands or index cases from 
1105 independent MHN families, (3.1%, 95% CI 0.021-0.043). 
The severity of myopathic changes was markedly different between MHS and MHN 
cases as none of the MHN cases had a severe form of pathology. We should take into 
consideration that our estimate of 10.8% of MHS cases, was only for patients with 
RYR1-related myopathic changes, on the contrary of 22% estimate of non-specific 
changes described earlier (Orlov et al., 2013). Furthermore, the “frank” myopathy 
described in this previous study, only included fibre size variability and internal 
nucleation. Therefore, our study provides the most recent estimate of the incidence of 
RYR1-related myopathic changes in unrelated MH susceptible index cases. We also 
tried to explore the relationship between the severity of RYR1-related myopathic 
changes in our cohort of patients and the basal CK levels in these patients, but we 
could not find any significant association. 
Similarly, the results of the three IVCT tests were not significantly different between 
the severity grades in our cohort, apart from a slight difference found in the results of 
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the dynamic halothane test. However, we have not corrected for multiple comparisons, 
which likely to abolish that slight difference found with the dynamic halothane tests. A 
future study with a bigger sample size should give us a better idea about the 
association between the severity of RYR1-related myopathic changes and the 
contracture strengths of the IVCT. 
During the transfer discussion for this PhD project, a valuable suggestion was to 
recontact patients who were diagnosed MH susceptible after an anaesthetic reaction 
and were found to have RYR1-related myopathic changes in their muscle biopsy 
without clinical muscle weakness. The purpose was to check if these patients 
developed any muscle weakness after the reaction, either temporal or permanent. The 
hypothesis behind this suggestion, based on our discussion, was to examine if the 
anaesthetic reaction could have any long-term effect on their muscle function. The 
possible cause could be the effects of triggering anaesthetic agents on gene 
expression in these patients that may trigger muscle weakness that was not apparent 
before the reaction. Another possible hypothesis is if the conformational changes in 
the Ca+2 homeostasis regulating proteins that happen with triggering volatile 
anaesthetics that may alter the muscle function for a longer time leading to clinical 
weakness. However, due to time restraints and issues with applying for another ethical 
approval to recontact these patients about their clinical condition, we were not able to 
test this hypothesis, although we consider this suggestion as a valuable continuation 
of our work and a base for future studies. 
As the RYR1 gene is considerably a large gene and more than 300 variants have been 
detected in this gene, it is not surprising the large number of variants detected in our 
cohort; 60 different RYR1 variants detected in 94 patients of the 110 genetically tested 
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patients. Taking into consideration that some of these patients have been tested using 
conventional DNA sequencing methods, which target certain spots of the gene, this 
number is likely to increase if, in all the tested patients, the whole RYR1 gene was 
screened using NGS. In table 5-5, we have labelled variants detected in our cohort 
according to their association with the MH phenotype; some variants have been 
functionally characterised as diagnostic for MH while other variants are labelled as 
likely pathogenic. All the diagnostic variants have been detected in patients who were 
tested MHS with IVCT, apart from the CM discordant patient who tested MHN and was 
found to have the diagnostic variant c.14582G>A. For the variants that are listed as 
likely-pathogenic for MH, all patients who were found to have one of these variants 
tested MHS, except for the RYR1 c.14678G>A variant that was detected in two MHS 
patients and one MHN patient who was referred because of clinical muscle weakness. 
This supports our theory of the possible effects of the underlying muscle pathology on 
the results of IVCT. 
On the other hand, studying the association between histopathological changes and 
the RYR1 genotype, 23 patients were found to have an RYR1 variant and a severe 
form of RYR1-related myopathic changes. All the ten patients who did not report any 
clinical muscle weakness, tested MHS with IVCT, while seven out of the 13 patients 
who were referred because of clinical CM tested MHN. These seven MHN patients 
include the two patients described early who were found to have a diagnostic and 
likely pathogenic RYR1 variants; c.14582G>A and c.14678G>A, respectively. 
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Codon protein Pathogenicity MH susceptibility Muscle weakness 
c.479A>G p.160Glu>Gly Likely MHS clinical CM 
c.479A>G p.160Glu>Gly Likely MHS 
 
c.487C>T  p.163Arg>Cys Diagnostic MHS 
 
c.4711A>G p.1571Ile>Val VUS MHN clinical CM 
c.6587A>G p.2196Asn>Ser VUS MHN clinical CM 
c.6617C>T p.2206Thr>Met Diagnostic MHS 
 
c.7036G>A p.2346Val>Met VUS MHS 
 
c.7043A>G p.2348Glu>Gly VUS MHS 
 
c.7048G>A  p.2350Ala>Thr Diagnostic MHS 
 
c.7361G>A  p.2454Arg>His Diagnostic MHS 
 
c.7523G>A p.2508Arg>His Diagnostic MHS clinical CM 
c.7523G>A p.2508Arg>His Diagnostic MHS 
 
c.13913G>A  p.4638Gly>Asp VUS MHS clinical CM 
c.13913G>A  p.4638Gly>Asp VUS MHS clinical CM 
c.13913G>A  p.4638Gly>Asp VUS MHN clinical CM 
c.14440C>T p.4814Leu>Phe VUS MHN clinical CM 
c.14471T>C p.4824Leu>Pro Likely MHS 
 
c.14582G>A  p.4861Arg>His Diagnostic MHN clinical CM 
c.14582G>A  p.4861Arg>His Diagnostic MHS clinical CM 
c.14678G>A p.4893Arg>Leu Likely MHN clinical CM 
c.14814C>G p.4938Ile>Met VUS MHS clinical CM 
c.14815G>T p.4939Asp>Tyr VUS MHN clinical CM 
c.14419_14421del VUS MHS 
 
Table 5-4: RYR1 variants that was found in patients with severe form of RYR1-related 
myopathic changes, the pathogenicity of these variants to MH, the MH susceptibility status 
of these patients and the clinical CM diagnosis. VUS= variant of unidentified significance. 
 
The mode of inheritance of MH and different entities of RYR1-related congenital 
myopathies are variable. Majority of the RYR1 mutations associated with MH and CCD 
are described to have an autosomal dominant mode of inheritance (Jungbluth, 2007). 
However, homozygosity and compound heterozygosity have been described with MH 
phenotype (Deufel et al., 1995, Lynch et al., 1997), and with CCD (Romero et al., 
2003, Wu et al., 2006). RYR1 mutations described with MmD are recessive in many 
cases (Monnier et al., 2003, Jungbluth et al., 2005). In CNM, a case was described 
with autosomal dominant RYR1 mutation (Jungbluth, 2007), and in another three 
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cases (Wilmshurst et al., 2010), while other four cases were described to have 
autosomal recessive RYR1 mutations. 
The molecular mechanisms behind the different RYR1 mutations’ effects on Ca+2 
homeostasis and muscle function vary. Recessive RYR1-related myopathies were 
found to have a quantitative decrease in the number of RYR1 receptors rather than a 
qualitative impairment of receptors function (Ducreux et al., 2006, Zhou et al., 2006, 
Zhou et al., 2013). The mechanism behind the effects of autosomal dominant RYR1 
mutations associated with MH is gain-of-function with an increase in Ca+2 release from 
the SR through the RyR1 receptor (Murayama et al., 2016). On the other hand, RYR1 
mutations associated with CCD cause loss-of-function of the receptor (Avila et al., 
2001, Dirksen and Avila, 2002, Avila et al., 2003). These different molecular 
mechanisms could offer an explanation for the heterogeneity of genetic findings in our 
cohort. However, or study is limited because the conventional sequencing methods 
used in the genetic analysis of patients included in our cohort, only search through a 
single strand of DNA; therefore, presence of another allele of the variant cannot be 
confidently excluded in addition to the possibility of the presence of other heterozygous 
variants in the same patient. 
In conclusion, this study added to the ongoing work aiming to explore the correlation 
between MH and congenital myopathies. The correlation between the clinical, 
histological and genetic findings of these disorders proved to be complex. Further work 
to include more members from families diagnosed with either MH phenotype or CM 
phenotype could offer more statistical power to these studies. Further studies of the 
molecular mechanisms by which different RYR1 mutations lead to the functional 
defects of the RyR1 receptors on muscle cells or myotubes, from patients presented 
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with different phenotypes, would provide us with a better understanding of the 
correlation between the histopathological findings and the CM and/or MH phenotypes. 
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6 Investigating the epidemiology of MH in Egypt 
6.1 Introduction 
Our knowledge about the incidence and prevalence of MH in Egypt is very limited due 
to multiple reasons related to the different health systems in Egypt and how they 
operate, the demographics of the Egyptian population, and the nature of MH disorder. 
Medical and health care in Egypt is distributed, unequally, between three different 
health systems. The public health system that serves the vast majority of the 
population operates through the three levels of healthcare: primary, secondary and 
tertiary hospitals distributed all over the country. Doctors working in these hospitals 
have completed a programme of training in different specialities at one of the major 
university hospitals across the country. The second system is the university hospitals 
that are considered as tertiary and highly specialised centres serving mainly the 
purposes of training doctors in different specialities and medical research. These 
hospitals are limited in number and only provide healthcare to a considerably limited 
number of patients across the country. Thirdly, is the private healthcare system where 
no exact official statistics about the extent of this system’s hospitals, the quality of care 
offered in these hospitals, and the number of patients who receive treatment and 
healthcare through this system. 
Despite the substantial differences between the three healthcare systems mentioned, 
they all share the same characteristics that limit our ability to track rare-occurring 
disorders such as MH. These characteristics include, for instance, the lack of a central 
recording system for patients’ data, the absence of an official morbidity and mortality 
committee in the majority of hospitals across the three systems, and the lack of a 
nationally recognised system for serious incidents reporting. In addition, management 
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protocols are usually localised to particular hospitals with no designated body 
responsible for ensuring the application of nationally agreed guidelines in all the 
hospitals across the three systems. Last but not least, limited resources in some areas 
in the country, in the form of poorly equipped hospitals, absence of diagnostic facilities, 
shortage in intensive care beds numbers and low doctors-to-patients’ ratio. 
Using PubMed and Google Scholar search engines to search through different 
databases for the keywords “(malignant hyperthermia) AND Egypt” trying to find any 
reported cases or epidemiological data about the disorder in Egypt, we were not able 
to obtain any results. Nevertheless, the disorder is a known complication of general 
anaesthesia among anaesthetists in the country and based on personal 
communication with a number of anaesthesia consultants and middle-grade doctors 
across the three healthcare systems, many of them have heard about a patient who 
developed a suspected MH reaction in their place of work, nevertheless, the majority 
of them did not experience such a case themselves. Due to limited resources and 
other administrative issues, dantrolene is not usually stocked in many of the Egyptian 
hospitals, including even hospitals with high patients flow rates and a significant 
number of surgeries performed under general anaesthesia on day by day basis. In 
addition to the characteristics of healthcare systems in the country that have been 
described earlier, propose to a high mortality rate of life-threatening disorders such as 
MH. 
Despite the absence of published epidemiological data or case reports about MH in 
Egypt, we have little doubt that this disorder happens among the Egyptian population. 
We have discussed earlier some of the reports of MH cases occurred in adjacent 
countries whose population share many of their ethnic and genetic characteristics with 
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Egypt. Therefore, we designed this study aiming to collect preliminary data about the 
extent of the problem among the country population. We will be able only to rely on 
the reporting anaesthetists accounts about any case suspected with MH regarding the 
clinical features of the reaction, management measures and the outcomes of these 
cases. However, this study should give us a rough idea about the epidemiology of MH 
in Egypt and mortality rates in patients suspected to have experienced this condition. 
This, in turn, should offer a cornerstone for future studies about the disorder in the 
region and direct decision-making officials towards the proper steps to tackle rare, 
though life-threatening, conditions such as MH. 
6.2 Methods 
6.2.1 Questionnaire design 
As we discussed early the limitations of the health system in Egypt regarding diagnosis 
and management of rare diseases including MH, we agreed that online questionnaire 
would be a good facility to provide us with preliminary information about MH on a local 
and national levels and would help us to assess participants knowledge about the 
disorder and any management protocols available in their place of work. However, 
due to the lack of a standardised online secure communication system between health 
workers in Egypt, apart from some highly specialised hospitals on an elementary and 
limited level, we had to rely on non-official social media groups of anaesthesiologists 
working in Egypt. 
The questionnaire was designed using Google Forms into four sections: the first 
section included an introduction to MH and the purpose of the survey, the second 
section aimed to collect information about the participant experience and pattern of 
practice, the third section collects information about any suspected MH reaction the 
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participant has experienced and if the participants recall a possible case of MH, in their 
judgement, clinical details of the reaction and any management measures that have 
been carried out is recorded, and the final section allows the participant to submit any 
other suspected cases and to opt-in for further discussion about the reported cases. 
A printout of the Google Form questionnaire is attached in the appendix. 
Questions in the second section of the questionnaire collected information about the 
age and level of experience of the participant and how many years of anaesthetic 
experience they have, in an attempt to validate their judgment of the suspected 
anaesthetic reactions reported. Also, the pattern of practice and the average number 
of patients they normally anaesthetise per week should give us an idea of the load of 
work they usually experience. In addition, we collected information about the health 
system in which participants used to have the majority of their anaesthetic practice. 
The third section starts with a question whether the participant has experienced a 
range of clinical situations where MH could be a possible diagnosis during their 
anaesthetic practice and if the answer was yes, a detailed description of the clinical 
reaction and management measures used is obtained. 
Anonymous details of the reaction collected included the age group of the affected 
patients, sex, and type of anaesthetic used, in addition to the manifestations of the 
anaesthetic reaction including muscular features and signs of hypermetabolic 
response. Any laboratory investigation results available were also recorded. 
Regarding management measures used, we aimed to check if a standardised 
management protocol was available at the participant place of work and to check for 
the availability of dantrolene. Any other supportive measures used were also recorded, 
and the outcome of the affected patients, including ICU admission, were also obtained. 
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6.2.2 Distribution of the questionnaire locally 
The questionnaire was initially published among anaesthetists of the department of 
anaesthesia and intensive care at Assiut University Hospitals. The department has an 
average of 60 anaesthesia trainees, an average of 30 specialists and middle-grade 
anaesthesia doctors and another 30-40 consultants and professors of anaesthesia in 
different working capacities. The average working load of the department ranges from 
80 to 100 elective cases per working day distributed over seven theatre complexes 
that include an average of four operating rooms in each complex. In addition to the on 
calls that provide anaesthesia for an average of 50-60 emergency cases/day during 
weekdays that increase to 60-80 cases/day during weekends. Worth mentioning that 
middle and higher-grade (consultants and professors) anaesthesia doctors could 
practice among different health systems, including private hospitals. 
We launched the questionnaire through a Google Form link to the non-official 
Facebook page of the department in January 2016, and the questionnaire was open 
to receive responses for three months until the end of March 2016. A reminder was 
published on the Facebook page every month and in the last month twice to encourage 
participation. After the end of the three months, participants who opted-in for further 
discussion by providing their email addresses were contacted to provide any further 
details about the suspected reaction available and to clarify any ambiguous 
information provided. No identifiable patients’ information was collected at any time to 
ensure patients’ confidentiality. 
6.2.3 National distribution of the questionnaire 
To collect information about any suspected MH reactions on a national level, we 
considered using a more official communication system to reach to as many Egyptian 
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anaesthesiologists as possible. We initially communicated with the officials at the 
Egyptian Fellowship of Anaesthesia and Intensive Care. Our communication with the 
head and trustee of the institute aimed to provide the Google Form link, or a paper-
based questionnaire version, to all applicants to the fellowship exams and/or 
applicants to the European Diploma of Anaesthesia and Intensive Care (EDAIC) 
examination that is held in Egypt, as the institute is the official representative of the 
European Society of Anaesthesiologists in Egypt. We aimed to reach to an average of 
300-500 Egyptian anaesthetists during the application period for the fellowship and 
EDAIC part I exam between January and April 2017, with a possibility to republish the 
questionnaire again during the same period in the next year. After three months of 
communication with the officials over the period from September to December 2016, 
we lost all means of contact with the officials as they stopped replying to our emails or 
calls. 
As attempts to publish this questionnaire officially failed, we repeatedly had to depend 
on the non-official Facebook page of the informal group “The Association of Egyptian 
Anaesthetists” which as of December 2017 was followed by more than 800 users; 
presumably, the majority of them are anaesthetists. The link to the Google Form 
questionnaire was published on the timeline of the Facebook page of the group. It was 
pinned to remain on top of the news feed for group members. The admin of the group 
was asked to post a reminder to all members of the group to actively participate, 
monthly and twice during April. Despite all these efforts to encourage the participation 
of Egyptian anaesthetists in this questionnaire, the percentage of participation 
remained very low. Therefore, another attempt to communicate with the official 
administration of the Egyptian Fellowship of Anaesthesia and Intensive care to 
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republish the questionnaire through their channels was made. However, this attempt 
proved again to be unsuccessful. 
6.2.4 Encouraging participation 
Different methods to encourage participation on the local and national levels of the 
questionnaire conduction was discussed. These included, for instance, offering some 
means of financial incentive in the form of shopping gift cards, but this proved 
impractical to be used in Egypt, in addition, this method could have compromised the 
integrity of the survey results as some people may submit fake cases in order to get 
these incentives. Another method discussed was to contact the clinical directors of 
different anaesthesia departments across the country to publish the questionnaire to 
their staff at their local hospitals. However, this method was not successful because 
of the absence of official communication channels, central email domain or official 
website, for example, for the clinical directories in different hospitals across the 
country. As stated earlier, several attempts to publish this questionnaire through an 
official institutional channel were all unsuccessful because of loss of communication 
with the administration. 
The only available mean of communication that we had to endorse was using the non-
official social media pages of different anaesthetists’ societies and sending reminders 
to the members of these pages to encourage them to share their anaesthetic 
experiences with MH cases. This method was only beneficial during the conduction of 
the questionnaire on a local level, at Assiut University Hospitals, but of limited value 
when the questionnaire was published on the Facebook page of the “The Association 
of Egyptian Anaesthetists”. 
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6.3 Results 
6.3.1 Cases reported at Assiut University Hospitals 
Participation from anaesthetists at the department of anaesthesia and intensive care, 
Assiut University Hospitals reached ~30% as 36 anaesthetists filled in the 
questionnaire of the department working capacity equivalent of an average 120 full-
time working anaesthetists. Participants represented the three levels of qualifications 
for anaesthetists working at the department: trainees, middle-grade doctors 
(specialists and assistant lecturers), and consultants and professors with the majority 
of them being middle-grade 20 of 36. The working pattern of participating anaesthetists 
is presented in table 6-1. The majority of middle-grade doctors who presented 55% of 
participants had an average of five to ten years of anaesthetic experience with five of 
them had less than five years. The main place of work for the majority of participants 
was a tertiary centre (including university hospitals) with only two anaesthetists worked 
at a secondary care hospital, and another middle-grade doctor worked at a private 
hospital. None of these three anaesthetists reported any suspected case of MH.
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Trainees (n. 8) <5 Yr. 57 case/week Tertiary centre 1 
Middle-grade (n. 20) 5-10 Yr. 28 case/week Tertiary centre 6 
Consultants (n. 8) 10-20 Yr. 16 case/week Tertiary centre 4 
Table 6-1: Participating anaesthetists in the questionnaire published at Assiut University Hospitals. Their level of qualification, average 
workload and main place of work. Also, the number of cases reported from each group is shown. 
 
ID# Muscular Metabolic Succinylcholine  Inhalation 
anaesthetic 
Operation Outcome 
1 Generalized rigidity/ 
Masseter spasm 
Yes Yes Isoflurane Emergency Dead 
2 Generalized rigidity Yes No Halothane Elective Dead 
3 Generalized rigidity Yes No Isoflurane Elective Dead 
4 Masseter Spasm Yes Yes Halothane Elective Dead 
5 Masseter Spasm Yes Yes Halothane Elective Dead 
6 No Yes Yes Halothane Emergency Live 
7 No Yes Yes Halothane Emergency Dead 
8 No Yes No Halothane Elective Dead 
9 No Yes No Halothane/Isoflurane Elective Dead 
10 No Yes No Isoflurane Elective Dead 
Table 6-2: Suspected MH cases reported by anaesthetists working at Assiut University Hospitals. The main features of the reaction; 
muscular and metabolic and the anaesthetic agents used are presented. The procedure either emergency or elective and the outcome of these 
cases are also shown. 
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Eleven cases were reported, four of them had a suspected MH reaction according to 
the judgment of reporting anaesthetists at the time of the reaction.  The remaining 
seven patients developed an unexplained cardiac arrest under general anaesthesia. 
Two of the eleven patients had a family history of unexplained death under 
anaesthesia. Information related to age group, sex, type of operation and anaesthetics 
used was provided for seven of the eleven cases reported. This information with the 
clinical details of the reaction available for the reported patients is presented in table 
6-2. 
All, but one patient, died after the reaction either in the operating room or after 
admission to the ICU. The only patient who had a suspected MH reaction and was 
reported to be discharged after improvement, the reporting anaesthetist did not 
provide any further clinical details of the reaction and declined to provide contact 
information for further discussion. Dantrolene was not available in any of the reported 
cases, and therefore management measures were in the form of supportive treatment 
of the hypermetabolic features of the reaction. Supportive treatment measures 
included fluid loading, active surface cooling, hyperventilation and bicarbonate 
administration. Based on personal communication with anaesthetists who provided 
contact details, no standardised management protocol was available in-place at the 
time of the reaction, and neither of them has checked if a gas-free anaesthetic 
machine was available at the theatre complex. Four patients died in the operating 
room before being admitted to the ICU. 
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6.3.2 A case report of a recent suspected MH reaction at Assiut University Hospitals 
Recently, after the questionnaire has been closed for accepting new responses, I was 
contacted by one of my colleagues about another case with a suspected MH reaction 
that occurred at Assiut University Hospitals: 
An eight years old female patient presented to the casualty department after a fall on 
the ground, and she sustained a right distal radius and ulna fracture while examination 
revealed no other injuries. The patient did not have any medical or past history of 
relevant importance and no history of any previous operation, nor a history of 
anaesthesia related complications in the family. The patient was scheduled for a K-
wire fixation of her fractures under general anaesthesia. On preoperative assessment, 
the patient Glasgow Coma Scale (GCS) was ±15, and her systematic examination 
revealed no abnormalities. Her vital signs were within normal range and was fasting 
for 10 hours. No premedication was given. 
Inhalational induction of anaesthesia with sevoflurane in 100% oxygen was carried out 
using a Jackson-Rees' modification of the Ayre's T-piece. After induction, a 22 G IV 
cannula was inserted on the dorsum of the left hand and after ensuring an adequate 
depth of anaesthesia, a laryngeal mask airway size 2 was inserted and secured in 
place. Anaesthesia was maintained using isoflurane 3% volume in 100% oxygen with 
her respiratory rate (RR)= 22 cycle/minute and etCO2 at 40mmHg. The patient 
received 300 mg of paracetamol for analgesia. After 30 minutes, the attending 
anaesthesia trainee noticed the etCO2 started to climb up to 50mmHg and therefore, 
the fresh gas flow was increased to 10 litres/minute. The etCO2 continued to climb up 
to 62mmHg after 60 minutes despite adequate ventilation throughout. At this stage, 
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the patient started to feel warm to touch, and the heart rate increased to 140 
beats/minute and a senior help from the middle-grade doctor, on-site, was sought. 
The attending anaesthetists at this stage agreed to intubate the patient to perform 
more controlled hyperventilation at a rate of 30-35 cycles/minute with a tidal volume 
of 230 ml and reduced the inhalation anaesthetic isoflurane to 1%volume. After 90 
minutes the patient was still warm to touch, a rigidity of the upper and lower limbs 
started to develop, the heart rate increased to 160 beats/minute, blood pressure 
dropped to 80/40 mmHg and the etCO2 increased to 90 mmHg despite 
hyperventilation at the mentioned rate. A series of arterial blood gas (ABG) samples 
were sent to the lab; the results are shown in table 6-3, which showed mixed acidosis, 
despite hyperventilation; therefore, correction of metabolic acidosis using sodium 
bicarbonate was started. The anaesthesia consultant on-call, off-site, was called and 
was informed about the updates and discussed with the middle-grade doctor about 
different possible diagnoses with MH as the most likely diagnosis. The inhalation 
anaesthesia was switched off and hyperventilation, and symptomatic treatment were 
continued in the operating room. 
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Time point 60 min. 90 min. 125 min. 170 min. 235 min. 
pH 7.16 6.99 7.17 7.22 7.29 
PaO2 372 mmHg 82 mmHg 338 mmHg 140 mmHg 75 mmHg 
PaCO2 62 mmHg 71 mmHg 67 mmHg 40 mmHg 35 mmHg 
HCO3- 22.1 mmol/L 17.1 mmol/L 24.4 mmol/L 18.8 mmol/L 16.8 mmol/L 
BEecf -6.6 mmol/L -14.3 mmol/L -4.1 mmol/L -8.9 mmol/L -9.8 mmol/L 
SO2 100% 88% 100% 99% 93% 
Table 6-3: Results of the arterial blood gases of the reported case at five time points. 
PaO2= arterial oxygen tension, PaCO2=arterial carbon dioxide tension, HCO3=bicarbonate 
level in the blood, BEecf= base excess in the extracellular fluid, and SO2=oxygen saturation. 
The fraction of in inspired oxygen was not recorded on any of the reported samples. 
 
Management measures at this stage, after 150 minutes, included continued 
hyperventilation, cold fomentation and cold IV fluids to control body temperature, and 
1 gram of magnesium sulphate was given slowly IV. After 180 minutes, blood pressure 
stabilised at 90/60 mmHg with heart rate 150 beats/minute and etCO2 55 mmHg and 
the respiratory rate on the ventilator reduced to 30 cycle/minute. Anaesthesia was 
believed at this stage to be worn off, and the patient was allowed to emerge from 
anaesthesia and breath spontaneously, but respiration at this stage was shallow with 
a RR of 50 cycle/minute, therefore, a decision to transfer the patient to the intensive 
care to maintain mechanical ventilation. At the ICU, despite discontinuation of any 
sedation, the patient’s GCS remained ±3. ICU reports could not be obtained; however, 
based on personal communication, we were informed that the patient had developed 
disseminated intravascular coagulopathy and required cardiovascular support. On the 
next day, the patient experienced cardiac arrest and attempts to restore circulation 
failed, and the patient was declared dead. 
6.3.3 Responses to the nationally distributed questionnaire 
As stated early, after failed attempts to publish this questionnaire through the official 
channels of the Egyptian Fellowship of Anaesthesia and Intensive Care, the response 
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to the questionnaire published on the non-official Facebook page of the informal group 
“the Association of Egyptian Anaesthetists” was feeble. We received only 30 
responses despite repeated reminders to the group members to encourage 
participation. Of the 30 participants who filled in the questionnaire, four were trainees, 
12 middle grade doctors and 14 consultant anaesthetists. The main place of work for 
the majority of them was tertiary hospitals (including university hospitals), 24 out of 30, 
and eight participants had more than one place of work. Middle-grade doctors had the 
highest workload with an average of 30 cases/week and consultants came second 
with 24, cases/week and the four trainees reported an average workload of 18 
cases/week. All participating consultants had a minimum of ten years of anaesthetic 
experience, while middle-grade doctors had at least five years of experience with four 
of them had more than ten years. Ten consultants, four middle grade doctors and two 
trainees reported 18 cases, as two anaesthetists reported two cases each. All the 
cases were reported at a tertiary hospital apart from one case reported at a secondary 
hospital and another case at a private practice. 
Of the 18 cases reported, three patients had either a previous or a family history of 
anaesthesia related complications suggestive of MH. According to the judgment of the 
reporting anaesthetists, of the remaining 15 patients who had an anaesthetic reaction, 
12 patients developed clinical features suggestive of MH under anaesthesia while 
another three patients presented with an unexplained death or cardiac arrest under 
general anaesthesia. The age and sex characteristics and clinical manifestations of 
the reaction of the 15 patients who experienced a suspected reaction in their most 
recent anaesthetic are presented in table 6-4. Laboratory investigation results were 
available for only six patients, and all of them reported acidosis, while hyperkalaemia 
was reported in three patients and elevated serum CK level in two patients. As shown 
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in table 6-4, 60% of those patients were males and all of them were either children or 
young adults below the age of 40 years old. Muscular manifestations in the form of 
masseter muscle spasm or generalised muscular rigidity were reported in eleven 
patients. However, one of the shortcomings of this questionnaire is not including 
questions about the anaesthetic drugs used. Regarding metabolic features of the 
reported reactions, fever was reported in all, but one patient, that could indicate a late 
recognition of the reaction while hypercapnia was reported in only six patients. 
Management measures were limited to supportive and symptomatic treatment in the 
form of active cooling such as surface cooling or intravesical or intragastric irrigation 
with iced saline, the use of bicarbonate to treat acidosis, and the use of diuretics. 
Seven anaesthetists reported the change of anaesthetic machine to a gas-free one. 
Two consultants reported the availability of dantrolene at the tertiary hospital they 
worked for; however, it was not used in any of these two cases. In the remaining 14 
patients with suspected anaesthetic reactions, dantrolene was not available, and 
consequently, was not used. Of the 15 patients who had a reaction in their current 
anaesthetics, 11 patients died after the reaction either in the operating room or after 
admission to the intensive care. Of the four cases who survived the reported reaction, 
three patients were admitted to the intensive care and discharged later on after 
improvement. The fourth patient developed clinical manifestation in the form of 
unexplained hyperthermia and arrhythmia with no muscular features or reports about 
any laboratory derangement. This patient was discharged without a need for ICU 
admission, and the reporting consultant anaesthetist did not use dantrolene despite 
availability, as stated earlier.
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ID# Reporter Age Sex Muscular 
signs 
Metabolic signs Lab results ICU Outcome 
1 Trainee 8-20Yr Male MMS, Rigidity  Fever, Cardiac arrest Acidosis Yes Died 
2 M-G 3-8Yr Male Rigidity ↑ ↑ CO2 Acidosis, K+, 
CK 
Yes Recovered 
3 Cons. 21-40Yr Male - Fever, Arrhythmia N/A No Recovered 
4 M-G 3-8Yr Female Rigidity Fever, ↑ ↑ CO2, Cardiac arrest Acidosis Yes Died 
5 Cons. <3Yr Female Rigidity Fever, ↑ ↑ CO2 N/A Yes Recovered 
6 Cons. 9-20Yr Male Rigidity Fever N/A Yes Died 
7 Cons. 9-20Yr Male Rigidity Fever K+ Yes Died 
8 Cons. 9-20Yr Female MMS, Rigidity Fever, Arrhythmia N/A No Died 
9 Cons. 21-40Yr Female - Fever, Cardiac arrest N/A No Died 
10 Cons. 9-20Yr Male Rigidity Fever, ↑ ↑ CO2, Arrhythmia Acidosis, K+ No Died 
11 M-G 3-8Yr Male - Fever, Cardiac arrest, Myoglobinuria N/A Yes Died 
12 Cons. 3-8Yr Female Rigidity Fever, ↑ ↑ CO2, Arrhythmia, Cardiac 
arrest 
Acidosis, K+ Yes Died 
13 Trainee 3-8 Female Rigidity Fever, ↑ ↑ CO2, Arrhythmia Acidosis, CK Yes Recovered 
14 M-G <3Yr Male - Fever, Cardiac arrest N/A No Died 
15 Cons. 9-20 Male Rigidity Fever, Cardiac arrest N/A No Died 
Table 6-4: The suspected cases reported in the questionnaire published nationally. The level of qualification of the reporting anaesthetists, 
age group and sex of the reported case are shown. Clinical features of the suspected reaction, any available lab results, and the outcome of the 
reaction are illustrated. N/A=not available, ↑ ↑ CO2= hypercapnia detected clinically using the capnograph. 
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The remaining three cases reported a history of anaesthesia related complications 
suggestive of MH. One patient reported the death of ten relatives under general 
anaesthesia, including the patient’s father. The other two patients reported a history 
of anaesthetic complications, although the exact details of the previous reactions could 
not be retrieved. During the current anaesthetics, trigger-free anaesthesia was used 
in all of the three patients, and no complications were reported. All the participants of 
the questionnaire declined to offer any contact details for further discussion about the 
reported cases. 
6.4 Discussion and limitations 
MH is a well-known complication of anaesthesia to all Egyptian anaesthetists I have 
worked with in different health systems in Egypt. Most of the Egyptian anaesthetists 
believe that MH still exists in the modern anaesthetic practice, although the majority 
of them have not experienced a suspected case of MH during their career. This is on 
the contrary to the worrying developing concept among some of the nowadays 
anaesthetists that “malignant hyperthermia is a disease of halothane anaesthesia” 
(Sneyd, 2017). This can be explained, partially, because of halothane being still in-
use in some hospitals in Egypt in different health systems, more in private poorly 
monitored hospitals due to financial considerations. However, due to administrative, 
organisational, and financial issues affecting the whole health system that serves an 
approximate of a hundred million people, measures to tackle this rare and fatal 
condition are still poorly implemented. 
Our long-term target of this study, is to have a more organised and systematic 
knowledge about the prevalence of MH in Egypt, the mortality rate of suspected and/or 
confirmed cases of MH, the in-place protocols for management and diagnosis of this 
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condition in different health systems’ hospitals, and to ensure this information will be 
available for the health administration officials to establish a national policy to tackle 
this condition. As our initial search confirmed the scarcity of available reports about 
MH and other rare-occurring similar genetic conditions in Egypt, we designed this 
study to collect preliminary data that would be of great value when conducting future 
research to serve our long-term plan. We tried to target practicing anaesthetists with 
our questionnaires to obtain as much as available information they might have through 
their practice in different health systems. 
It is not logical to make assumptions on the dynamics of anaesthetic practice in Egypt 
based on the results of our published questionnaires, due to the minimal number of 
participants. Due to the limitations we discussed earlier, we could not have organised 
systematic access to a bigger slice of practicing anaesthetists in Egypt. Additionally, it 
is highly likely that despite publishing the questionnaire through a Facebook page 
directed mainly for anaesthetists working in the country, that the questionnaire, itself, 
did not attract as many anaesthetists except those who have experienced a suspected 
case themselves, or at least, heard of a possible case in their place of work. This might 
explain the high number of cases reported compared to the small number of 
participants, 12 cases reported by 36 participants from the questionnaire published at 
Assiut University Hospitals and 18 cases by 30 participants from the nationally 
published questionnaire. We made it clear when we launched the questionnaire, that 
all the data collected are only for the purpose of this research and data will be dealt 
with anonymously and confidentially. However, some anaesthetists may have 
declined to report their experience with MH cases, fearing this information may be 
used against them if any investigation was launched. Another explanation for this poor 
participation is the probability that some anaesthetists in Egypt endorse the concept 
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of MH being obsolete now with the modern anaesthetic agents. A lack of motive to 
participate and a feeling of the worthlessness of their responses in tackling this 
problem could be other possible causes. 
The main place of work for most participants, and subsequently, most cases reported, 
was a tertiary centre including university hospitals. These centres are usually better 
equipped with monitoring facilities with a more organised training and supervision 
system for junior anaesthetic staff. However, anaesthetists working in these centres 
were not aware of any in-place management protocol for MH, and the majority of them 
reported the lack of dantrolene stock in these centres. This reflects the importance of 
implementing management protocols and measures at more national and by higher 
administrative levels. 
On the other hand, this study is considered as the first attempt to gather evidence to 
confirm the occurrence of the classical picture of hypermetabolic MH reactions among 
the Egyptian population. Previous case reports of suspected MH reactions were 
published from other countries in the region, such as Bahrain and Saudi Arabia 
(Centre for Arab Genomic Studies, 2016). We are also aware of some patients referred 
from Iraq, Saudi Arabia and Bahrain who have been tested MH susceptible at the 
Leeds MH Investigation Unit. These countries share similarities in the population 
characteristics with the Egyptian population. However, the ethnicity of the Egyptian 
population is more mixed and diverse according to some recent reports that compared 
DNA results of different ethnic populations 
(https://genographic.nationalgeographic.com). Therefore, it was crucial to perform a 
study based merely on the Egyptian population to evaluate the extent of the condition 
in the country. 
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My status as an insider researcher with regard to the questionnaire published among 
anaesthetists at Assiut University Hospitals, allowed a relatively better participation 
from the staff working at the department of anaesthesia at the hospital (36 participants 
of ~100 anaesthetists), in comparison to the questionnaire aimed to target ~800 
anaesthetists nation-wide that only triggered 30 participants. In addition, it enabled us 
to obtain more detailed information about the recent case of suspected MH. Moreover, 
it was easier for us to validate the responses to the local questionnaire regarding the 
reported cases by further contacting participants and to ensure avoiding double 
reporting. We also can confirm the reported dynamics of the anaesthetic practice at 
the hospital and the reported lack of management protocols and dantrolene stock. 
This status could be of a beneficial value in future studies about MH by maintaining a 
contact point between the department of anaesthesia and ICU at Assiut University 
Hospitals and the Leeds MH Investigation Unit. We also aim to publish the results of 
the current study in the department annual conference in order to highlight our findings 
and to ensure a proper management process being initiated. 
It is evident that there are many missing details about the reported cases, as apart 
from the recent case at Assiut University Hospitals, all details were solely dependent 
on the anaesthetists’ recall of the events. We used the categories of clinical 
presentation of MH published by (Ellis et al., 1990) to evaluate the reported cases and 
the possibility of MH diagnosis in each case. With regard to the cases reported at 
Assiut University Hospitals, three patients can be included within category “a” or 
fulminant reaction, and the probability of MH diagnosis is 0.96 in this category. Another 
three patients had moderate signs of MH or category “b” with an MH diagnosis 
probability of 0.88 while another three patients had masseter muscle spasm with signs 
of metabolic derangement, category “e”, and the probability of MH is 0.56. The last 
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patient who had mild metabolic features and the reaction did not appear to be life-
threatening is considered to be in category “c” with 0.14 probability for patients in this 
category to be diagnosed MHS. 
Cases that have been reported through the national questionnaire was categorised 
using the same method. Ten patients had the fulminant or classic clinical picture of 
MH according to the reported manifestation. They are considered to be category “a”, 
and the probability of MH diagnosis is 0.96. Two patients had a moderate clinical 
picture, and they recovered after the anaesthetic without the use of dantrolene, and 
they are considered category “b” with a probability of 0.88. Two other patients had an 
unexplained cardiac arrest under anaesthesia, and according to the reporting 
anaesthetists, there was no other apparent cause. This category “g” has a probability 
of 0.66 of MH diagnosis. The clinical picture of category “c” includes mild signs of MH 
and has a probability of MH diagnosis of 0.14. Only one patient in this cohort is 
considered to be in this category. 
This categorisation of reported cases depends on the recall of intraoperative events 
of suspected reactions. No written notes, lab results, nor morbidity and mortality 
committee reports could be obtained for any of the reported cases, apart from the 
recent case at Assiut University hospitals. Additionally, no time scale was given for the 
occurrence of the reported events, and for when a suspected MH crisis, if at all, has 
been recognised. In addition, from the available information, we are not able to assess 
the efficiency of management measures, which lacks the use of dantrolene due to its 
unavailability. A solid conclusion on the incidence of MH among the Egyptian 
population or the extent of this problem in Egyptian hospitals cannot be made, by any 
means, based on the available information, though, this preliminary study served the 
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purpose of confirming that MH does exist in the Egyptian population and when it is 
reported, it carries a very high mortality rate. 
The larger proportion of patients in each cohort were classified clinically in categories 
“a” and “b”, six out of ten and 12 out of 15 patients, locally at Assiut University Hospitals 
and nationally, respectively. This support our assumption about a positive response 
bias, we stated earlier, explaining poor participation. This observation can also be 
explained by insufficient monitoring equipment available in many operating theatres 
leading to late recognition of an MH crisis, which leads, subsequently, to the poor 
outcome. Based on this observation, it is very likely that there is a large number of 
mild clinical presentations of the reaction and/or early aborted cases, are passed 
unnoticed. Even for the severe forms of the reaction that may end into the death of the 
suspected case, one of the issues limiting our ability to obtain accurate clinical details 
about the case, is the family refusal, in many cases, for a post-mortem examination 
due to a social stigma associated with it. The coroners’ report in many of these cases 
would lack crucial details to ascertain a definitive diagnosis and hence, uninformative. 
The recently reported case of the suspected anaesthetic reaction offers many insights 
about the anaesthetic practice in the country and management of emergency 
situations such as an MH crisis. This deceased case did not have any family history 
of anaesthesia related complications and was apparently a healthy fit child before she 
sustained the fracture for which she had the operation. Monitoring during anaesthesia 
was less than standard as the temperature was not recorded at any time during the 
course of the reaction. In addition, the patient was kept under the care of a junior 
anaesthesia resident, and we are not sure about the time elapsed between the 
induction of anaesthesia and the recognition of reaction. The middle-grade 
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anaesthesia doctor on-site was available immediately, though, no senior anaesthesia 
consultant was available at any time point to assess the case directly. Another flaw 
that reflects the lack of an organised management plan is that the volatile anaesthetic 
was not switched off until ~60 minutes after the recognition of the reaction. Last but 
not least, the anaesthetic machine has not been changed, no activated charcoal filters 
were available and, more crucial, no dantrolene was available for use. 
A confirmation of MH diagnosis is hard to ascertain, as the patient did not survive the 
reaction and our attempts to make contact with her parents to, at least, obtain a blood 
sample for genetic screening proved unsuccessful. However, from the available 
clinical details of the reaction, we used the clinical grading scale (Larach et al., 1994) 
to calculate a raw score of 56 which reflects an almost certain likelihood of this 
anaesthetic reaction to be a true MH reaction. In addition, some of the other differential 
diagnoses could be, cautiously, excluded from the available clinical information such 
as pheochromocytoma, thyroid crisis and sepsis as the patient did not report any 
medical history of importance prior to the operation. Additionally, the patient did not 
report any regular medications intake that excludes the possibility of drug-related 
causes such as neuroleptic malignant syndrome. We also can assume that 
anaesthetic equipment malfunction is not an accepted cause as no similar reactions 
reported with other patients in the same operating room on that day, based on 
personal communication. Other causes, related to the inadequate depth of 
anaesthesia or pain control, are not readily excluded, though, the climbing etCO2 and 
a GCS of ±3 after the anaesthesia had worn off, reduce the plausibility of these 
causes. 
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Apparently, there are many measures to be taken to improve the management of such 
suspected cases in Egyptian hospitals in the future. First of all, and the most important 
is to generalise a management protocol for MH crisis in all Egyptian hospitals across 
different health systems and to ensure the medical staff working in operative theatres 
aware of this protocol and how to implement it in case of a suspected reaction. The 
published protocol for the management of MH crisis (Glahn et al., 2010) is of great 
value and lists step-by-step management of such an emergency situation. Although, 
many anaesthetists working in Egypt could be aware of this protocol as the condition 
itself and its management is part of the anaesthetic curriculum taught to all 
anaesthetists during their postgraduate training, a printed version should be made 
available in all theatres. Also, other medical staff such as surgeons, theatre nurses 
and anaesthesia technicians have to be trained on how to apply this protocol. 
Secondly, dantrolene should be stocked in all hospitals with theatre complexes where 
volatile anaesthetic being used as it has a dramatic rule in reducing the mortality rate 
of MH reactions (Strazis and Fox, 1993). We have not studied thoroughly the possible 
logistic issues preventing dantrolene from being available in case of a MH crisis; 
however, we hope this study will bring the importance of this issue to the Egyptian 
health administrative officials’ attention. Another essential management line is the 
availability of activated charcoal filters that have many advantages to replacing the 
anaesthetic machine with a gas-free one (Bilmen and Hopkins, 2018). This could be 
another logistic issue that needs to be discussed, but in the meanwhile, we 
recommend a gas-free machine to be available in each operative theatre complex. 
With a population approaching 100 million and with the availability of many university 
hospitals and research centres, Egypt can serve as a major diagnosis centre and a 
research hub for the condition in the whole region, however, several steps need to be 
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taken. On the local level of operative theatres, in addition to generalising a printed 
version of the management protocol, we recommend designing a form for recording 
any adverse anaesthetic reactions describing the full clinical details of the reaction 
with any available lab results, or alternatively, using the EMHG anonymous 
registration form of suspected MH reactions available online at (https://mh-
event.emhg.org). These forms, either paper or online, should be filled in by the 
anaesthetist attending the reaction, and a photocopy of this form to be kept in patient’s 
notes and another copy to be saved in the hospital archive. All practising 
anaesthetists, either qualified or still in training, should be made aware of this form 
and encouraged to fill it in. This form will be of a great benefit for future studies about 




7 General discussion 
This project has utilised the most extensive resource for clinical, genetic and IVCT 
data of MH in the world. We have explored the male: female ratio in different cohorts 
of patients; confirmed MHS probands, patients who developed an anaesthetic reaction 
and tested MHN, and first-degree relatives of MHS probands and compared our 
results to the previously published data. We have conducted the first correlation 
analysis in confirmed MHS probands between the common UK RYR1 genotypes and 
the clinical features of the suspected anaesthetic reactions in these patients. 
Additionally, we added to the ongoing work to explore the association between MH 
and the broad spectrum of RYR1-related congenital myopathies. Last but not least, 
this is the first attempt to explore the epidemiology of MH among the Egyptian 
population. We have identified the challenges and limitations towards the recognition, 
management and diagnosis of MH and similar rare-occurring conditions. 
7.1 The role of succinylcholine in MH 
In this study, we still could not totally confirm, nor confidently exclude the role of 
succinylcholine in triggering a hypermetabolic MH reaction solely, without the use of 
volatile anaesthetics. However, a few observations that we have reported in previous 
chapters need to be interpreted together in this context. Firstly, muscular-only 
anaesthetic reactions only occurred when the triggering anaesthetic involved the use 
of succinylcholine. Secondly, patients who developed these muscular-only 
anaesthetic reactions had a statistically weaker IVCT response compared to patients 
who developed hypermetabolic reactions to volatile anaesthetics. Thirdly, 
succinylcholine had no statistically significant effect on the maximum derangement 
values of the metabolic features of MH, while its use was associated with a statistically 
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higher postoperative serum CK level, a muscle-related feature. Lastly, the reports of 
the hypermetabolic reactions, when volatile anaesthetics were not reported, lack 
essential details to ascertain that succinylcholine was the only trigger. 
However, despite the lack of convincing evidence of the role of succinylcholine in 
triggering hypermetabolic MH reactions, it must be avoided when a possibility of MH 
is suspected for several reasons. First of all, the potentially fatal outcome of an MH 
reaction mandates prioritising patients’ safety over the scientific evidence, or the lack 
of it in this case. Moreover, there is a possibility that MHS patients have an increased 
sensitivity to succinylcholine that is presented in the form of exaggerated muscular 
response and rhabdomyolysis, which may lead to comorbidities such as acute kidney 
injury and acute renal failure. Furthermore, it is evident that the use of succinylcholine 
is associated with an increased incidence of postoperative complications, though the 
majority of these complications were muscle-related. 
7.2 Male predominance and MH 
It has been long claimed that MH has a preferential predominance in males. This was 
based on several statistical studies of the epidemiology of MH. Confirming this 
observation should consider the difference between MH susceptibility diagnosis and 
the clinical diagnosis of an MH anaesthetic reaction. The earlier is confirmed by an 
invasive biopsy test; IVCT in Europe, CHCT in North America, and skinned fibre test 
in Japan; or by genetic screening for diagnostic mutations, which is complicated further 
by the discordance reported with many of these mutations. The latter diagnosis is more 
difficult to ascertain because of the nonspecific characteristic of the clinical features of 
MH reactions and the overlap between MH and other differential diagnoses in these 
features. The data presented in this thesis imply that male predominance is noticed in 
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patients who presented with the nonspecific features of MH regardless of their 
susceptibility status, which was confirmed with IVCT. Our preliminary analysis of the 
IVCT results of first-degree relatives of our MHS probands offered a glimpse of a slight 
predominance of MH susceptibility in male first-degree relatives of MHS probands 
compared to their female counterparts. However, a future study properly analysing 
these results will be of greater value, especially if all of these probands and their first-
degree relatives have been genetically screened using NGS. 
7.3 Incidence of MH in recent years 
According to a recently published correspondence (Kaura et al., 2018), an observation 
of the rate of referral to the Leeds MH Investigation Unit has not remarkably changed 
over the last 30 years. In our study, though, we noticed a steady decrease in the 
number of MH reactions according to the year at which this reaction has occurred. 
This discrepancy could be explained by the delay of referral of some cases and the 
difference between the date of referral and the actual date of the anaesthetic reaction 
in our records. The possible reasons for this decline in the number of MH episodes 
over the last thirty years, could be related to the apparent decrease in the rate of use 
of succinylcholine and the improvement in the local and regional anaesthetic 
techniques, together with an increased popularity of TIVA, which might have 
decreased the number of patients exposed to the triggering general anaesthetics. Our 
results should not send a negative message that the importance of MH in the clinical 
practice or in the research field is diminishing, as this may jeopardise the patients’ 
safety. We repeatedly confirm that all volatile anaesthetics still in use in the modern 
anaesthetic practice can trigger an MH reaction in susceptible patients. 
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7.4 RYR1 genotypes influence the clinical phenotype 
When we compared between the clinical details of anaesthetic reactions reported in 
patients found to have one of the common genotype groups, one genotype group 
c.1021G>A, the second most common in the UK MH population, was found to have a 
consistently more severe form of the metabolic features of the reaction, compared to 
the most common genotype group among the UK MH population; the c.7300G>A. 
Nevertheless, this observation should be treated with caution, as the sample size was 
relatively small, the level of significance was low, and we have not corrected for 
multiple comparisons. One the other hand, more patients in the former group 
developed a reaction triggered by volatile anaesthetics only without the use of 
succinylcholine, compared to a majority of patients in the c.7300G>A group who 
developed a reaction triggered by anaesthetics involved the use of succinylcholine. 
To our knowledge, this the first attempt to correlate the RYR1 genotypes to the severity 
of the clinical features of the MH reaction. The genotype group c.1021G>A was 
reported to be common in France and Belgium (Robinson et al., 2003b) and further 
studies including more patients with these variants from different centres would give 
these studies a better statistical power. However, the differences in ethnicity of the 
included patients and the different anaesthetic practice may affect the results of these 
multicentre studies. As we have recommended earlier, studies focusing on the 
biochemical changes in muscle cells and myotubes from patients found with different 
genotype groups, need to include the different clinical phenotypes as one of their 
variables. 
 190 
7.5 Consistency of IVCT measurements 
The IVCT is still considered as the gold standard test for diagnosis of MH susceptibility 
despite the recent advances in genetic diagnosis. This is due to the inability to 
confidently exclude MH susceptibility based solely on the absence of a genetic variant, 
and due to the discordance reported between genotypes and phenotypes. However, 
the consistency of IVCT results over the years has been dependent on several factors: 
the standardisation of the test protocols, the muscle specimens’ viability and the 
interpretation of the test traces. In this study, we have been able to control the latter 
factor by reassessing the included traces by a single interpreter. The other two factors 
need further investigation to insure the consistency of the IVCT results. To our 
knowledge, parameters such as the muscle specimens’ weight and length are 
recorded for each specimen used in the test. Another parameter that could also affect 
the muscle viability and the results of the test, is the time between the muscle 
specimen being biopsied to the time of the test. 
A further study to explore factors related to standardisation of test protocols and 
muscle viability will enable us to ensure the consistency of IVCT measurements. 
Comparing different time periods such as before and after the establishment of the 
European protocol for IVCT or before and after the introduction of computerised test 
procedure, should enable us to reassess the sensitivity and specificity of the test. 
Additionally, a multi-centre study comparing the test results to the previously 
mentioned parameters from different MH labs that follow the European protocol for 
IVCT could also add to the value of IVCT as the standard diagnostic test for MH. 
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7.6 MH and the broader spectrum of CM 
With the approved overlap of the histopathological findings and clinical presentations 
between different entities of congenital myopathies and the complexity of the 
association between this group of diseases and the MH phenotype, it is highly 
recommended to manage patients with CM who found to have an RYR1 variant with 
extra caution, with regard to MH triggering anaesthetics. The ongoing work to explore 
the association between both conditions should continue; considering the broader 
spectrum of CM, taking the discordance between RYR1 genotype and IVCT 
phenotype into account, and including more family members of index cases diagnosed 
with these conditions. As has been suggested in the transfer viva for this project, a 
follow-up study to assess any recently-developed clinical muscle weakness in patients 
who developed an anaesthetic reaction and found to have histopathological features 
of RYR1-myopathy, will help us to examine the effect of age and or anaesthetic 
reactions on the development of muscle weakness in these patients. 
7.7 Myopathy families and MH susceptibility 
We have attempted to perform a segregation study between the IVCT results, genetic 
testing results, histopathological findings and the clinical myopathy status of CM 
families who were tested at the Leeds MH Investigation Unit to explore the association 
between MH and CM within these families. Significant segregation was found in two 
large families tested at the unit, which suggests that the two RYR1 variants found in 
these families have a significant functional effect on both MH and CM phenotypes. On 
the other hand, no such positive segregation was found in other families included in 
this segregation study. This study was limited in these families by the small number of 
other members tested at the unit and the few information available about these other 
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members’ clinical and genetic status. Additionally, it would be of greater value if the 
members of these families are from three different generations, which would enable 
estimating the LOD score (log of the odds) to statistically estimate the link segregation 
between the detected RYR1 variants and the MH and/or CM phenotypes.   
7.8 MH in Egypt still exists in the pre-dantrolene era 
Unfortunately, due to the many limitations that we have discussed earlier, we were not 
able to gather much information about the situation of MH among the Egyptian 
population. Furthermore, our data revealed that Egypt is in a situation where halothane 
is still being used in several hospitals across the different health systems, monitoring 
in the operating theatres is below the standard level, management protocols are not 
standardised, and dantrolene stock is not readily available in many hospitals. This 
study should ring the bell for the health officials in the country about the mandatory 
measures to be taken to tackle this problem. Additionally, anaesthetists working in the 
different health systems should be extra vigilant towards the clinical features of MH, 
including family and previous anaesthetic history, to recognise any suspected reaction 
as early as possible, switch off all triggering agents, and commence supportive and 
symptomatic treatment for better survival rates, and definitely, administer dantrolene 
if it is available. 
7.9 Limitations 
Specific limitations to each particular study in this project have been partially discussed 
in different chapters. The two main limitations that face any study about MH are; the 
small sample size, which limits the statistical power of these studies and hinders 
obtaining conclusive statistical findings, and the inconsistency in the recorded clinical 
details of the suspected anaesthetic reactions. Both limitations were obvious in our 
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study; the effect of the small sample size was even exaggerated when conducting 
statistical analysis on subgroups such as different RYR1 genotype and clinical 
phenotype groups. That was the main reason for not correcting the p values for 
multiple comparisons, which could have vanished any statistical significance found. In 
addition, the limitation related to inconsistency of the recorded clinical details 
prevented us from drawing solid conclusions, about the role of succinylcholine in 
triggering a hypermetabolic MH reaction, for instance. 
Selection bias is also limiting segregation studies of CM and MH. This is because 
family members of index cases who test MHN with IVCT are not referred for further 
testing. As the IVCT is an invasive procedure that carries its own risks such as 
infection and bleeding, it is unethical and impractical to refer patients with a low chance 
to benefit from the test to such an invasive procedure. On the other hand, the 
assumption that other members of the family are not susceptible to MH based on the 
test results of the index case is limiting the validity of these segregation studies. 
Additionally, no data about the histopathological findings in other members will be 
available, limiting the correlation analysis between the clinical phenotype and 
histological phenotype. Furthermore, patients who test MHN with IVCT are usually not 
referred for genetic testing, although discordance has been reported. 
The study about MH in Egypt was loaded with its own limitations that have been 
discussed thoroughly in the sixth chapter. However, it is important to restate the main 
points about this study to enable future studies about MH, or other rare-occurring 
conditions, to address these limitations at the early stage of planning. Firstly, 
communication is challenging either with officials or with candidates, due to the lack 
of a central communication system. Therefore, a plan should be in place to facilitate 
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contact either through personal or phone interviews or appointing a contact person at 
each site for the study. Secondly, the inefficiency of medical recording limits the 
capabilities for retrospective studies. Therefore, collection of clinical details at the time 
of the event through paper forms or an online referral system, as we have suggested, 
should improve the validity of the collected information. However, in rare-occurring 
conditions, such as MH, it may take a long time to obtain data that is sufficient to 
perform statistical analysis. Thirdly, cultural and religious considerations may affect 
the ability to perform certain procedures; post-mortem examination, for example.  
7.10 Future directions 
A future study of the MH susceptibility in family members of index cases would offer a 
better understanding of the genetic heterogeneity of the disorder within families. This 
study will be of higher value if the clinical details of any previous anaesthetic exposure 
are retrieved and reviewed. Comparing the genetic and IVCT results within families 
and between probands and their relatives should give the genotype-phenotype 
correlation studies broader spectrum and more depth into the genetic mechanisms 
underlying the different IVCT responses. In particular, with the transition to a whole-
exome sequencing approach at the Leeds MH Investigation Unit, this broader strategy 
would increase the scope of variant detection in these patients. With the ongoing 
research projects at the unit that are adopting different approaches to functionally 
characterise RYR1 variants. These projects use immortalised human muscle cells 
harbouring the specific RYR1 variants to compare Ca+2 release to wild-type cells. 
Another method is CRISPR-Cas9 that is used to introduce variants to cell lines and 
measure relative Ca+2 release to wild-type RyR1 receptors. In addition, these studies 
could offer potential explanations for the possible genetic background behind different 
clinical presentations. 
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We have attempted to explore and identify the obstacles facing future studies 
exploring the epidemiology of MH in Egypt and other countries in the Middle East 
region. With better co-operation from health administration officials to conduct similar 
future epidemiological studies, many of the limitations that we have discussed in this 
thesis could be resolved, offering more reliable results and a better understanding of 
the extent of the condition among the country population. Directing anaesthetists 
working in the country to fill in the online reporting form of any suspected anaesthetic 
reaction will help to build up a database for future studies. Additionally, educating 
patients about the possible serious outcomes of MH in other family members should 
encourage them to seek further help and engage more in future screening 
programmes. Indeed, the outcomes of any future studies will be dependent on the will 
of the government to invest in funding a research and investigation facility for MH in 
the country. 
Overall, this thesis added to the ongoing effort to investigate the association between 
MH and CM. It also highlighted the effects of recent changes in the anaesthetic 
practice on the clinical epidemiology of MH. We also proposed possible ideas about 
the genetic backgrounds of different clinical presentations that need a further 
investigation. Last but not least, we have established a cornerstone for future work 
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9.1 Appendix A 
Serial Codon change Amino acid change Detection rate ExAC MAF 
1 c.38T>G p.13Leu>Arg 1  
2  c.131G>A  p.44Arg>His 1  
3  c.178G>A  p.60Asp>Asn 1  
4  c.326G>A  p.109Arg>Gln 1  
5  c.479A>G  p.160Glu>Gly 1  
6  c.487C>T  p.163Arg>Cys 15 Not found 
7  c.488G>T  p.163Arg>Leu 1  
8  c.526G>A  p.176Glu>Lys 1  
9  c.529C>T  p.177Arg>Cys 9 0.000008652 
10  c.533A>C  p.178Tyr>Ser 1  
11  c.641C>T  p.214Thr>Met 1  
12  c.652G>A  p.218Val>Ile 1  
13  c.742G>A  p.248Gly>Arg 4 Not found 
14  c.742G>C  p.248Gly>Arg 2 0.00002479 
15  c.1021G>A  p.341Gly>Arg 18 Not found 
16  c.1201C>G  p.401Arg>Cys 1  
17  c.1201C>T  p.401Arg>Cys 1  
18  c.1202G>A  p.401Arg>His 1  
19  c.1459C>G  p.487Leu>Val 1  
20  c.1475G>A  p.492Arg>His 1  
21  c.1565A>G  p.522Tyr>Cys 1  
22  c.1598G>A  p.533Arg>His 1  
 217 
Serial Codon change Amino acid change Detection rate ExAC MAF 
23  c.1609G>A  p.537Ala>Thr 1  
24  c.1615T>C  p.539Phe>Leu 1  
25  c.1654C>T  p.552Arg>Trp 4 Not found 
26  c.1840C>T  p.614Arg>Cys 9 0.00008236 
27  c.1841G>A_hom  p.614Arg>His 1 0.00002471 
28  c.2050G>C  p.684Gly>Arg 1  
29  c.2320G>A  p.774Gly>Arg 1  
30  c.2645C>T  p.882Ala>Val 1  
31  c.3095G>A  p.1032Arg>His 1  
32  c.3166G>C  p.1056Asp>His 1  
33  c.3172G>A  p.1058Glu>Lys 1  
34  c.3224G>A  p.1075Arg>Gln 1  
35  c.3418C>T  p.1140Arg>Cys 1  
36  c.3527C>T  p.1176Thr>Ile 1  
37  c.4024A>G  p.1342Ser>Gly 1  
38  c.4088C>T  p.1363Ala>Val 1  
39  c.4178A>G  p.1393LYS>ARG 3 0.005072 
40  c.4405C>T  p.1469Arg>Trp 1  
41  c.4711A>G  p.1571Ile>Val 1  
42  c.4763C>T  p.1588Pro>Leu 1  
43  c.5024T>C  p.1675Leu>Pro 2 Not found 
44  c.5033A>G  p.1678Asn>Ser 1  
45  c.5183C>T  p.1728Ser>Phe 5 Not found 
46  c.5186T>G  p.1729Met>Arg 1  
47  c.5360C>T  p.1787Pro>Leu 2 0.01957 
 218 
Serial Codon change Amino acid change Detection rate ExAC MAF 
48  c.5440A>G  p.1814Met>Val 1  
49  c.5441T>A  p.1814Met>Lys 1  
50  c.6178G>T  p.2060Gly>Cys 5 0.06937 
51  c.6488G>A  p.2163Arg>His 5 Not found 
52  c.6502G>A  p.2168Val>Met 4 Not found 
53  c.6599C>T  p.2200Ala>Val 1  
54  c.6612C>G  p.2204His>Gln 2 Not found 
55  c.6617C>G  p.2206Thr>Arg 1  
56  c.6617C>T  p.2206Thr>Met 16 0.00003305 
57  c.6742C>T  p.2248Arg>Cys 1  
58  c.6961A>G  p.2321Ile>Val 1  
59  c.7007G>A  p.2336Arg>His 5 Not found 
60  c.7025A>G  p.2342Asn>Ser 3 0.001073 
61  c.7043A>G  p.2348Glu>Gly 1  
62  c.7048G>A  p.2350Ala>Thr 7 Not found 
63  c.7089C>G  p.2364Cys>Trp 1  
64  c.7090T>G  p.2364Phe>Val 1  
65  c.7123G>A  p.2375Gly>Arg 1  
66  C.7291G>A  p.2431Asp>Asn 1  
67  c.7291G>T  p.2431Asp>Tyr 2 Not found 
68  c.7300G>A  p.2434Gly>Arg 84 0.00002479 
69  c.7304G>A  p.2435Arg>His 6 Not found 
70  c.7304G>T  p.2435Arg>Leu 1  
71  c.7307G>A  p.2436Cys>HIS 1  
72  c.7354C>T  p.2452Arg>Trp 1  
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73  c.7361G>A  p.2454Arg>His 9 0.000008298 
74  c.7373G>A  p.2458Arg>His 10 0.000008287 
75  c.7373G>T  p.2458Arg>Leu 1  
76  c.7522C>T  p.2508Arg>Cys 1  
77  c.7523G>A  p.2508Arg>His 4 Not found 
78  c.7528T>C  p.2510Tyr>His 1  
79  c.7816T>A  p.2606Cys>Ser 1  
80  c.7879G>A  p.2627Val>Met 1  
81  c.7879G>C  p.2627Val>Leu 1  
82  c.8026C>T  p.2676Arg>Trp 2 0.000008253 
83  c.8198G>T  p.2733Gly>Asp 1  
84  c.8729C>T  p.2910Thr>Met 1  
85  c.9152G>A  p.3051Arg>His 1  
86  c.9268G>A  p.3090Ala>Thr 1  
87  c.9310G>A  p.3104Glu>Lys 2 0.00001649 
88  c.9353C>T  p.3188Ala>Val 1  
89  c.9652G>A  p.3218Val>Met 1  
90  c.9676G>C  p.3226Glu>Gln 1  
91  c.9797T>C  p.3266Met>Thr 1  
92  c.10042C>T  p.3348Arg>Cys 1  
93  c.10097G>A  p.3366Arg>His 3 0.0009272 
94  c.10252A>G  p.3418Asn>Asp 2 Not found 
95  c.10616G>A  p.3539Arg>His 4 0.001792 
96  c.10732G>C  p.3578Glu>Gln 1  
97  c.10747G>C  p.3583Glu>Gln 2 0.01494 
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98  c.10870C>T  p.3624Arg>Trp 1  
99  c.11132C>T  p.3711Thr>Met 1  
100  c.11251C>G  p.3751Gln>Glu 1  
101  c.11266C>G  p.3756Gln>Glu 3 0.03374 
102  c.11315G>A  p.3772Arg>Gln 4 Not found 
103  c.11708G>A  p.3903Arg>Gln 1  
104  c.11941C>T  p.3981His>Tyr 1  
105  c.11943C>G  p.3981Asp>Glu 1  
106  c.11958C>G  p.3986Asp>Glu 4 Not found 
107  c.11969G>T  p.3990Gly>Val 9 Not found 
108  c.12149C>A  p.4050Ser>Tyr 2 Not found 
109  c.12533G>T  p.4178Gly>Val 1  
110  c.12553G>A  p.4185Ala>Thr 1  
111  c.12700G>C  p.4234Val>Leu 3 Not found 
112  c.12881C>T  p.4294Thr>Met 1  
113  c.13111G>A  p.4371Ala>Thr 1  
114  c.13487C>T  p.4496Pro>Leu 1  
115  c.13513G>C  p.4505Asp>His 1  
116  c.13672C>T  p.4558Arg>Trp 1  
117  c.13913G>A  p.4638Gly>Asp 2 Not found 
118  c.14168G>A  p.4723Arg>His 1  
119  c.14210G>A  p.4737Arg>Gln 4 0.000008253 
120  c.14344G>A  p.4782Gly>Arg 1  
121  c.14458G>T  p.4821Gly>Trp 1  
122  c.14471T>C  p.4824Leu>Pro 2 Not found 
 221 
Serial Codon change Amino acid change Detection rate ExAC MAF 
123  c.14477C>T  p.4826Thr>Ile 3 Not found 
124  c.14512C>G  p.4838Leu>Val 1  
125  c.14545G>A  p.4849Val>Ile 6 0.000008254 
126  c.14590T>C  p.4864Tyr>His 1  
127  c.14678G>T  p.4893Arg>Gln 1  
128  c.14814C>G  p.4938Ile>Met 1  
129  c.14918C>T  p.4973Pro>Leu 2 0.00004136 
Table 9-1: List of all RYR1 variants detected in our cohort of MHS index cases. MAFà 




9.2 Appendix B 
Serial Codon change Amino acid change Detection rate ExAC MAF 
1 c.520C>T p.174Arg>Trp 2 0.00003306 
2 c.743C>T p.248Thr>Met 1  
3 c.1426A>C p.476Thr>Pro 1  
4 c.1817G>A p.606Ser>Asn 13 0.008764 
5 c.1849A>G p.617Thr>Ala 1  
6 c.2047C>T p.683Arg>Cys 1  
7 c.2048G>A p.683Arg>His 1  
8 c.2273C>T p.758Pro>Leu 1  
9 c.2296C>A p.766Leu>Met 1  
10 c.2480T>C p.827Met>Thr 1  
11 c.2654T>C p.885Leu>Pro 1  
12 c.2700G>T p.900Arg>Ser 1  
13 c.2726A>G p.909Asn>Ser 1  
14 c.2974C>G p.992His>Asp 1  
15 c.3256C>A p.1086Arg>Ser 2 0.00003295 
16 c.3628G>A p.1210Gly>Arg 1  
17 c.3811G>A p.1271Ala>Thr 1  
18 c.3905G>A p.1302Arg>Gln 1  
19 c.4060A>T p.1354Thr>Ser 5 0.002364 
20 c.5515C>T p.1839Pro>Ser 2 0.002299 
21 c.5570G>A p.1857Ser>Asn 3 0.00187 
Table 9-2: List of CACNA1S variants detected in our cohort of MHS index cases. 
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